Document:

Exhibit 10.1

 

EXECUTION COPY

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ASSET PURCHASE AGREEMENT

 

between

 

H2-PHARMA,
llc

 

AND

 

ANI PHARMACEUTICALS, INC.

 

DATED AS OF JANUARY 28, 2016

 

     

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	ARTICLE I DEFINITIONS AND TERMS	1
	 	 	 
	Section 1.1	Definitions	1
	 	 	 
	Section 1.2	Other Definitional and Interpretive Provisions	7
	 	 	 
	ARTICLE II PURCHASE AND SALE	8
	 	 	 
	Section 2.1	Purchase and Sale of Assets	8
	 	 	 
	Section 2.2	Excluded Assets	8
	 	 	 
	Section 2.3	Assumption of Liabilities	9
	 	 	 
	Section 2.4	Retained Liabilities	10
	 	 	 
	Section 2.5	Purchase Price	11
	 	 	 
	Section 2.6	Wrong Pocket Assets	12
	 	 	 
	ARTICLE III CLOSING	12
	 	 	 
	Section 3.1	Closing	12
	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER	14
	 	 	 
	Section 4.1	Organization	14
	 	 	 
	Section 4.2	Authority; Binding Effect	14
	 	 	 
	Section 4.3	No Conflicts; Consents	14
	 	 	 
	Section 4.4	Governmental Authorization	15
	 	 	 
	Section 4.5	Absence of Material Changes	15
	 	 	 
	Section 4.6	No Litigation	15
	 	 	 
	Section 4.7	Compliance with Laws	15
	 	 	 
	Section 4.8	Product Registrations; Regulatory Compliance	15
	 	 	 
	Section 4.9	Intellectual Property	16
	 	 	 
	Section 4.10	Assets	17
	 	 	 
	Section 4.11	Taxes	17
	 	 	 
	Section 4.12	Contracts	18
	 	 	 
	Section 4.13	Brokers	18
	 	 	 
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER	19
	 	 	 
	Section 5.1	Organization and Qualification	19
	 	 	 
	Section 5.2	Corporate Authorization	19
	 	 	 
	Section 5.3	Binding Effect	19

 

    	 	-i-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS (cont’d)

 

	 	 	Page
	 	 	 
	Section 5.4	No Conflict; Consents	19
	 	 	 
	Section 5.5	Governmental Authorization	19
	 	 	 
	Section 5.6	Compliance with Laws	20
	 	 	 
	Section 5.7	Litigation	20
	 	 	 
	ARTICLE VI COVENANTS	20
	 	 	 
	Section 6.1	Insurance	20
	 	 	 
	Section 6.2	Filings	20
	 	 	 
	Section 6.3	Confidentiality	21
	 	 	 
	Section 6.4	Procedures; Transition of Business; Inventory	21
	 	 	 
	Section 6.5	Use of Seller NDC Number	25
	 	 	 
	Section 6.6	Post-Closing Cooperation	26
	 	 	 
	Section 6.7	Correspondence	26
	 	 	 
	ARTICLE VII NON-COMPETE	27
	 	 
	ARTICLE VIII INDEMNIFICATION	27
	 	 	 
	Section 8.1	Indemnification by Seller	27
	 	 	 
	Section 8.2	Indemnification by Purchaser	27
	 	 	 
	Section 8.3	Notice of Direct Claims	28
	 	 	 
	Section 8.4	Third Party Claims	29
	 	 	 
	Section 8.5	Expiration	30
	 	 	 
	Section 8.6	Limitations on Indemnification	30
	 	 	 
	Section 8.7	Reimbursement	31
	 	 	 
	Section 8.8	Subrogation	31
	 	 	 
	Section 8.9	Sole Remedy/Waiver	31
	 	 	 
	ARTICLE IX MISCELLANEOUS	32
	 	 	 
	Section 9.1	Notices	32
	 	 	 
	Section 9.2	Amendment; Waiver	33
	 	 	 
	Section 9.3	Assignment	33
	 	 	 
	Section 9.4	Entire Agreement	33
	 	 	 
	Section 9.5	Parties in Interest	33
	 	 	 
	Section 9.6	Public Disclosure	34

 

    	 	-ii-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS (cont’d)

 

	 	 	Page
	 	 	 
	Section 9.7	Expenses; Transfer Taxes	34
	 	 	 
	Section 9.8	Schedules	34
	 	 	 
	Section 9.9	Governing Law	34
	 	 	 
	Section 9.10	WAIVER OF JURY TRIAL	35
	 	 	 
	Section 9.11	Counterparts	35
	 	 	 
	Section 9.12	Headings	35
	 	 	 
	Section 9.13	Severability	35
	 	 	 
	Section 9.14	Specific Performance	36
	 	 	 
	Section 9.15	Non-Recourse	36

 

    	 	-iii-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

SCHEDULES OTHER THAN DISCLOSURE SCHEDULES

 

	 	1.1(a)	Knowledge of Purchaser and Sellers
	 	1.1(b)	Products
	 	1.1(c)	Required Third Party Consents
	 	2.1(a)	Assumed Contracts
	 	6.4(f)	Fee Payable

 

    	 	-iv-	 

     

    

  

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement
is made and entered into as of the 28th day of January 2016, by and between H2-Pharma, LLC, a Florida limited liability company
(“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Purchaser”).

 

RECITALS

 

WHEREAS, Seller
licenses the rights to market, sell and distribute the Products in the Territory (the “Business”);

 

WHEREAS, Seller
desires to sell, transfer and assign to Purchaser, and Purchaser desires to acquire and assume from Seller, all of the Purchased
Assets and Assumed Liabilities, all as more specifically provided herein.

 

NOW, THEREFORE,
in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, hereby agree as follows:

 

ARTICLE
I

DEFINITIONS AND TERMS

 

Section
1.1    Definitions. As used in this Agreement, the following terms shall have the meanings set
forth or as referenced below:

 

"2016 Seller
Royalty" shall have the meaning set forth in Section 3.1(b)(vii).

 

"Additional Payment"
shall have the meaning set forth in Section 6.4(g).

 

“Affiliate”
means with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with,
such Person at any time during the period for which the determination of affiliation is being made.

 

“Agreement”
means this Asset Purchase Agreement.

 

“AG Agreement”
means the Authorized Generic Distribution Agreement dated March 14, 2014, between Kowa and Seller.

 

“Ancillary Agreements”
means, collectively the Bill of Sale, assignments of Assumed Contracts, Intellectual Property assignments, assumption agreements,
or other instruments evidencing the assumption by Purchaser of the Assumed Liabilities, the [***] Amendment and each other agreement,
document, instrument and/or certificate contemplated by this Agreement to be executed by Purchaser or Seller in connection with
the transactions contemplated hereby.

 

     

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Assumed Contracts”
shall have the meaning set forth in Section 2.1(a).

 

“Assumed Liabilities”
shall have the meaning set forth in Section 2.3.

 

“Bankruptcy
and Equity Exception” shall have the meaning set forth in Section 4.2(b).

 

“Business”
shall have the meaning set forth in the Recitals.

 

“Business Day”
means any day other than a Saturday, a Sunday or a day on which commercial banks in New York City are authorized or obligated by
applicable law or executive order to close.

 

“Cap”
shall have the meaning set forth in Section 8.6(c).

 

“Closing”
means the closing of the transactions contemplated by this Agreement pursuant to the terms of this Agreement.

 

“Closing Date”
shall have the meaning set forth in Section 3.1(a).

 

"Closing Royalty
Report" shall have the meaning set forth in Section 3.1(b)(vii).

 

"CMS"
shall have the meaning set forth in Section 6.2.

 

“Code”
means the Internal Revenue Code of 1986, as amended, from time to time.

 

"Competing Business"
shall have the meaning set forth in Article VII.

 

“Confidential
Information” shall have the same meaning as is given to "Transaction Material" in Section 1 of the Confidentiality
Agreement.

 

“Confidentiality
Agreement” means the Confidentiality Agreement between Seller and Purchaser, dated November 5, 2015, as amended or supplemented
from time to time.

 

“Contract”
means any binding contract, agreement, lease, license or commitment.

 

"[***] Amendment"
means a Product Supply Agreement Addendum, entered into as of January 26, 2016, by and between [***], the Seller and the Purchaser,
in form and substance acceptable to Purchaser.

 

“Excluded Assets”
shall have the meaning set forth in Section 2.2.

 

“Excluded Contracts”
means all Contracts that are not Assumed Contracts.

 

    	 	-2-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Exploitation”
(including, with correlative meanings, the terms “Exploit” and “Exploited”) means commercializing,
labeling, packaging, marketing, promoting, selling, distributing and/or transporting.

 

“FDA Act”
means the Food, Drug and Cosmetics Act of 1938, as amended, supplemented or replaced.

 

"Final Q2 Sales"
shall have the meaning set forth in Section 6.4(i)(iv).

 

“Fundamental
Representations” shall have the meaning set forth in Section 8.5.

 

“GAAP”
means United States generally accepted accounting principles, consistently applied.

 

“Governmental
Authority” means any supranational, national, federal, state or local judicial, legislative, executive or regulatory
authority.

 

“Governmental
Authorizations” means all licenses, permits, certificates and other authorizations and approvals pertaining to the Products
under the applicable Laws of any Governmental Authority.

 

“Governmental
Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.

 

“Indemnity Notice”
shall have the meaning set forth in Section 8.3.

 

“Indemnified
Party” shall have the meaning set forth in Section 8.3.

 

“Indemnifying
Party” shall have the meaning set forth in Section 8.3.

 

“Indemnity Threshold”
shall have the meaning set forth in Section 8.6(b).

 

“Independent
Accountant” shall have the meaning set forth in Section 2.5(c).

 

“Intellectual
Property” means any and all worldwide rights in, arising from or associated with the following, whether protected, created
or arising under the Laws of the United States or any other jurisdiction or under any international convention to the extent related
to the Products: (1) all patents and applications therefor and all reissues, divisions, re-examinations, renewals, extensions,
provisionals, substitutions, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the
world in inventions and discoveries including, without limitation, invention disclosures (“Patent Rights”),
if any; (2) all trade secrets and other proprietary information which derives independent economic value from not being generally
known to the public (collectively, “Trade Secrets”); and (3) all copyrights, copyrights registrations and applications
therefor (“Copyrights”).

 

“Inventories”
means all inventory of the Products owned by Seller on the Closing Date.

 

    	 	-3-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Knowledge of
Seller” means the actual knowledge any of the individuals listed on Schedule 1.1(a)(ii) has or would have following
reasonable inquiry into the subject matter in the course of performing each of their respective duties.

 

“Kowa”
means Kowa Pharmaceuticals America, Inc., a Delaware corporation.

 

"Kowa Royalty"
means the amounts described in Section 5.1 of the AG Agreement that are payable in respect of the sale of Products by Seller, with
respect to the period prior to Closing and Purchaser, with respect to the period following Closing.

 

“Laws”
means any federal, state, foreign or local law, common law, statute, ordinance, rule, regulation, code or Governmental Order.

 

“Liabilities”
means any and all Losses, debts, liabilities and obligations, whether accrued or unaccrued, fixed, known or unknown, absolute or
contingent, matured or unmatured or determined or determinable, including any liability for Taxes and including all costs and expenses
relating thereto.

 

“Licensed Intellectual
Property” shall have the meaning set forth in Section 4.9(b)(i).

 

“Liens”
means any lien, security interest, mortgage, pledge, assessment, hypothecation, easement, title retention clause, title defect,
right of first refusal, charge or similar encumbrance.

 

“Loss”
or “Losses” means any liabilities, losses, damages, fines, penalties, amount paid in settlement or other outlay
of cash, or other non-cash consideration, whether resulting from a judgment, a settlement or an award, including those arising
out of any Proceeding, Law or Contract, including the Taxes, costs and expenses (including reasonable fees and expenses of counsel,
consultants, experts, and other professional fees) associated therewith.

 

“NDC Number”
means the unique 10-digit, 3-segment number assigned by the U.S. Food & Drug Administration to each human drug processed for
commercial distribution, which number is published in the NDC Directory pursuant to Section 510 of the FDA Act.

 

“NonFAMP Eligible
Transactions” means those transactions relating to a Product that are used to calculate the Non-Federal Average Manufacturer
Price as defined by Veteran’s Health Care Act of 1992.

 

“Owned Intellectual
Property” has the meaning set forth in Section 4.9(a).

 

“Party”
means each of Purchaser and each Seller.

 

“Permitted Encumbrances”
means (i) Liens approved in writing by Purchaser; (ii) statutory Liens arising by operation of Law with respect to a Liability
incurred in the ordinary course of business and which is not delinquent; (iii) Liens for Taxes not yet subject to penalties for
nonpayment; (iv) mechanics’, materialmens’, carriers’, workmens’, warehousemens’, repairmens’,
landlords’ or other like Liens and security obligations that are not delinquent; (v) Liens that will be released and, as
appropriate, removed of record, at or prior to the Closing Date in accordance with the terms of this Agreement; (vi) Liens arising
in connection with any consignment arrangement entered into in the ordinary course of business; and (vii) Liens arising in connection
with the transactions contemplated by this Agreement.

 

    	 	-4-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Person”
means an individual, a limited liability company, joint venture, a corporation, a partnership, an association, a trust, a division
or operating group of any of the foregoing or any other entity or organization.

 

“Post-Closing
Tax Period” means any Tax period (or portion thereof) beginning after the Closing Date.

 

"Pre-Closing
Royalty" means the Kowa Royalty payable under the AG Agreement with respect to all periods prior to January 1, 2016.

 

“Pre-Closing
Tax Period” means any Tax period (or portion thereof) ending on or before the Closing Date.

 

“Proceeding”
means any claim, action, arbitration, mediation, hearing, proceeding, suit, warning letter, or notice of violation.

 

“Product Registrations”
means all Governmental Authorizations (including NDAs, ANDAs and INDs) and comparable regulatory filings granted or applications
therefor that are pending with, any Governmental Authority required to manufacture, commercialize, develop, package, label, store,
use, market, import, export, distribute and/or sell any of the Products.

 

“Products”
means the products listed on Schedule 1.1(b) hereto.

 

“Purchased Assets”
shall have the meaning set forth in Section 2.1, it being understood that the Purchased Assets do not include the Excluded
Assets.

 

“Purchased Documents”
means all books, records, files and papers, whether in hard copy or computer format, to the extent related to the Products (including
with respect to research and development, medical safety or regulatory affairs), including (i) all documents, if any, relating
to the calculation of baseline AMP (but excluding any proprietary methodology documents created by Seller or any of its Affiliates
with respect to the calculation of baseline AMP), (ii) an electronic version of each Product’s Medical Information Inquiry
Database, (iii) any and all regulatory files (including correspondence with regulatory authorities) owned by or in the possession
or control of Seller or any of its Subsidiaries to the extent relating to the Purchased Assets or the operation of the Business
(including safety and adverse event data) and (iv) copies of all books, records, files and papers, whether in hard copy or computer
format, to the extent related to nonFAMP-Eligible Transactions from March 1, 2014 through the end of the Transition Period.

 

    	 	-5-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Purchased Intellectual
Property” means the Seller’s rights to the Owned Intellectual Property and the Licensed Intellectual Property.

 

“Purchase Price”
shall have the meaning set forth in Section 2.5(a).

 

“Purchaser”
has the meaning set forth in the preamble of this Agreement.

 

“Purchaser Disclosure
Schedules” shall have the meaning set forth in Article V.

 

“Purchaser Indemnified
Parties” shall have the meaning set forth in Section 8.1.

 

"Q1 Estimated
Report" shall have the meaning set forth in Section 6.4(i)(i).

 

"Q1 Final Report"
shall have the meaning set forth in Section 6.4(i)(ii).

 

"Q2 Estimated
Report" shall have the meaning set forth in Section 6.4(o)(iii).

 

"Q2 Final Report"
shall have the meaning set forth in Section 6.4(i)(iv).

 

“Representatives”
means, with respect to any Person, the directors, managers, employees, independent contractors, agents or consultants of such Person.

 

“Required Third
Party Consents” means the consents and approvals set forth on Schedule 1.1(e).

 

“Retained Liabilities”
shall have the meaning set forth in Section 2.4.

 

“Seller”
has the meaning set forth in the preamble of this Agreement.

 

“Seller Disclosure
Schedules” shall have the meaning set forth in Article IV.

 

“Seller Indemnified
Parties” shall have the meaning set forth in Section 8.2.

 

"September Report"
shall have the meaning set forth in Section 6.4(i)(v).

 

"Shipped Products"
shall have the meaning set forth in Section 2.4(b).

 

"Subsidiary"
means, with respect to any Person, any entity a majority of the capital stock or other voting equity interests of which is owned
by such Person, or one or more of such Person's Subsidiaries or which is controlled by such Person or one or more of its Subsidiaries.

 

“Tax”
or “Taxes” means all taxes, levies or other assessments, including income, excise, property, sales or use, value
added, profits, license, withholding (with respect to compensation or otherwise), payroll, employment, net worth, capital gains,
transfer, stamp, social security, environmental, occupation and franchise taxes, imposed by any Taxing Authority, and including
any interest, penalties and additions attributable thereto.

 

    	 	-6-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Tax Return”
or “Tax Returns” means any return, report, declaration, information return, statement or other document filed
or required to be filed with any Taxing Authority, in connection with the determination, assessment or collection of any Tax or
the administration of any Laws relating to any Tax.

 

“Taxing Authority”
means any Governmental Authority, body or instrumentality exercising any authority to impose, regulate or administer the imposition
of Taxes.

 

“Territory”
means the United States and its territories and possessions.

 

“Third Party
Claim” shall have the meaning set forth in Section 8.4(a).

 

“Transfer Taxes”
means any federal, state, county, local, foreign and other sales, use, transfer, value added, conveyance, documentary transfer,
stamp, recording, registration or other similar Tax (including any notarial fee) imposed in connection with, or otherwise relating
to, the transactions contemplated by this Agreement or the recording of any sale, transfer or assignment of property (or any interest
therein) effected pursuant to this Agreement.

 

“Transition
Period” shall have the meaning set forth in Section 6.4(e).

 

"Transition Period
Report" shall have the meaning set forth in Section 6.4(g).

 

"WAC"
means, with respect to the 50 mg Product, $[***] and with respect to the 150 mg Product, $[***], in each case per bottle of ninety
(90) capsules.

 

Section
1.2     Other Definitional and Interpretive Provisions     (a)    The words “hereof”, “herein”, “hereto” and “hereunder” and words of
similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this
Agreement.

 

(b)          The
terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

 

(c)          The
terms “dollars” and “$” shall mean United States of America dollars.

 

(d)          The
term “including” (and with correlative meaning “include”) shall mean “including, without limitation.”

 

(e)          Reference
to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are permitted
by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity.

 

(f)          Reference
to any agreement (including this Agreement), document or instrument means such agreement, document or instrument as amended, modified
or supplemented and in effect from time to time in accordance with the terms thereof and, if applicable, the terms hereof.

 

    	 	-7-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(g)          When
a reference is made in this Agreement to an Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article
of, a Section of, an Exhibit to or a Schedule to, this Agreement unless otherwise indicated.

 

(h)          The
Parties acknowledge that: (i) this Agreement is the result of negotiations between the Parties and shall not be deemed or
construed as having been drafted by any one Party; (ii) each Party and its counsel have reviewed and negotiated the terms
and provisions of this Agreement (including any exhibits and disclosure schedules attached hereto) and have contributed to its
revision; (iii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall
not be employed in the interpretation of this Agreement; and (iv) the terms and provisions of this Agreement shall be construed
fairly as to all Parties and not in favor of or against any Party, regardless of which party was generally responsible for the
preparation of this Agreement.

 

ARTICLE
II

PURCHASE AND SALE

 

Section
2.1    Purchase and Sale of Assets. Upon the terms and subject to the conditions set forth herein,
at the Closing, Seller shall sell, convey, assign and transfer to Purchaser, and Purchaser shall purchase, acquire and accept
from Seller, free and clear of all Liens, other than Permitted Encumbrances, all of Seller’s right, title and interest in,
to and under those assets described in the following clauses (a) through (e) (collectively, the “Purchased
Assets”):

 

(a)          all
the Contracts relating to the Products set forth on Schedule 2.1(a), including with respect to the Licensed Intellectual
Property (the “Assumed Contracts”);

 

(b)          all
customer lists for each Product and research data to the extent related to the Products and in the possession of Seller;

 

(c)          all
Inventories other than the Inventory bearing Seller’s NDC Number, if any, and all packaging materials, active pharmaceutical
ingredients, work-in-process or finished good to the extent used or held for use by or for the benefit of Seller for the operation
of the Business, as currently conducted;

 

(d)          all
the Purchased Documents; and

 

(e)          all
of Seller's causes of actions, claims, credits, demands or rights of set-off against third parties to the extent related to the
Business and/or the Purchased Assets, including any claims that may arise under Assumed Contracts.

 

Section
2.2     Excluded Assets. Nothing herein contained shall be deemed to sell, transfer, assign
or convey the Excluded Assets to Purchaser, and the Seller shall retain all right, title and interest to, in and under the Excluded
Assets. “Excluded Assets” means all assets, properties, interests and rights of Seller other than the Purchased
Assets, including each of the following assets:

 

    	 	-8-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(a)          all
cash, cash equivalents, bank deposits or similar cash items and accounts receivable of Seller;

 

(b)          all
books and records of Seller other than the Purchased Documents; provided, however, that Purchaser shall have the right to
make copies of any portions of any such retained books and records that relate to any of the Purchased Assets;

 

(c)          all
rights of Seller to any other Intellectual Property, other than Intellectual Property included in the Purchased Assets;

 

(d)          all
insurance policies or rights to proceeds thereof relating to the Purchased Assets or Products;

 

(e)          all
rights, claims or causes of action of Seller against third parties in connection with the Purchased Assets or Products arising
out of events occurring on or prior to the Closing Date;

 

(f)          all
Tax Returns and financial statements of Seller and all records (including working papers) related thereto;

 

(g)          all
refunds for Taxes relating to the Purchased Assets with respect to a Pre-Closing Tax Period;

 

(h)          all
of Seller’s rights in respect of real property, including leasehold interests;

 

(i)          the
membership interests in Seller, and Seller’s minute book and corporate records;

 

(j)          all
rights that accrue to Seller under this Agreement and the Ancillary Agreements;

 

(k)          all
of Seller’s causes of action, claims, credits, demands or rights of set-off against third parties, to the extent related
to any Excluded Asset or Retained Liabilities;

 

(l)          all
uniform resource locators, e-mail and other internet addresses and domain names and applications and registrations therefor (“URLs”);

 

(m)          all
trade names, corporate names, logos, slogans, trade dress, trademarks, service marks, and trademark and service mark registrations
and applications therefor and all goodwill associated therewith (“Trademarks”); and

 

(n)          those
assets described on Schedule 2.2(n).

 

    	 	-9-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
2.3     Assumption of Liabilities.

 

(a)          Upon
the terms and subject to the conditions of this Agreement, Purchaser agrees, effective at the Closing, to assume and to satisfy
and discharge when due only those Liabilities of Seller (other than the Retained Liabilities), specifically set forth below (all
of such Liabilities and other than the Retained Liabilities being herein collectively referred to as the “Assumed Liabilities”):

 

(i)          all
Liabilities arising from the Exploitation of any Products, including Liabilities for returns, rebates and chargebacks related to
any of the Products bearing Purchaser’s NDC Number;

 

(ii)         Liabilities
to fulfill certain purchase orders, as and to the extent provided in Section 6.4(k); and

 

(iii)        all
Liabilities under Assumed Contracts relating to the period following the Closing Date, other than any Liabilities directly arising
out of, or resulting from, a breach of any such Assumed Contract by Seller prior to the Closing Date.

 

Section
2.4    Retained Liabilities. Notwithstanding any provision in this Agreement, Seller shall retain
and be responsible only for the following Liabilities (the “Retained Liabilities”):

 

(a)          all
Liabilities of Seller related to the Excluded Assets;

 

(b)          all
Liabilities arising out of or relating to (i) the return of any Product bearing Seller’s NDC Number (including the Inventories)
shipped by Seller to a third party prior to the end of the Transition Period (“Shipped Products”) or (ii) rebates
or chargebacks related to any Shipped Products;

 

(c)          all
Liabilities of Seller in respect of any Proceeding (whether class, individual or otherwise in nature, in law or in equity) commenced
or asserted prior to the Closing, whether related to the Purchased Assets or the Excluded Assets;

 

(d)          all
Liabilities arising out of or relating to any product liability, breach of warranty or similar claim for injury to any Person or
property that resulted from the use or misuse of the Products or otherwise related to the Products, including the Inventories (including
any Proceeding relating to any such Liabilities) shipped or sold by or on behalf of Seller before the end of the Transition Period
or otherwise bearing Seller's NDC Number;

 

(e)          all
Liabilities of Seller to its suppliers for materials and services relating to the manufacture of finished goods Inventory that
were delivered or provided to Seller prior to Closing;

 

(f)          the
Pre-Closing Royalty;

 

(g)          any
Liability arising out of any Permitted Encumbrance of the type set forth in clauses (iii) or (iv) of the definition
thereof;

 

    	 	-10-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(h)          any
Liability under Seller’s employee benefits or compensation arrangements; and

 

(i)          all
Liabilities of Seller for Taxes relating to the Purchased Assets or the Products other than as provided in Section 9.7.

 

Section
2.5     Purchase Price.

 

(a)          On
the terms and subject to the conditions set forth herein, in consideration of the sale and transfer of the Purchased Assets:

 

(i)          at
the Closing, Purchaser (A) shall assume the Assumed Liabilities and (B) pay an amount in cash equal to the sum of:

 

(1)         Ten
Million Dollars ($10,000,000); plus

 

(2)         $20,000
as reimbursement for the $20,000 prepayment of the purchase order identified in Schedule 2.1(a); minus

 

(3)         the
Kowa Royalty set forth in the Closing Royalty Report; and

 

(ii)         no
later than ten (10) days following Seller's delivery of the Transition Period Report to Purchaser, Purchaser shall pay the Additional
Payment described in Section 6.4(i)

 

(the amount
set forth in clauses (i) and (ii) together being, the “Purchase Price”), which in the case of
the amounts described in clause (i)(B) and clause (ii), shall be paid to the Seller in immediately available funds
by wire transfer to the account(s) specified in written instructions given by the Seller to Purchaser on or prior to the Closing
Date.

 

(b)          The
Parties to this Agreement agree that the allocation of the Purchase Price shall be proposed by Purchaser prior to or within ninety
(90) days following the Closing. Purchaser shall deliver to Seller a copy of such allocation (which in the case of the covenant
contained in Article VII shall be a nominal amount) promptly after Seller’s determination of the proposed allocation,
and Seller shall have the right to review and raise any objections in writing to the proposed allocation during the ten (10) day
period after Purchaser’s receipt thereof. If Seller does not notify Purchaser of a disagreement with the proposed allocation
during such ten (10) day period, the proposed allocation shall become final. If Seller disagrees with respect to any item in the
allocation, the Parties shall negotiate in good faith to resolve the dispute. If the Parties are unable to agree on the allocation
within thirty (30) days after the commencement of such good faith negotiations (or such longer period as Seller and Purchaser may
mutually agree in writing), then the parties shall refer such dispute to an independent internationally recognized accounting firm
(“Independent Accountant”) at that time to review the allocation, and make a determination as to the resolution
of such allocation. The determination of the Independent Accountant regarding the allocation shall be delivered as soon as practicable
following engagement of the Independent Accountant, but in no event more than sixty (60) days thereafter, and shall be final, conclusive
and binding upon Seller and Purchaser, and Sellers shall revise the allocation accordingly. Seller, on the one hand, and Purchaser
on the other hand, shall each pay one-half of the cost of the Independent Accountant. The finalized allocation shall be binding
on Seller and Purchaser for all Tax reporting purposes and Seller and Purchaser agree to refrain from taking any position inconsistent
therewith unless required by applicable Law or a final determination of a Taxing Authority.

 

    	 	-11-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
2.6    Wrong Pocket Assets. If at any time or from time to time after the Closing Date, Seller
or any of its Affiliates, on the one hand, or Purchaser or any of its Affiliates, on the other, shall receive or otherwise possess
any asset (including cash) that should belong to Purchaser, on the one hand, or Seller, on the other, pursuant to this Agreement,
such Person shall promptly transfer, or cause to be transferred, such asset to the Person so entitled thereto. Prior to any such
transfer in accordance with this ‎Section 2.6, the Person receiving or
possessing such asset shall hold such asset in trust for such other Person. In furtherance thereof, Purchaser and Seller hereby
agree to reimburse one another, U.S. dollar for dollar, in the event that (i) any of Seller’s or Purchaser’s customers,
or their respective Affiliates’ customers, offset against accounts payable by such customer to Seller or Purchaser or their
respective Affiliates, the cost of any Product returned by such customer, or (ii) Seller or Purchaser or any of their respective
Affiliates are required to issue a credit for the account of, or reimburse, any customer for returns, in each case which are the
responsibility of the other Party hereto pursuant to ‎Section 2.3(a)(i) and Section
2.4(b). Purchaser and Seller hereby agree to, and to cause their respective Affiliates to, provide notice to one another of
any such offset, issuance of credit or reimbursement for which such party or its Affiliate is entitled to be reimbursed pursuant
to this ‎Section 2.6. Payment shall be made promptly following receipt of notice
of any such offset by or issuance of a credit to a customer (together with supporting documentation). Following the Closing, Purchaser
and Seller shall cooperate to ensure that a customer does not offset returns of any Product against both Seller (or any of its
Affiliates) and Purchaser (or any of its Affiliates).

 

ARTICLE
III

CLOSING

 

Section
3.1     Closing   (a)   The Closing
shall take place at the offices of Dentons US LLP, located at 1221 Avenue of the Americas, New York, New York 10020 on the date
hereof (the “Closing Date”). The Closing shall be deemed to occur and be effective as of 12:01 a.m. on the
Closing Date.

 

(b)          At
the Closing, Seller shall deliver or cause to be delivered to Purchaser the following instruments and documents, in each case,
in form and substance reasonably acceptable to Purchaser:

 

(i)          a
receipt for payment of the Purchase Price at Closing;

 

    	 	-12-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         a
certificate of an authorized officer of Seller as to the resolutions adopted by the members, board of managers or similar governing
body of Seller relating to the transactions contemplated hereby;

 

(iii)        executed
copies of the Required Third Party Consents;

 

(iv)        assignments
of Assumed Contracts duly executed by the Seller;

 

(v)         Bill
of Sale and all other Ancillary Agreements, duly executed by an authorized officer of the Seller;

 

(vi)        copies
of the Purchased Documents, provided that the Purchased Documents may be delivered in accordance with Section 6.4(c);

 

(vii)       a
calculation of Seller's good faith estimate of the Kowa Royalty that would be payable by Seller under the terms of the AG Agreement,
with respect to the portion of the 2016 calendar year occurring prior to the Closing Date (the "2016 Seller Royalty"),
together with documentation supporting such calculation, all in form and substance reasonably acceptable to Purchaser (the "Closing
Royalty Report");

 

(viii)      the
[***] Amendment, duly executed by [***] and the Seller; and

 

(ix)         any
federal, state, local or foreign Tax forms, certificates, instruments or other documents reasonably requested by Purchaser or otherwise
required to be provided by Seller in connection with the consummation of the transactions contemplated by this Agreement.

 

(c)          At
the Closing, Purchaser shall deliver or cause to be delivered to Seller, the following: (x) the Purchase Price, as and to the extent
provided in Section 2.5(a)(i)(B), and (y) the following instruments and documents, in each case, in form and substance reasonably
acceptable to Seller:

 

(i)          assignments
of Assumed Contracts duly executed by Purchaser;

 

(ii)         the
Bill of Sale and other Ancillary Agreements and all other instruments appropriate to evidence Purchaser’s assumption of the
Assumed Liabilities, duly executed by an authorized officer of the Purchaser; and

 

(iii)        certificate
of an authorized officer of Purchaser as to the resolutions adopted by the Boards of Directors of Purchaser relating to the transactions
contemplated hereby.

 

    	 	-13-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ARTICLE
IV

REPRESENTATIONS AND WARRANTIES OF SELLER

 

Except as set forth in
the section of the disclosure schedules attached hereto that relates to such Section of this Agreement (the “Seller Disclosure
Schedules”), the Seller hereby make the representations and warranties contained in this Article IV to Purchaser.

 

Section
4.1     Organization. Seller is (i) a limited liability
company duly organized, validly existing and in good standing under the Laws of Florida and (ii) is duly qualified or licensed
to do business and is in good standing in each jurisdiction in which such qualification or licensing is necessary under applicable
Laws or where the Exploitation of the Products requires such qualification, except where the failure to be so qualified would
not reasonably be expected to be material to the Business, Purchased Assets or the Products, taken as a whole. Seller has no Subsidiaries.

 

Section
4.2      Authority; Binding Effect     (a)   Seller
has all requisite limited liability company power and authority to execute and deliver this Agreement and the Ancillary Agreements
and to consummate the transactions contemplated hereby and thereby and perform its obligations hereunder. The execution, delivery
and performance by Seller of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated
hereby and thereby have been duly authorized by all necessary limited liability action on behalf of Seller.

 

(b)          This
Agreement and each Ancillary Agreement has been duly executed and delivered by Seller and, assuming
the valid execution and delivery by Purchaser, constitutes a valid and binding obligation of Seller, in each case enforceable against
Seller in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent
conveyance, moratorium or similar laws affecting creditors’ rights generally or by general principles of equity (regardless
of whether enforcement is sought in a proceeding in equity or law) (the “Bankruptcy and Equity Exception”).

 

Section
4.3    No Conflicts; Consents. The execution, delivery and performance of this Agreement and
the Ancillary Agreements by Seller and the consummation of the transactions contemplated hereby and thereby do not and will not
(i) violate any provision of the organizational documents of Seller; (ii) subject to obtaining the consents referred to in Schedule
4.3 of the Seller Disclosure Schedules, conflict with, or result in the breach of, constitute a default under, result in the
termination, cancellation or acceleration (whether after the giving of notice or the lapse of time or both) of any right or obligation
of Seller under, or to a loss of any benefit to which Seller is entitled under, any Assumed Contract; and (iii) assuming compliance
with the matters set forth in Sections 4.4 and 5.5, violate or result in a breach of or constitute a default under
any Law or other restriction of any Governmental Authority to which Seller is subject; except, with respect to clauses (ii)
and (iii), for any violations, breaches, conflicts, defaults, terminations, cancellations or accelerations as would
not reasonably be expected to be material to the Business, Purchased Assets or the Products.

 

    	 	-14-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
4.4    Governmental Authorization. The execution and delivery of this Agreement and the Ancillary
Agreements by Seller do not require any consent or approval of any Governmental Authority, except for the consents or approvals
set forth in Schedule 4.4 of the Seller Disclosure Schedules.

 

Section
4.5     Absence of Material Changes. Except as otherwise
contemplated or permitted by this Agreement, from December 15, 2015 to the date of this Agreement:

 

(a)          there
has not been any material adverse effect with respect to the Business, Purchased Assets or the Products, taken as a whole; and

 

(b)          other
than with respect to the transactions contemplated by this Agreement and the exploration of strategic alternatives for the Purchased
Assets by Seller, Seller operated the Purchased Assets, in all material respects, in the ordinary course of business.

 

Section
4.6     No Litigation. No Proceeding by or before any
Governmental Authority is pending against or, to the Knowledge of Seller, threatened in writing against Seller with respect to
the Purchased Assets that would reasonably be expected to be material to the Business, the Purchased Assets and the Products,
taken as a whole, or that in any manner challenges or seeks to prevent, enjoin, alter or materially delay the transactions contemplated
by this Agreement or the Ancillary Agreements. None of Seller or any of the Purchased Assets are subject to any Governmental Order
or arbitration award that is material to the Purchased Assets, taken as a whole, or that imposes any material limitation on the
ability of Purchaser to operate the Business as currently conducted.

 

Section
4.7     Compliance with Laws.

 

(a)          Since
March 1, 2014, except as would not reasonably be expected to be material to the Business, the Purchased Assets or the Products,
Seller has operated the Business in material compliance with all Laws applicable to the Purchased Assets, including the FDA Act;
and

 

(b)          Seller
directly or indirectly through its contractual arrangements, possesses all Governmental Authorizations necessary for the ongoing
operation of the Business and the Purchased Assets as currently conducted; and

 

(c)          since
March 1, 2014, no Governmental Authority has notified Seller in writing that Seller (with respect to the Product, the Purchased
Assets or the operation of the Business) is in violation of any applicable Law.

 

Section
4.8     Product Registrations; Regulatory Compliance.

 

(a)          Schedule
4.8(a) of the Seller Disclosure Schedules sets forth, a list of all Product Registrations with respect to any of the Products
in the Territory, which constitute all material registrations, applications, approvals, licenses or permits granted by any Governmental
Authority.

 

    	 	-15-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          All
of the Products sold under the Product Registrations are, and at all times since March 1, 2014, have been marketed in accordance
with applicable Laws, except where the failure to comply therewith would not reasonably be expected to be material to the Business,
the Purchased Assets and the Product, taken as a whole.

 

(c)          Seller
is the licensee of the Product Registrations, free and clear of any Liens, other than Permitted Encumbrances.

 

(d)          To
Seller’s Knowledge: (i) the Product Registrations are in full force and effect, (ii) all product fees, establishment
fees and other fees invoiced by or payable to any Governmental Authority with respect to any of the Product Registrations for the
annual period commencing October 1, 2015, have been paid (other than any branded prescription drug fees) and (iii) there
are no Proceedings pending (or to the Seller's knowledge, threatened) which could result in the revocation, cancellation or suspension
of any of the Product Registrations.

 

(e)          No
right of reference has been granted by Seller or to Seller’s Knowledge, the respective owners of the Product Registration
to any Person with respect to any of Product Registrations.

 

(f)          To
the Knowledge of Seller, there are no pending requirements to conduct any Phase IV or other clinical studies with respect
to any Product in the United States for any approved indication.

 

(g)          Neither
Seller nor to Seller’s Knowledge any of Seller’s contractors has (nor, to the Knowledge of Seller, has any other Person)
at any time since March 1, 2014: (i) received or been subject to a warning letter, untitled letter, Form FDA 483, or any other
similar Governmental Authority notice or action relating to any Product; (ii) been subject to any Governmental Authority detention,
seizure, injunction, consent decree, notice of criminal investigation, indictment, sentencing memorandum, plea agreement, court
order, target or no-target letter, or other investigation relating to any Product; or (iii) initiated or been subject to any product
recall, market withdrawal, stock replacement or post-sale warning relating to any Product.

 

Section
4.9     Intellectual Property.

 

(a)          Schedule
4.9(a)(i) – (iii) of the Seller Disclosure Schedules set forth a true and correct list of all (i) Patent Rights, (ii)
applications and registrations for Trademarks, and (iii) applications and registrations for Copyrights, in each case to the extent
owned by Seller and used solely in connection with the Exploitation of Products (“Owned Intellectual Property”).

 

(b)          With
respect to the Intellectual Property:

 

(i)          there
is no action or proceeding pending, nor any notice of any objection or claim (other than objections or claims that have been previously
resolved) asserted against Seller in writing or, to the Knowledge of Seller, threatened by any Person, with respect to or challenging,
the ownership, validity or enforceability of any Owned Intellectual Property (or, to the Knowledge of Seller, any Intellectual
Property licensed to Seller pursuant to an Assumed Contract (“Licensed Intellectual Property”));

 

    	 	-16-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         the
Owned Intellectual Property and the rights of Seller to any Licensed Intellectual Property are free and clear of any Liens, other
than Permitted Encumbrances; and

 

(iii)        none
of the Owned Intellectual Property (nor, to the Knowledge of Seller, the rights of Seller to any Licensed Intellectual Property)
is the subject of (A) any pending (or, to the Knowledge of Seller, threatened) material adverse claim, judgment, injunction, order,
decree or agreement restricting (1) its use in connection with any Product or (2) assignment thereof by Seller as contemplated
hereunder, or (B) any other pending (or, to the Knowledge of Seller, threatened) material litigation or claim of infringement.

 

(c)          Except
for the rights and assets set forth on Schedule 4.9(c) of the Seller Disclosure Schedules, the (i) Owned Intellectual
Property, (ii) the rights of Seller to Licensed Intellectual Property under the Assumed Contracts and (iii) any Intellectual Property
with respect to the Seller or Product identifiers, names or marks, collectively, include all of the Intellectual Property used
by Seller to Exploit the Products as of the date of this Agreement in all material respects.

 

(d)          To
the Knowledge of Seller, the Exploitation of Seller’s Products in the manner in which such Products are Exploited as of the
date hereof, does not infringe, misappropriate or otherwise violate any Intellectual Property or proprietary right of any Person.

 

(e)          Seller
has not granted any license, option or other rights with respect to any of its Owned Intellectual Property or, solely with respect
to Seller’s Products, any rights of Seller to any Licensed Intellectual Property to any other Person, in each case to the
extent such license, option or other rights is material to the Exploitation of the Products.

 

Section
4.10   Assets.

 

(a)          Seller
owns or has the legal right to use all of its Purchased Assets. Seller has good and marketable title to all its Purchased Assets,
free of Liens, except for Permitted Encumbrances.

 

(b)          Except
for the rights and assets set forth on Schedule 4.10 of the Seller Disclosure Schedules, the Purchased Assets constitute
all of the assets and rights of Seller used or held for use by Seller in the Exploitation of the Products.

 

Section
4.11   Taxes.

 

(a)          Seller
has duly and timely filed, including extensions (or caused to be filed) with the appropriate Taxing Authorities all Tax Returns
relating to its Purchased Assets required to be filed. No claim has ever been made in writing by a Taxing Authority in any jurisdiction
where Seller does not file Tax Returns that Seller is or may be subject to taxation by that jurisdiction as a result of its operation,
ownership or use of Purchased Assets.

 

    	 	-17-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          Seller
has paid (or caused to be paid) all Taxes relating to its Purchased Assets due and payable (whether or not shown on any Tax Return)
on or prior to the Closing Date. Seller has withheld or collected (or caused to be withheld or collected) all Taxes relating to
its Purchased Assets required to be withheld or collected.

 

(c)          There
are no Liens for Taxes nor is any Taxing Authority in the process of imposing any Lien on any of Seller’s Purchased Assets,
other than for Permitted Encumbrances set forth in clause (ii) of such definition. There exists no claimed or proposed assessment,
deficiency or other adjustment for Taxes against Seller which, if not satisfied or resolved, would result in a Lien on the Purchased
Assets or in liability of Purchaser or its Affiliates as a transferee of or successor to Seller’s Purchased Assets.

 

(d)          Seller
has not waived any statute of limitations, agreed to any extension of time, or entered into any written agreement in respect of
Taxes the nonpayment or underpayment of which would result in a Lien on its Purchased Assets that would survive the Closing Date
or in Liability of Purchaser or its Affiliates as a transferee of or successor to such Purchased Assets.

 

Section
4.12   Contracts.

 

(a)          Schedule 2.1(a)
of the Seller Disclosure Schedules sets forth, as of the date of this Agreement, a true, correct and complete list of all of the
Assumed Contracts (including all amendments or modifications thereto), to which Seller is a party or by which any of its Purchased
Assets are bound.

 

(b)          Seller
has delivered to Purchaser true, complete and correct copies of all Assumed Contracts including any and all amendments, supplements
or modifications thereto, or detailed descriptions of any oral Assumed Contracts, to which it is a party. Each such Assumed Contract
is a legal, valid and binding obligation enforceable against Seller and, to the Knowledge of Seller, the other party thereto, and
is in full force and effect, subject to the Bankruptcy and Equity Exception. Neither Seller nor, to the Knowledge of Seller, any
other party thereto (i) is in breach or violation of, or default under, or has delivered a notice of termination of, any such
Assumed Contract and no event has occurred that, with the giving of notice or lapse of time or both, would constitute a breach
or default of any such Assumed Contract, (ii) has delivered a written notice to terminate or to cancel any such Assumed Contract.
Except for the Assumed Contracts, Seller is not a party to or bound by any Contract that is presently used or held for use with
respect to the Business or the Purchased Assets or that is material to the operation of the Business as currently conducted.

 

Section
4.13   Brokers. Except for [***], whose fees shall be paid at
Closing by the Seller, no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

    	 	-18-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ARTICLE
V

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Except as set forth
in the section of the disclosure schedules attached hereto that relates to such Section of this Agreement (the “Purchaser
Disclosure Schedules”), Purchaser hereby represents and warrants to each Seller as follows:

 

Section
5.1    Organization and Qualification. Purchaser is
a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to conduct its business as it is presently being conducted and to own and lease its properties
and assets.

 

Section
5.2    Corporate Authorization. No vote of holders
of capital stock of Purchaser or any of its Affiliates is necessary to approve this Agreement or the transactions contemplated
by this Agreement.  Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and each
Ancillary Agreement to which it will be a party, and to perform its obligations hereunder and thereunder. The execution, delivery
and performance by Purchaser of this Agreement and each such Ancillary Agreement, and the performance by Purchaser of its obligations
hereunder and thereunder, have been duly authorized by all requisite or other legal entity action on the part of Purchaser.

 

Section
5.3    Binding Effect. This Agreement and each Ancillary
Agreement has been duly executed and delivered by Purchaser and constitutes a valid and binding obligation of Purchaser, enforceable
against Purchaser in accordance with its terms subject to the Bankruptcy and Equity Exception.

 

Section
5.4    No Conflict; Consents. The execution, delivery and performance by Purchaser of this Agreement,
and the consummation of the transactions contemplated hereby, do not and will not (i) violate any provision of the certificate
of incorporation, bylaws or other organizational documents of Purchaser; (ii) result in a breach of, or default under, or right
to accelerate with respect to, any term or provision of any Contract to which Purchaser or any of its Affiliates is a party or
is subject; (iii) assuming compliance with the matters set forth in Sections 4.4 and 5.5, violate or result in a
breach of or constitute a default under any Law or other restriction of any Governmental Authority to which Purchaser is subject;
or (iv) require any consents, waivers, authorizations or approvals of, filings with, any Persons which have not been obtained
by Purchaser (other than as contemplated by Section 5.5).

 

Section
5.5    Governmental Authorization. The execution and
delivery of this Agreement by Purchaser do not and will not require any material consent or approval of or any filing with any
Governmental Authority, except for the consents, approvals or filings set forth in Schedule 5.5 of the Purchaser Disclosure Schedules.

 

    	 	-19-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
5.6     Compliance with Laws.

 

(a)          The
businesses of each of Purchaser and its Subsidiaries are being conducted in compliance in all material respects with applicable
Laws. No material audit or, to the knowledge of Purchaser, investigation, or review by any Governmental Authority with respect
to Purchaser or any of its Subsidiaries is pending or, to the knowledge of Purchaser, threatened, nor has any Governmental Authority
indicated an intention to conduct the same.

 

(b)          Purchaser
and each of its Subsidiaries has obtained and is in compliance with all Licenses necessary for it to own, lease or operate its
properties, rights and other assets and to conduct its business and operations as presently conducted in all material respects
and all such Licenses are in full force and effect in all material respects. No material default under, or material violation of,
any material License has occurred. To Purchaser’s knowledge there is not currently threatened any revocation, adverse modification
or cancellation of any material License.

 

Section
5.7    Litigation. There is no material action, order,
writ, injunction, judgment or decree outstanding, or Proceeding, labor dispute (other than routine grievance procedures or routine,
uncontested claims for benefits under any benefit plans for any officers, employees or agents of Purchaser), arbitration, investigation
or reported claim, pending or, to the knowledge of Purchaser, threatened, before any court, Governmental Authority or arbitrator,
which seeks to delay or prevent the consummation of the transactions contemplated by this Agreement or would, if successful, materially
and adversely affect the Business or the Purchased Assets or ability of Purchaser to consummate the transactions contemplated
by this Agreement.

 

ARTICLE
VI

COVENANTS

 

Section
6.1    Insurance. From and after the Closing Date
through the end of the Transition Period, Seller shall maintain all of its insurance policies as in effect on the date hereof.
The coverage under all such Seller’s insurance policies, including as they may relate to the Purchased Assets, shall continue
in force only for the benefit of Seller and not for the benefit of Purchaser or any of its Affiliates. Purchaser agrees to arrange
for its own insurance policies with respect to the Purchased Assets covering all periods and agrees not to seek, through any means,
to benefit from any of Seller’s insurance policies that may provide coverage for claims relating in any way to the Purchased
Assets prior to the Closing.

 

Section
6.2     Filings.

 

Promptly after the Closing
and in any event within thirty (30) calendar days after the Closing, Sellers and Purchaser shall make all appropriate filings and
submissions with Governmental Authorities, including the Centers for Medicare & Medicaid Services (“CMS”)
and the FDA to the extent, if any, required to transfer all regulatory responsibilities of Seller for each Product, excluding all
Retained Liabilities and except as contemplated hereby, from Seller to Purchaser. All such filings and submissions shall be in
form and substance reasonably acceptable to Seller and Purchaser.

 

    	 	-20-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.3     Confidentiality. From and after the Closing:

 

(a)          The
Confidentiality Agreement will terminate without further action by the parties thereto.

 

(b)          Seller
shall treat as confidential, shall not use and shall safeguard any and all information, knowledge and data included in the Purchased
Assets by using the same degree of care, but no less than a reasonable standard of care, to prevent the unauthorized use, dissemination
or disclosure of such information, knowledge and data as Seller or its Affiliates used with respect thereto prior to the execution
of this Agreement.

 

(c)          Purchaser
shall treat as confidential and shall safeguard any and all information, knowledge or data included in any information relating
to the business of Seller, other than the Products, the Purchased Assets or the Assumed Liabilities, and except as otherwise agreed
to by Seller in writing; provided, however, that nothing in this Section 6.3(c) shall prevent the disclosure
of any such information, knowledge or data to any agents, advisors, directors, officers or employees of Purchaser to whom such
disclosure is necessary or desirable in the conduct of Purchaser’s business if such Persons are informed by Purchaser of
the confidential nature of such information and are directed by Purchaser to comply with the provisions of this Section 6.3(c).

 

(d)          Purchaser
and Seller acknowledge that the confidentiality obligations set forth herein shall not extend to information, knowledge and data
that is publicly available or becomes publicly available through no act or omission of the Party owing a duty of confidentiality,
or becomes available on a non-confidential basis from a source other than a party owing a duty of confidentiality so long as such
source is not reasonably known by such Party to be bound by a confidentiality agreement with or other obligations of secrecy to
the other Party.

 

(e)          In
the event of a breach of the obligations hereunder by Purchaser or Seller, the non-breaching party, in addition to all other available
remedies, will be entitled to injunctive relief to enforce the provisions of this Section 6.3 in any court of competent
jurisdiction.

 

Section
6.4     Procedures; Transition of Business; Inventory.

 

(a)          From
and after the Closing, Purchaser agrees that it will not take any action (i) with the intent to encourage, through the offering
of incentives or changes in the return, rebate or chargeback policies or practices of the Business or otherwise (other than in
the ordinary course of business consistent with the past practice of the Business prior to Closing), customers to return any Product
shipped by Seller or any of its Affiliates prior to the end of the Transition Period, or to initiate any chargeback, rebate or
similar request in respect of such Product, except as required by applicable Law, or (ii) that would reasonably be expected to
adversely affect Seller’s obligations to make rebate payments to, or entitlements to refunds for overpayments from (including
in each case the amount thereof), CMS for Products shipped prior to the end of the Transition Period.

 

    	 	-21-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          Promptly
after the Closing Date, the Parties shall notify all customers of the Business in writing, in a form agreed by the Parties prior
to the date hereof, (i) of the transfer of the Purchased Assets to Purchaser including related transitional matters and (ii) that
all purchase orders for the Products received by the Seller prior to the Closing Date but not filled as of such date will be filled
in the ordinary course provided that Seller and Purchaser shall cooperate with each other to ensure that such purchase orders as
well as any additional purchase orders received between the Closing Date and the end of the Transition Period are filled in accordance
with the provisions of Sections 6.4(e) and 6.4(k). All purchase orders for the Product received by Seller after the
end of the Transition Period shall be forwarded by Seller to Purchaser or Purchaser’s distributor at the address to be provided
by Purchaser prior to the end of the Transition Period and will be fulfilled by or on behalf of Purchaser.

 

(c)          On
or as promptly as reasonably practicable after the Closing Date, Seller shall (i) transfer (or implement arrangements reasonably
satisfactory to Purchaser for the transfer and delivery of physical possession of) all tangible assets included in the Purchased
Assets to the Purchaser or its designated representatives, and (ii) upon reasonable request of the Purchaser, notify all of its
agents that hold files or other tangible material included in the Purchased Assets that, effective as of the Closing, the Purchaser
owns such Purchased Assets, with directions to transfer such Purchased Assets to Purchaser in accordance with the Purchaser’s
reasonable instructions. Purchaser shall pay for any costs or expenses associated with the delivery of the Purchased Assets to
Purchaser or any of its designees. Notwithstanding the foregoing, to the extent the following are included in the Purchased Assets
and are not delivered at the Closing, Seller shall deliver and cause its Subsidiaries to deliver all of the Purchased Documents
(in electronic and non-electronic form) to Purchaser no later than 60 calendar days after the Closing Date; provided that Seller
shall only have an obligation to deliver such books, records and files that, to Seller’s Knowledge, are in the possession
or control of Seller.

 

(d)          Following
the Closing, the parties agree to use commercially reasonable efforts to transition the Business to the Purchaser. In this regard,
Seller shall remove its Products from the DailyMed website as soon as reasonably practicable following the expiration of the last
to expire lot of Products sold under Seller’s NDC Number.

 

(e)          Immediately
following the Closing and until the earlier of (x) April 30, 2016 and (y) the date specified in a written notice from Purchaser
to Seller that it will be able to commence commercial sales of the Products using its own NDC Number (the period from the Closing
Date until the earlier of (x) and (y), the “Transition Period”), Seller shall act as a distributor
for Purchaser, and direct each of its distributors to:

 

(i)          continue
to sell the Inventories bearing Seller’s NDC Numbers, and Seller’s existing packaging materials and to otherwise operate
under the applicable Excluded Contracts, in each case in the ordinary course of business until the earlier of the expiration of
the Transition Period or the exhaustion of all Inventories on-hand with Seller or its contractors (it being acknowledged that the
Seller undertakes no obligation to acquire additional Inventories and such sales by Seller may be on terms and prices determined
by Seller in its discretion); and

 

    	 	-22-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         continue
to (1) process purchase orders and ship Inventories, (2) process returns of Inventories, (3) process rebates and chargebacks
relating to Inventories, each in the ordinary course of business and (4) delivery a copy of any ordinary course reports provided
to Seller regarding the foregoing to Seller and Purchaser.

 

Notwithstanding the
foregoing, in the event Purchaser has not received a supply of finished goods of one or more Products by the scheduled termination
of the Transition Period, it shall have the unilateral right, in its sole discretion, to extend the Transition Period by thirty
(30) calendar days, which period shall be deemed to be part of the "Transition Period" for purposes of this Agreement.
Promptly following the end of the Transition Period, Seller shall follow the reasonable directions of the Purchaser with respect
to the destruction or return to Purchaser of any remaining Inventory on hand with Seller.

 

(f)          From
and after the Closing Date, Seller shall remit to Purchaser or instruct its distributors to remit to Purchaser, as applicable,
in accordance with the wire instructions provided to Seller prior to the date hereof and no later than thirty (30) days following
the end of each calendar month, a fee equal to the amount per unit of Inventory sold set forth on Schedule 6.4(f), which
shall be used by the Purchaser to pay the Kowa Royalty. The balance of any proceeds from the sale of Inventory during the Transition
Period shall be retained by Seller in consideration of the services rendered by it to Purchaser under this Section 6.4.
Seller shall not terminate the Excluded Contracts with its distributors with respect to the Products with an effective date prior
to the end of the Transition Period (as such may be extended in accordance with the terms hereof).

 

(g)          No
later than five (5) Business Days following the last day of the Transition Period, Seller shall provide Purchaser with an inventory
report from each of its top three distributors setting forth the Inventory of each Product on hand as of the last day of the Transition
Period (together, the "Transition Period Report"). No later than five (5) Business Days after Purchaser's receipt
of the complete Transition Period Report, Purchaser shall deliver to Seller its calculation of the "Additional Payment,"
which shall be calculated as [***] and paid in accordance with Section 2.5(a)(ii) above.

 

(h)          Seller
shall pay the Pre-Closing Royalty as and when due pursuant to the terms of the AG Agreement.

 

(i)          From
and after the Closing Date, Seller shall timely provide Purchaser with sales reports and such other information relating to Products
bearing Seller's NDC Number as may be necessary to permit Purchaser to pay the Kowa Royalty in accordance with the terms thereof.
In furtherance thereof, the Parties agree as follows:

 

(i)          On
April 1, 2016, Seller shall deliver to Purchaser its estimation of the Kowa Royalty payable for the calendar quarter ended March
31, 2016, which shall be consistent in form and substance with the reports Seller shall have historically provided to Kowa (the
"Q1 Estimated Report"). Purchaser shall review and forward the Q1 Estimated Report to Kowa in a timely manner.

 

    	 	-23-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         On
May 15, 2016, Seller shall deliver to Purchaser its calculation of the actual Kowa Royalty for the calendar quarter ended March
31, 2016 based on sales of the Products during the Transition Period, which shall be provided together with documentation evidencing
actual chargebacks, returns, Medicaid rebates and all other payments in respect of programs sponsored by applicable Governmental
Authorities in the Territory during the period from January 1, 2016 (to the extent not previously taken into consideration in calculating
any Kowa Royalty payment) through May 15, 2016, which shall be consistent in form and substance with the reports Seller shall have
historically provided to Kowa (the "Q1 Final Report"). Purchaser shall review and forward the Q1 Final Report
to Kowa in a timely manner. The amount of all chargebacks, returns, Medicaid rebates and all other payments in respect of programs
sponsored by applicable Governmental Authorities in the Territory set forth in the Q1 Final Report shall be allocated between the
Parties, based on the sales of the Product that occurred on or after January 1, 2016 and prior to the Closing Date, which shall
be for the Seller's account and the sales of the Product on or after the Closing Date, which shall be for the Buyer's account.
If as a result of such allocation the amount of the 2016 Seller Royalty was (A) less than the amount of the Kowa Royalty that should
have been set forth in the Closing Royalty Report taking in to consideration such allocation, then Seller shall promptly remit
such difference to Purchaser or (B) greater than the amount of the Kowa Royalty that should have been set forth in the Closing
Royalty Report taking in to consideration such allocation, then Purchaser shall promptly remit such difference to Seller. In addition,
following such allocation, if the Kowa Royalty resulting from the actual amount of Net Sales (calculated pursuant to the AG Agreement)
(less the sales attributable to the period prior to Closing) set forth in the Q1 Final Report is (x) greater than the sum of the
payments made by Seller to Purchaser in respect of such calendar quarter pursuant to Section 6.4(f) above, then Seller shall
promptly remit such amount to Purchaser or (y) less than the sum of the payments made by Seller to Purchaser in respect of such
calendar quarter pursuant to Section 6.4(f) above, then Purchaser shall promptly remit such amount to Seller.

 

(iii)        On
July 1, 2016, Seller shall deliver to Purchaser its estimation of the Kowa Royalty payable for the calendar quarter ended June
30, 2016, which shall be consistent in form and substance with the reports Seller shall have historically provided to Kowa (the
"Q2 Estimated Report"). Purchaser shall review and forward the Q2 Estimated Report to Kowa in a timely manner.

 

(iv)        On
August 15, 2016, Seller shall deliver to Purchaser its calculation of the actual Kowa Royalty for the calendar quarter ended June
30, 2016 based on sales of the Products during the Transition Period, which shall be provided together with documentation evidencing
actual chargebacks, returns, Medicaid rebates and all other payments in respect of programs sponsored by applicable Governmental
Authorities in the Territory during the period from April 1, 2016 (to the extent not previously taken into consideration in calculating
any Kowa Royalty payment) through August 15, 2016, which shall be consistent in form and substance with the reports Seller shall
have historically provided to Kowa (the "Q2 Final Report"). Purchaser shall review and forward the Q2 Final Report
to Kowa in a timely manner. If the Kowa Royalty resulting from the actual amount of Net Sales (calculated pursuant to the AG Agreement)
set forth in the Q2 Final Report is (x) greater than the sum of the payments made by Seller to Purchaser in respect of such calendar
quarter pursuant to Section 6.4(f) above, then Seller shall promptly remit such amount to Purchaser or (y) less than the
sum of the payments made by Seller to Purchaser in respect of such calendar quarter pursuant to Section 6.4(f) above, then
Purchaser shall promptly remit such amount to Seller (Net Sales as so determined, the "Final Q2 Sales").

 

    	 	-24-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(v)         On
September 15, 2016, Seller shall deliver to Purchaser documentation evidencing actual chargebacks, returns, Medicaid rebates and
all other payments in respect of programs sponsored by applicable Governmental Authorities in the Territory during the period from
July 1, 2016 (to the extent not previously taken into consideration in calculating any Kowa Royalty payment) through September
15, 2016 (the "September Report"). Purchaser shall review the September Report and, if the Final Q2 Sales, adjusted
as reflected in the September Report were (x) greater than the Final Q2 Sales previously reported, then Seller shall promptly remit
such amount to Purchaser or (y) less than the Final Q2 Sales previously reported, then Purchaser shall promptly remit such amount
to Seller.

 

(j)          Purchaser
shall (i) use reasonable best efforts to obtain its own NDC Number and to enable itself to commence commercial sales of the Products
using its own NDC Number (including by causing to be manufactured Product bearing Purchaser’s NDC Number) as promptly as
practicable after Closing, (ii) promptly inform Seller in writing upon receipt of its NDC Number and (iii) reasonably cooperate,
and cause its Affiliates to reasonably cooperate, with Seller, in providing any information or assistance reasonably requested
by Seller in connection with this ‎Section 6.4(j), including any
information Purchaser possesses in respect of sales of Inventories as Seller may require to include in any regulatory filings to
be made in respect of the Products sold bearing a Seller’s NDC Number.

 

(k)          No
Seller or Affiliate of a Seller shall have any Liability to Purchaser or any of its Affiliates in connection with its provision
of services under this ‎Section 6.4, except to the extent caused
by a Seller’s fraud or intentional misconduct and except to the extent such Liability constitutes a Retained Liability. Notwithstanding
anything in this Agreement to the contrary, any purchase order for Product issued by a customer that is received by Seller prior
to the end of the Transition Period with a scheduled delivery date following the end of the Transition Period, including pursuant
to an Excluded Contract, shall be deemed to be a Purchased Asset hereunder, and all Liabilities arising under such purchase order
shall be deemed to be Assumed Liabilities hereunder; provided, in each case, that Purchaser has received a copy of any such purchase
order no later than five (5) calendar days after Seller's receipt thereof.

 

Section
6.5    Use of Seller NDC Number. For a period not to
exceed three (3) months following the end of the Transition Period, Purchaser shall have the right, exercisable by delivering written
notice to Seller no less than five (5) Business Days prior to the expiration of the Transition Period, to utilize Seller's NDC
Number and the name "H2-Pharma, LLC", together with related trade dress, in connection with its sale of the Products
and Seller hereby grants to Purchaser a fully-paid up, non-exclusive, royalty-free, transferable license with respect thereto.
In the event Purchaser exercises its right under this Section 6.5, the Parties agree to negotiate in good faith the appropriate
terms regarding their respective indemnity obligations with respect to such Products, including in connection with chargebacks,
returns, rebates and product liability claims in order to allocate the responsibility therefore to Purchaser.

 

    	 	-25-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.6     Post-Closing Cooperation.

 

(a)          Following
the Closing, each Party will afford the other Party, its counsel and its accountants, during normal business hours, reasonable
access to the books, records and other data relating to the Business in its possession with respect to periods prior to the Closing
and any period commencing before and ending after the Closing and the right to make copies and extracts therefrom, to the extent
that such access may be reasonably required by the requesting party in connection with (i) the preparation of Tax returns, (ii)
the determination or enforcement of rights and obligations under this Agreement or any of the Ancillary Agreements, (iii) compliance
with the requirements of any Governmental Authority, or (iv) in connection with any actual or threatened action or Proceeding.
Further each Party agrees for a period extending six (6) years after the Closing Date not to destroy or otherwise dispose of any
such books, records and other data unless such Party shall first offer in writing to surrender such books, records and other data
to the other Party and such other Party shall not agree in writing to take possession thereof and pay the cost of shipping during
the forty-five (45) day period after such offer is made.

 

(b)          If,
in order properly to prepare its Tax returns, other documents or reports required to be filed with Governmental Authorities or
its financial statements or to fulfill its obligations hereunder, it is necessary that a Party be furnished with additional information,
documents or records relating to the Business not referred to in paragraph (a) above, and such information, documents or records
are in the possession or control of the other Party, such other Party shall use its commercially reasonable efforts to furnish
or make available such information, documents or records (or copies thereof) at the recipient’s request, cost and expense.
Any information obtained by such Party in accordance with this paragraph shall be held confidential by such Party.

 

(c)          Notwithstanding
anything to the contrary contained in this Section 6.6, if the parties are in an adversarial relationship in litigation
or arbitration, the furnishing of information, documents or records in accordance with this Section 6.6 shall not operate
as a waiver to any otherwise applicable rules relating to discovery in such proceeding.

 

Section
6.7     Correspondence. Seller authorizes Purchaser
on and after the Closing Date to receive and open all mail and other communications received by Purchaser relating to the Purchased
Assets and to deal with the contents of such communications in good faith and in a proper manner. Seller shall use commercially
reasonable efforts to promptly deliver, or cause to be delivered, to Purchaser any mail or other communications received by Seller
from any Person (including the FDA) related to the Purchased Assets (including any mail or other communications in respect of
the Products, the subject matter of this Agreement and the Ancillary Agreements).

 

    	 	-26-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ARTICLE
VII

NON-COMPETE

 

For a period of three
(3) years from Closing Date, Seller shall not, directly or indirectly through any Subsidiary, market or sell, or license to any
other party the right to market or sell, the Products, or any “AB-rated” generic thereof, in the Territory (a “Competing
Business”); provided that, notwithstanding the foregoing, Seller shall not be restricted from:

 

(a)          collectively
owning less than five percent (5%) of any class of securities of any publicly traded company conducting a Competing Business if
such securities are held as a passive investment; or

 

(b)          acquiring
one or more Persons or businesses that include within its business a Competing Business, so long as (1) the Competing Business
comprises no more than 25% of the acquired business and (2) Seller completes the sale of the Competing Business within six months
of the acquisition; provided, however, that if such sale is subject to regulatory approval, then such six-month period shall be
extended until five Business Days after all regulatory approvals have been received, but only to the extent that the parties to
such sale are using commercially reasonable efforts to obtain any such approvals.

 

ARTICLE
VIII

INDEMNIFICATION

 

Section
8.1     Indemnification by Seller. Subject to the provisions of this Article VIII,
from and after the Closing, the Seller agrees to defend, indemnify and hold harmless Purchaser and its Affiliates, and, if applicable,
their respective directors, officers, agents, employees, successors and assigns (collectively, the “Purchaser Indemnified
Parties”) from and against any Losses to the extent arising out of or related to:

 

(a)          any
breach of any representation or warranty of Seller contained in this Agreement or any Ancillary Agreement;

 

(b)          any
failure of Seller to perform or any breach by Seller of any of its covenants or agreements contained in this Agreement or any Ancillary
Agreement; or

 

(c)          any
Retained Liability.

 

Section
8.2    Indemnification by Purchaser. Subject to the provisions of this Article VIII,
from and after the Closing Purchaser agrees to defend, indemnify and hold harmless Seller and its Affiliates, and, if applicable,
their respective directors, officers, agents, employees, successors and assigns (collectively, the “Seller Indemnified
Parties”) from and against any and all Losses to the extent arising out of or related to:

 

    	 	-27-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(a)          any
breach of any representation or warranty of Purchaser contained in this Agreement or any Ancillary Agreement;

 

(b)          any
failure to perform or breach by Purchaser of any of its covenants or agreements in this Agreement or any Ancillary Agreement; or

 

(c)          any
Assumed Liability, including those arising out of the Exploitation, development, manufacture, supply, marketing or distribution
of the Products following the Closing Date.

 

Section
8.3    Notice of Direct Claims.  
If any of the Persons to be indemnified under this Article VIII (the “Indemnified Party”) has suffered
or incurred any Loss subject to indemnification under this Article VIII that does not involve a Third Party Claim, the
Indemnified Party shall so notify the Party responsible for providing indemnification therefor under this Agreement (the “Indemnifying
Party”) promptly in a writing describing such Loss, the basis for indemnification hereunder, the amount or estimated
amount of such Loss, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable
particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred
(an “Indemnity Notice”). A failure by the Indemnified Party to give notice in a timely manner pursuant to this
Section 8.3 shall not limit the obligation of the Indemnifying Party under this Article VIII, except (i) to the
extent such Indemnifying Party is materially prejudiced thereby or (ii) as provided by Section 8.5. In the event that the
Indemnifying Party agrees to or is determined to have an obligation to reimburse the Indemnified Party for Losses as provided
in this Article VIII, the Indemnifying Party shall, subject to the provisions of Section 8.6, promptly (but, in
any event, within 30 calendar days) pay such amount to the Indemnified Party by wire transfer of immediately available funds to
the account specified in writing by the Indemnified Party. The Indemnifying Party may defer making such payment if it objects
in a written statement to the claim made in an Indemnity Notice and delivers such statement to the Indemnifying Party prior to
the expiration of such 30- calendar day period, provided that an Indemnifying Party’s failure to object within such 30-
calendar day period to any claim set forth in an Indemnity Notice shall not be deemed to be the Indemnifying Party’s acceptance
of, or waiver of any objections to, such claim. If an Indemnifying Party shall so object in writing to any claim or claims made
in any Indemnity Notice, the Indemnifying Party and the Indemnified Party shall attempt in good faith for a period of 20 calendar
days following the Indemnified Party’s receipt of such objection notice to agree upon the respective rights of the parties
with respect to each of such claims. If no such agreement can be reached after such 20- calendar day period of good faith negotiation,
either the Indemnifying Party or the Indemnified Party may initiate a Proceeding for purposes of having the matter settled in
accordance with the terms of this Agreement.

 

    	 	-28-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
8.4     Third Party Claims.

 

(a)          If
any Proceeding is instituted by or against a third party with respect to which the Indemnified Party intends to seek indemnity
under this Article VIII (a “Third Party Claim”), the Indemnified Party shall promptly notify the Indemnifying
Party of such Third Party Claim and tender to the Indemnifying Party the conduct or defense of such Third Party Claim. A failure
by the Indemnified Party to give notice and to tender the conduct or defense of the Third Party Claim in a timely manner pursuant
to this Section 8.4 shall not limit the obligation of the Indemnifying Party under this Article VIII, except (i)
to the extent such Indemnifying Party is materially prejudiced thereby or (ii) as provided by Section 8.5

 

(b)          The
Indemnifying Party shall have the right to defend the Indemnified Party against such Third Party Claim as provided herein. If the
Indemnifying Party notifies the Indemnified Party that the Indemnifying Party elects to assume the defense of the Third Party Claim
(such election to be without prejudice to the right of the Indemnifying Party to dispute whether such claim is an indemnifiable
Loss under this Article VIII), then the Indemnifying Party shall have the right to defend such Third Party Claim with
counsel selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party, in all appropriate proceedings,
to a final conclusion or settlement at the discretion of the Indemnifying Party in accordance with this Section 8.4(b),
provided, however, that the Indemnifying Party shall keep the Indemnified Party reasonably advised of the status
of such claim and defense thereof and shall consider in good faith recommendations made by the Indemnified Party with respect thereto.
The Indemnifying Party shall have full control of such defense and proceedings, including any compromise or settlement thereof;
however, neither Party shall enter into any settlement agreement without the written consent of the Indemnified Party (which consent
shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, such consent shall not be required
if (i) the settlement agreement contains a complete and unconditional general release by the third party asserting the Third Party
Claim to all Indemnified Parties affected by the claim and (ii) the settlement agreement does not contain any admission of liability
by or other obligation on the part of the Indemnified Party or sanction or restriction upon the conduct or operation of any business
by the Indemnified Party or its Affiliates. The Indemnified Party may participate in, but not control, any defense or settlement
of any Third Party Claim controlled by the Indemnifying Party pursuant to this Section 8.4(b), and the Indemnified
Party shall bear its own costs and expenses with respect to such participation provided, however, that if the Indemnifying
Party assumes control of the defense of such claim and the Indemnifying Party and the Indemnified Party have materially conflicting
interests or different defenses available with respect to such claim that cause the Indemnified Party to hire its own separate
counsel with respect to such proceeding, the reasonable fees and expenses of a single counsel to all Indemnified Parties shall
be considered “Losses” for purposes of this Agreement.

 

    	 	-29-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)          If
the Indemnifying Party does not notify the Indemnified Party that the Indemnifying Party elects to defend the Indemnified Party
pursuant to Section 8.4(b) within thirty (30) days after receipt of any Claim Notice, then the Indemnified Party shall
defend, and be reimbursed for its reasonable cost and expense (but only if the Indemnified Party is actually entitled to indemnification
hereunder) in regard to the Third Party Claim with counsel selected by the Indemnified Party, in all appropriate proceedings, which
proceedings shall be prosecuted diligently by the Indemnified Party. In such circumstances, the Indemnified Party shall defend
any such Third Party Claim in good faith and have full control of such defense and proceedings; provided, however,
that the Indemnified Party may not enter into any compromise or settlement of such Third Party Claim if indemnification is to be
sought hereunder, without the Indemnifying Party’s consent (which consent shall not be unreasonably withheld, conditioned
or delayed). The Indemnifying Party may participate in, but not control, any defense or settlement controlled by the Indemnified
Party pursuant to this Section 8.4(c), and the Indemnifying Party shall bear its own costs and expenses with respect
to such participation; provided, however, if at any time the Indemnifying Party acknowledges in writing that such
Third Party Claim is an indemnifiable Loss under this Article VIII, the Indemnifying Party shall be entitled to assume
the defense of such Third Party Claim in accordance with Section 8.4(b).

 

(d)          If
requested by the Party controlling the defense if a Third Party Claim, the other Party agrees to cooperate with the controlling
Party and its counsel in contesting any Third Party Claim being contested, including providing access to documents, records and
information; provided that all out-of-pocket costs reasonably incurred by it in connection with such cooperation shall be paid
by the controlling Party. In addition, the Party that is not controlling the defense will make its personnel available at no cost
to the Indemnifying Party for conferences, discovery, proceedings, hearings, trials or appeals as may be reasonably required by
the Indemnifying Party. The Party not controlling the defense also agrees to cooperate with the controlling Party and its counsel
in the making of any related counterclaim against the Person asserting the Third Party Claim or any cross complaint against any
Person and executing powers of attorney to the extent necessary.

 

Section
8.5    Expiration. Each Party’s obligation to indemnify any Indemnified Party under this
Article VIII shall expire and terminate on the following dates, unless a claim therefor is asserted in writing in accordance
with the terms of this Agreement prior to the applicable survival date, failing which such claim shall be waived and extinguished:
the date that is (i) thirty (30) days after the statute of limitations with respect to any claim for indemnification based on
a breach of Sections 4.1, 4.2, 4.7, 4.10(a), 4.11, 4.13, 5.1, 5.2 or 5.3
(“Fundamental Representations”) or (ii) twelve (12) months from the Closing Date, in the case of any other
claim for indemnification based on the representations or warranties of the other Party contained in this Agreement. In addition,
none of the covenants or agreements contained in this Agreement shall survive the Closing other than those that by their terms
expressly contemplate performance after the Closing Date and such surviving covenants and agreements shall survive the Closing
until fully performed.

 

Section
8.6     Limitations on Indemnification.

 

(a)          De
Minimis. Notwithstanding any other provision of this Agreement to the contrary, except for claims arising out a breach of a
Fundamental Representation, no Indemnifying Party shall be required to indemnify, defend or hold harmless any Indemnified Party
pursuant to Sections 8.1(a) or 8.2(a) against, or reimburse any Indemnified Party for, any Losses with respect to
any individual claims (or series of related claims) unless such claim (or series of claims) involves Losses in excess of $[***]
(nor shall such item be applied to or considered for purposes of calculating the Indemnity Threshold).

 

    	 	-30-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          Threshold.
Except for claims arising out a breach of a Fundamental Representation, no Indemnifying Party shall be liable with respect to claims
to provide indemnification pursuant to Sections 8.1(a) or 8.2(a) for any Losses suffered by any Indemnified Party
unless the aggregate of all Losses suffered by the Indemnified Parties under such claim exceeds, on a cumulative basis, an amount
equal to $[***] (the “Indemnity Threshold”), and then an Indemnifying Party shall be liable to provide indemnification
to the extent of all such Losses.

 

(c)          Cap.
Except for claims arising out a breach of a Fundamental Representation, in no event shall any Indemnified Party be liable to provide
indemnification pursuant to Article VIII for Losses in the aggregate in excess of an amount equal to [***] (the “Cap”),
other than with respect to claims for indemnification for Losses directly arising out of the breach of a Fundamental Representation,
fraud or intentional misconduct of an Indemnifying Party in respect of a provision of this Agreement, in which event such Indemnifying
Party shall not be liable for Losses in excess of an aggregate amount equal to (i) the portion of the Purchase Price actually received
by the Seller, in the case of an Indemnifying Party that is Seller and (ii) the Purchase Price, in the case of Purchaser.

 

(d)          Adjustment
to Purchase Price. Seller and Purchaser agree to treat all payments made either to or for the benefit of the other Party under
this Agreement as adjustments to the Purchase Price for Tax purposes to the extent permitted under applicable Tax Law.

 

Section
8.7    Reimbursement. If an Indemnified Party recovers an amount from a third party in respect
of a Loss that is the subject of indemnification hereunder after all or a portion of such Loss has been paid by an Indemnifying
Party pursuant to this Article VIII, the Indemnified Party shall promptly remit to the Indemnifying Party the amount received
from the third party in respect thereof, net of all costs associated with the recovery thereof.

 

Section
8.8    Subrogation. If the Indemnifying Party makes any payment on any claim pursuant to Section
8.1 or Section 8.2, the Indemnifying Party shall be subrogated, to the extent of such payment, to all rights and remedies
of the Indemnified Party to any insurance benefits or other claims of the Indemnified Party with respect to such claim. Without
limiting the generality or effect of any other provision hereof, each Indemnified Party shall duly execute upon request all instruments
reasonably necessary to evidence and perfect the subrogation rights detailed herein and otherwise cooperate in the prosecution
of such claims.

 

Section
8.9    Sole Remedy/Waiver. Should the Closing occur, the remedies provided for in this Article
VIII shall be the sole and exclusive remedies of any Indemnified Party in respect of this Agreement, the Ancillary Agreements,
the Purchased Assets, the Products, the Excluded Assets, the Assumed Liabilities, the Retained Liabilities or the transactions
contemplated hereby or by the Ancillary Agreements, other than (i) for actions for specific performance or other equitable remedies
or (ii) for claims against a Party directly arising out of the fraud or intentional misconduct of such Party in respect of a provision
of this Agreement. In furtherance of the foregoing, each Party hereby waives (on behalf of itself and the relevant Indemnified
Parties) any provision of applicable Law to the extent that it would limit or restrict the agreement contained in this Section
8.9, and each Party hereby waives (on behalf of itself and the relevant Indemnified Parties) for periods following the Closing
any and all other rights, claims or causes of action it or its Affiliates or relevant Indemnified Parties may have against the
other Party or its Affiliates or Representatives now or in the future arising under or based upon this Agreement, any Ancillary
Agreement, any document or certificate delivered in connection herewith. IN NO EVENT SHALL ANY PARTY HERETO BE LIABLE TO THE OTHER
FOR CONSEQUENTIAL, SPECIAL, INDIRECT OR PUNITIVE DAMAGES ARISING OUT OF ANY BREACH OF THE PROVISIONS OF THIS AGREEMENT OR ANY
ANCILLARY AGREEMENT, EXCEPT IN THE CASE OF FRAUD OR WILLFUL MISCONDUCT OR TO THE EXTENT PAYABLE TO A THIRD PARTY.

 

    	 	-31-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ARTICLE
IX

MISCELLANEOUS

 

Section
9.1     Notices.

 

(a)          All
notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall
be in writing and shall be deemed to have been given (a) when personally delivered, (b) when transmitted (except if not
a Business Day then the next Business Day) via (with transmission confirmed), (c) the day following the day (except
if not a Business Day then the next Business Day) on which the same has been delivered prepaid to a reputable national overnight
air courier service or (d) the third Business Day following the day on which the same is sent by certified or registered
mail, postage prepaid. Notices, demands and communications, in each case to the respective Parties, shall be sent to the applicable
address or facsimile number set forth below, unless another address or facsimile number has been previously specified in writing
by such Party:

 

To Seller:

 

H2-Pharma, LLC

2010 Berry Chase Place

Montgomery, AL 36117

Telephone: [Tel. number]

Facsimile: [Fax number]

Attn: President

 

to Purchaser:

 

ANI Pharmaceuticals, Inc.

510 Main Street West

Baudette, MN 56623

Telephone: [Tel. number]

Facsimile: [Fax number]

Attn: Arthur Przybyl

 

 

    	 	-32-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

with a copy to:

 

Dentons US LLP

1221 Avenue of the Americas

New York, NY 10020

Telephone: [Tel. number]

Facsimile: [Fax number]

Attn: Paul A. Gajer

 

(b)          This
Agreement and any signed agreement entered into in connection herewith or contemplated hereby, and any amendments hereto or thereto,
to the extent signed and delivered by means of a facsimile machine or scanned pages via electronic mail, shall be treated
in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were
the original signed version thereof delivered in person. No Party hereto or to any such contract shall raise the use of a facsimile
machine or email to deliver a signature or the fact that any signature or contract was transmitted or communicated through the
use of facsimile machine or email as a defense to the formation of a contract and each such Party forever waives any such defense.
This Agreement is not binding unless and until signature pages are executed and delivered by each of the Purchaser, Sellers and
the Seller Representative.

 

Section
9.2     Amendment; Waiver. Any provision of this Agreement
may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by Purchaser
and Sellers, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any Party
in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

 

Section
9.3     Assignment. No Party to this Agreement may
assign any of its rights or obligations under this Agreement without the prior written consent of the other Parties hereto; except
that no such consent shall be required in connection with (a) the sale of all or substantially all of the assets of the Purchaser
in one or a series of related transactions or (b) Purchaser's assignment of this Agreement to any Affiliate of the Purchaser,
provided that such assignment shall not relieve the Purchaser of any of its obligations hereunder.

 

Section
9.4     Entire Agreement. This Agreement (including
all Schedules and Exhibits hereto) and the Ancillary Agreements contain the entire agreement between the Parties hereto with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters.

 

Section
9.5     Parties in Interest. This Agreement shall inure to the benefit of and be binding
upon the Parties hereto and their respective successors and permitted assigns. Nothing in this Agreement, express or implied,
is intended to confer upon any Person other than Purchaser, Sellers, or their successors or permitted assigns, any rights or remedies
under or by reason of this Agreement, provided, that (i) the provisions of Article VIII shall inure to the benefit
of the Indemnified Parties and (ii) the provisions of Section 9.14(b) shall inure to the benefit of the Persons referenced
therein.

 

    	 	-33-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.6    Public Disclosure. Notwithstanding anything
herein to the contrary, each of the Parties to this Agreement hereby agrees with the other Parties hereto that, except as may
be required to comply with the requirements of any applicable Laws, and the rules and regulations of each stock exchange upon
which the securities of one of the Parties is listed, if any, no press release or similar public announcement or communication
shall be made or caused to be made concerning the execution or performance of this Agreement unless the Parties shall have consulted
in advance with respect thereto. The parties agree that except as set forth above, any press release shall be agreed upon prior
to its publication.

 

Section
9.7    Expenses; Transfer Taxes.
Except as otherwise expressly provided in this Agreement, whether or not the transactions contemplated by this Agreement are consummated,
all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by the
Party incurring such expenses. Notwithstanding the foregoing, all Transfer Taxes, if any, shall be shared equally by Seller and
Purchaser.

 

Section
9.8     Schedules. The disclosure of any matter in
any Schedule to this Agreement, as may be amended or supplemented prior to the Closing, shall be deemed to be a disclosure with
respect to any other section or subsection of this Agreement with respect to which its relevance is reasonably apparent on its
face for all purposes of this Agreement, but shall expressly not be deemed to constitute an admission by a Seller or Purchaser,
or to otherwise imply, that any such matter is material for the purposes of this Agreement.

 

Section
9.9      Governing Law; Jurisdiction.  

 

(a)          This
Agreement and its negotiation, execution, performance or non-performance, interpretation, termination, construction and all claims
or causes of action (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of, or relate to this
Agreement, or the transactions contemplated hereby (including any claim or cause of action based upon, arising out of or related
to any representation or warranty made in connection with this Agreement or as an inducement to enter this Agreement), shall be
exclusively governed by, and construed in accordance with, the laws of the State of Delaware regardless of Laws that might otherwise
govern under any applicable conflict of laws principles.

 

(b)          Any
Proceeding based upon, arising out of, or related to this Agreement and its negotiation, execution, performance, non-performance,
interpretation, termination, construction or the transactions contemplated hereby shall be heard and determined in the state or
federal courts located in Wilmington, Delaware. The Parties hereto hereby irrevocably submit to the exclusive jurisdiction and
venue of such courts in any such Proceeding and irrevocably and unconditionally waive the defense of an inconvenient forum, or
lack of jurisdiction to the maintenance of any such Proceeding. The consents to jurisdiction and venue set forth herein shall not
constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except as provided
in this Section 9.9 and shall not be deemed to confer rights on any Person other than the Parties hereto. Each Party hereto
agrees that the service of process upon such Party in any Proceeding arising out of or relating to this Agreement shall be effective
if notice is given by overnight courier at the address set forth in Section 9.1. Each of the Parties also agrees that any
final, non-appealable judgment against a Party in connection with any Proceeding arising out of or relating to this Agreement shall
be conclusive and binding on such Party and that such award or judgment may be enforced in any court of competent jurisdiction,
either within or outside of the United States. A certified or exemplified copy of such award or judgment shall be conclusive evidence
of the fact and amount of such award or judgment.

 

    	 	-34-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.10  WAIVER OF JURY TRIAL. TO THE FULLEST EXTENT PERMITTED
BY LAW, THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY
PROCEEDING (whether in contract, in tort, at law or otherwise) BASED UPON, ARISING OUT OF, OR RELATED TO THIS AGREEMENT
OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY
AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE PARTIES HERETO ACKNOWLEDGE
THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN
ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE PARTIES HERETO
FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE
MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS
TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTIONS CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION,
THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

 

Section
9.11   Counterparts. This Agreement may be executed in one or
more counterparts (including by facsimile or electronic .pdf submission), each of which shall be deemed an original, and all of
which shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by
each of the Parties and delivered (by telecopy or otherwise) to the other Party, it being understood that both Parties need not
sign the same counterpart.

 

Section
9.12  Headings. The heading references herein and the table
of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof.

 

Section
9.13  Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the
other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any circumstance,
is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out,
so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder
of this Agreement and the application of such provision to other Persons, entities or circumstances shall not be affected by such
invalidity, illegality or unenforceability, nor shall such invalidity, illegality or unenforceability affect the validity or enforceability
of such provision, or the application thereof, in any other jurisdiction.

 

    	 	-35-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.14  Specific Performance. Each of the Parties acknowledges that the rights of Purchaser under Article
VII of this Agreement are unique and recognizes and affirms that in the event of a breach thereof by Seller, money damages
may be inadequate and Purchaser may have no adequate remedy at Law. Accordingly, the Parties agree that Purchaser shall have the
right, in addition to any other rights and remedies existing in its favor at Law or in equity, to enforce its rights and the Seller's
obligations under Article VII not only by a Proceeding or Proceedings for damages but also by an Proceeding or Proceedings
for specific performance, injunctive and/or other equitable relief (without posting of bond or other security). Seller agrees
that it shall not oppose the granting of an injunction, specific performance and other equitable relief when expressly available
pursuant to the terms of this Agreement, and hereby waives (x) any defenses in any Proceeding for an injunction, specific
performance or other equitable relief, including the defense that the other Parties have an adequate remedy at Law or an award
of specific performance is not an appropriate remedy for any reason at Law or equity and (y) any requirement under Law to
post a bond, undertaking or other security as a prerequisite to obtaining equitable relief.

 

Section
9.15  Non-Recourse.

 

(a)          This
Agreement may only be enforced against, and any claim or cause of action based upon, arising out of or related to this Agreement
may only be brought against the entities that are expressly named as Parties hereto and then only with respect to the specific
obligations set forth herein with respect to such Party. Except to the extent a named Party to this Agreement (and then only to
the extent of the specific obligations undertaken by such named Party in this Agreement), no past, present or future director,
officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney or other Representative of any Party
hereto shall have any liability (whether in contract or in tort, in law or in equity, or based upon any theory that seeks to impose
liability of an entity party against its owners or Affiliates) for any obligations or liabilities of any Party hereto under this
Agreement or for any claim based on, in respect of, or by reason of, the transactions contemplated hereby or in respect of any
oral representations made or alleged to have been made in connection herewith

 

(b)          The
provisions of this Section 9.15 are intended to be for the benefit of, and enforceable by, the directors, officers, employees,
incorporators, members, partners, stockholders, Affiliates, agents, attorneys and other Representatives of the Parties hereto,
and each such Person shall be a third party beneficiary of this Section 9.15.

 

[Remainder of Page Intentionally Left
Blank]

 

    	 	-36-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

IN WITNESS WHEREOF,
the Parties have executed or caused this Agreement to be executed as of the date first written above.

 

	 	H2-PHARMA, LLC
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	ANI PHARMACEUTICALS, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]Exhibit 10.2

 

[EXECUTION VERSION]

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ASSET PURCHASE AGREEMENT

 

between

 

CRANFORD PHARMACEUTICALS, LLC,

 

and

 

ANI PHARMACEUTICALS, INC.

 

DATED AS OF MARCH 10, 2016

 

    	 	 	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	Article I DEFINITIONS AND TERMS	1
	 	 	 
	Section 1.1	Definitions	1
	 	 	 
	Section 1.2	Other Definitional and Interpretive Provisions	12
	 	 	 
	Article II PURCHASE AND SALE	13
	 	 	 
	Section 2.1	Purchase and Sale of Assets	13
	 	 	 
	Section 2.2	Consents	14
	 	 	 
	Section 2.3	Excluded Assets	14
	 	 	 
	Section 2.4	Assumption of Liabilities	15
	 	 	 
	Section 2.5	Retained Liabilities	16
	 	 	 
	Section 2.6	Purchase Price	17
	 	 	 
	Section 2.7	Purchase Price Adjustment	18
	 	 	 
	Section 2.8	Milestone Payments	20
	 	 	 
	Article III CLOSING	27
	 	 	 
	Section 3.1	Closing	27
	 	 	 
	Article IV REPRESENTATIONS AND WARRANTIES OF SELLER	29
	 	 	 
	Section 4.1	Organization	29
	 	 	 
	Section 4.2	Authority; Binding Effect	29
	 	 	 
	Section 4.3	No Conflicts; Consents	30
	 	 	 
	Section 4.4	Governmental Authorization	30
	 	 	 
	Section 4.5	Absence of Material Changes	30
	 	 	 
	Section 4.6	No Litigation	30
	 	 	 
	Section 4.7	Compliance with Laws	31
	 	 	 
	Section 4.8	Product Registrations; Regulatory Compliance.	31
	 	 	 
	Section 4.9	Intellectual Property	32
	 	 	 
	Section 4.10	Assets	33
	 	 	 
	Section 4.11	Taxes	33
	 	 	 
	Section 4.12	Contracts	34
	 	 	 
	Section 4.13	Financial Statements	36
	 	 	 
	Section 4.14	Suppliers and Customers	37

 

    	 	-i -	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS (cont’d)

 

	 	 	Page
	 	 	 
	Section 4.15	Brokers	37
	 	 	 
	Section 4.16	Inventories	37
	 	 	 
	Section 4.17	Ordinary Course	37
	 	 	 
	Section 4.18	Base Period AMP	38
	 	 	 
	Section 4.19	No Other Representations or Warranties	38
	 	 	 
	Article V REPRESENTATIONS AND WARRANTIES OF PURCHASER	38
	 	 	 
	Section 5.1	Organization and Qualification	39
	 	 	 
	Section 5.2	Corporate Authorization	39
	 	 	 
	Section 5.3	Binding Effect	39
	 	 	 
	Section 5.4	No Conflict; Consents	39
	 	 	 
	Section 5.5	Governmental Authorization	39
	 	 	 
	Section 5.6	Financing	39
	 	 	 
	Section 5.7	Compliance with Laws.	40
	 	 	 
	Section 5.8	Condition of the Purchased Assets	40
	 	 	 
	Section 5.9	Litigation	41
	 	 	 
	Section 5.10	Brokers	41
	 	 	 
	Section 5.11	Solvency	41
	 	 	 
	Article VI COVENANTS	42
	 	 	 
	Section 6.1	Information and Documents	42
	 	 	 
	Section 6.2	Conduct	42
	 	 	 
	Section 6.3	Member Approvals; Efforts to Consummate Generally	44
	 	 	 
	Section 6.4	Bulk Transfer Laws	45
	 	 	 
	Section 6.5	Insurance	45
	 	 	 
	Section 6.6	Trade Notification	45
	 	 	 
	Section 6.7	Seller-Labeled Products	45
	 	 	 
	Section 6.8	NDC Numbers	46
	 	 	 
	Section 6.9	No-Shop	47

 

    	 	-ii -	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS (cont’d)

 

	 	 	Page
	 	 	 
	Section 6.10	Transfer of Product Registrations, Related Applications and Dossiers	47
	 	 	 
	Section 6.11	Confidentiality	48
	 	 	 
	Section 6.12	Know-How License	49
	 	 	 
	Section 6.13	Correspondence	49
	 	 	 
	Section 6.14	Escrow Account	49
	 	 	 
	Section 6.15	Pharmacovigilance	49
	 	 	 
	Section 6.16	Warehousing Services	50
	 	 	 
	Section 6.17	Milestone Payments Covenants	50
	 	 	 
	Section 6.18	Certain Financial Information	50
	 	 	 
	Section 6.19	Wrong-Pocket Assets	51
	 	 	 
	Section 6.20	Consultation and Cooperation	51
	 	 	 
	Article VII NON-COMPETE	51
	 	 	 
	Section 7.1	Non-Compete	51
	 	 	 
	Article VIII CONDITIONS TO CLOSING	52
	 	 	 
	Section 8.1	Conditions to the Obligations of Purchaser and Seller	52
	 	 	 
	Section 8.2	Conditions to the Obligations of Purchaser	52
	 	 	 
	Section 8.3	Conditions to the Obligations of Seller	53
	 	 	 
	Section 8.4	Frustration of Closing Conditions	53
	 	 	 
	Article IX INDEMNIFICATION	54
	 	 	 
	Section 9.1	Indemnification by Seller	54
	 	 	 
	Section 9.2	Indemnification by Purchaser	54
	 	 	 
	Section 9.3	Notice of Direct Claims	55
	 	 	 
	Section 9.4	Third Party Claims	55
	 	 	 
	Section 9.5	Expiration	57
	 	 	 
	Section 9.6	Limitations on Indemnification and other Matters	57
	 	 	 
	Section 9.7	Losses Net of Insurance, Etc.	59
	 	 	 
	Section 9.8	Reimbursement	59

 

    	 	-iii -	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

TABLE OF CONTENTS (cont’d)

 

	 	 	Page
	 	 	 
	Section 9.9	Subrogation	59
	 	 	 
	Section 9.10	Sole Remedy/Waiver	59
	 	 	 
	Section 9.11	Milestone Payment Offset	60
	 	 	 
	Article X TERMINATION	61
	 	 	 
	Section 10.1	Termination	61
	 	 	 
	Section 10.2	Effect of Termination	61
	 	 	 
	Article XI MISCELLANEOUS	62
	 	 	 
	Section 11.1	Notices	62
	 	 	 
	Section 11.2	Amendment; Waiver	63
	 	 	 
	Section 11.3	Assignment	64
	 	 	 
	Section 11.4	Entire Agreement	64
	 	 	 
	Section 11.5	Parties in Interest	64
	 	 	 
	Section 11.6	Public Disclosure	64
	 	 	 
	Section 11.7	Return of Information	64
	 	 	 
	Section 11.8	Expenses, Transfer Taxes and Property Taxes	65
	 	 	 
	Section 11.9	Schedules	65
	 	 	 
	Section 11.10	Governing Law; Jurisdiction	65
	 	 	 
	Section 11.11	WAIVER OF JURY TRIAL	66
	 	 	 
	Section 11.12	Counterparts	66
	 	 	 
	Section 11.13	Headings	66
	 	 	 
	Section 11.14	Severability	67
	 	 	 
	Section 11.15	Specific Performance	67
	 	 	 
	Section 11.16	Non-Recourse	67
	 	 	 
	Section 11.17	Conflict of Interest	68

 

    	 	-iv -	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

EXHIBITS

 

	Exhibit A	Form of Services Agreement
	Exhibit B	Form of Trademark License-Back Agreement
	Exhibit C	Form of FDA Letter
	Exhibit D	Form of Bill of Sale 
	Exhibit E	Form of Escrow Agreement
	Exhibit F	Form of [***] Supply Agreement
	Exhibit G	Matters to be Addressed by the Side Letter

 

SCHEDULES OTHER THAN DISCLOSURE SCHEDULES

 

	1.1(a)(i)	Knowledge of Purchaser 
	1.1(a)(ii)	Knowledge of Seller
	1.1(b)	Permitted Encumbrances
	1.1(c)	Products
	1.1(d)	Certain Specified Purchased Documents
	1.1(e)	Required Third Party Consents
	2.1(a)	Assumed Contracts
	2.7(a)	Form of Closing Statement

 

    	 	-v -	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement
is made and entered into as of the 10th day of March 2016, by and between Cranford Pharmaceuticals, LLC, a Delaware
limited liability company (“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of
Delaware (“Purchaser”).

 

RECITALS

 

WHEREAS, Seller
holds the rights to manufacture, market, sell and distribute the Products in the Territory (the “Business”);
and

 

WHEREAS, Seller
desires to sell, transfer and assign to Purchaser, and Purchaser desires to acquire and assume from Seller, all of the Purchased
Assets and Assumed Liabilities, all as more specifically provided herein;

 

NOW, THEREFORE,
in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, hereby agree as follows:

 

Article
I

DEFINITIONS AND TERMS

 

Section
1.1           Definitions. As used in this Agreement, the
following terms shall have the meanings set forth or as referenced below:

 

“Acquisition
Proposal” shall have the meaning set forth in Section 6.9.

 

“Affiliate”
means with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with,
such Person at any time during the period for which the determination of affiliation is being made. Without limitation, Rouses
Point Pharmaceuticals, LLC and Akrimax Pharmaceuticals, LLC shall each be deemed for all purposes hereunder an Affiliate of Seller.
Solely for purposes of Section 6.11 and Section 7.1, Cranford Therapeutics LLC and its respective Affiliates shall
be deemed Affiliates of Seller.

 

“Agreement”
means this Asset Purchase Agreement.

 

“AMP”
means the average manufacturer price, as defined at 42 U.S.C. § 1396r-8(k)(1) and 42 C.F.R. § 447.500 et seq.

 

“Ancillary Agreements”
means, collectively, the Escrow Agreement, the Services Agreement, the Trademark License-Back Agreement, Bill of Sale, assignments
of Assumed Contracts, patent assignments, trademark assignments, assumption agreements or other instruments evidencing the assumption
by Purchaser of the Assumed Liabilities, and each other agreement, document, instrument and/or certificate contemplated by this
Agreement to be executed by Purchaser or Seller in connection with the transactions contemplated hereby.

 

    	 	-1-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Annual Gross
Profit Milestone” shall have the meaning set forth in Section 2.8(a)(i).

 

“Annual Milestone
Payment” shall have the meaning set forth in Section 2.8(a)(ii).

 

“Annual Milestone
Payment Statement” shall have the meaning set forth in Section 2.8(e)(i).

 

“Annual Period”
shall have the meaning set forth in Section 2.8(a)(i).

 

“[***]
Supply Agreement” shall have the meaning set forth in Section 3.1(b)(xiv).

 

“Assumed Contracts”
shall have the meaning set forth in Section 2.1(a).

 

“Assumed Liabilities”
shall have the meaning set forth in Section 2.4(a).

 

“Audited Financial
Statements” shall have the meaning set forth in Section 4.13(a).

 

“Bankruptcy
and Equity Exception” shall have the meaning set forth in Section 4.2(b).

 

“Bill of Sale”
means a bill of sale, dated as of the Closing Date, in the form set forth as Exhibit D hereto.

 

“Business”
shall have the meaning set forth in the Recitals.

 

“Business Day”
means any day other than a Saturday, a Sunday or a day on which commercial banks in New York City are authorized or obligated by
applicable law or executive order to close.

 

“Cap”
shall have the meaning set forth in Section 9.6(c).

 

“Challenged
Amount” shall have the meaning set forth in Section 2.7(e).

 

“Challenged
Amount(s)” shall have the meaning set forth in Section 2.8(f)(iv).

 

    	 	-2-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Change of Control”
means the occurrence of any of the following events prior to the end of the Milestone Payments Term: (a) any Person or group of
Persons within the meaning of §13(d)(3) of the Securities Exchange Act of 1934 becomes the beneficial owner, directly or indirectly,
of fifty percent (50%) or more of the outstanding equity interests of Purchaser (other than as part of an internal reorganization
of Purchaser where Persons who beneficially own more than 50% of the outstanding equity interests of the Purchaser immediately
prior to such reorganization continue to own more than 50% immediately thereafter), (b) the sale by Purchaser of all or substantially
all of its assets, including the Purchased Assets, or (c) a sale of any one of the Products without the express written consent
of Seller (it being acknowledged and agreed by the Parties that notwithstanding the terms of this clause (c), any sale of
both of the Products together to any one Person or related Persons in a single or related transactions shall not be deemed a Change
of Control for purposes hereof and shall be subject to the terms and conditions of Section 2.8(h)).

 

“Closing”
means the closing of the transactions contemplated by this Agreement pursuant to the terms of this Agreement.

 

“Closing Consideration”
means the total amount of cash and the fair market value of all other property paid (excluding any amounts paid into escrow and
all contingent or future payments) to the Purchaser or its Affiliates in connection with any Sale Transaction at the closing thereof,
net of (i) income taxes actually paid or payable by or on behalf of Purchaser or its Affiliates in connection with the receipt
of such consideration and (ii) reasonable transaction costs associated with such Sale Transaction, including brokers’ fees.
For purposes of determining the fair market value of any non-cash consideration, such determination shall be made on the Business
Day preceding the closing of the relevant Sale Transaction, except that if any part of the aggregate consideration consists of
marketable securities, for purposes of determining the amount of the aggregate consideration, the value of those securities shall
be determined by using the average of the last sale prices for those securities on the three (3) trading days ending on the last
Business Day preceding the closing of the relevant transaction.

 

“Closing Date”
shall have the meaning set forth in Section 3.1(a).

 

“Closing Date
Inventory Value” means the aggregate value of all the Inventories of the Products owned by Seller (including finished
goods to the extent used or held for use by or for the benefit of Seller for the operation of the Business, as currently conducted)
as at 23:59 New York time on the Business Day immediately preceding the Closing Date, determined on the basis of Seller’s
cost basis in such Inventories; provided, however, that the cost basis of any Inventories that are damaged, defective
or otherwise not saleable in the ordinary course of business on customary terms shall be excluded from the calculation of Closing
Date Inventory Value.

 

“Closing Purchase
Price” shall have the meaning set forth in Section 2.6(a).

 

“Code”
means the Internal Revenue Code of 1986, as amended, from time to time.

 

“Collateral
Source” shall have the meaning set forth in Section 9.7.

 

"Competing Business"
shall have the meaning set forth in Section 7.1.

 

    	 	-3-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Confidential
Information” shall have the meaning set forth in the Confidentiality Agreement.

 

“Confidentiality
Agreement” means the Confidentiality Agreement between Akrimax Pharmaceuticals, LLC and Purchaser, dated June 30, 2015,
as amended or supplemented from time to time.

 

“Contingent
Consideration” means any additional amount of cash and the fair market value of all other property paid (including any
amounts paid into escrow and all contingent or future payments) to the Purchaser or its Affiliates in connection with any Sale
Transaction after the closing thereof above and beyond the Closing Consideration paid in connection therewith, net of (i) income
taxes actually paid or payable by or on behalf of Purchaser or its Affiliates in connection with the receipt of such consideration
and (ii) reasonable transaction costs associated with such Sale Transaction, including brokers’ fees For purposes of determining
the fair market value of any non-cash consideration, such determination shall be made on the Business Day preceding the payment
of such non-cash consideration, except that if any part of the aggregate consideration consists of marketable securities, for purposes
of determining the amount of the aggregate consideration, the value of those securities shall be determined by using the average
of the last sale prices for those securities on the three (3) trading days ending on the last Business Day preceding the payment
of such non-cash consideration.

 

“Contract”
means any binding contract, agreement, lease, license or commitment.

 

“Copyrights”
shall have the meaning set forth in the definition for Intellectual Property.

 

"Covered Proceeds"
shall have the meaning set forth in Section 2.1(h).

 

[***] shall have the
meaning set forth in Section 6.16.

 

“Dentons”
shall have the meaning set forth in Section 11.17(b).

 

“Distribution
Activities” shall have the meaning set forth in Section 6.8(d).

 

“Escrow Agent”
means the Person mutually selected by Seller and Purchaser to serve as escrow agent under the Escrow Agreement.

 

“Escrow Agreement”
means an escrow agreement, in the form attached hereto as Exhibit E.

 

“Excluded Assets”
shall have the meaning set forth in Section 2.3.

 

“Exploitation”
(including, with correlative meanings, the terms “Exploit” and “Exploited”) means developing,
commercializing, manufacturing, labeling, packaging, marketing, promoting, selling, distributing and/or transporting.

 

    	 	-4-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Excess Amount”
shall have the meaning set forth in Section 9.11(a).

 

“FDA Act”
means the Food, Drug and Cosmetics Act of 1938, as amended, supplemented or replaced.

 

“Final Inventory
Value” shall have the meaning set forth in Section 2.7(d).

 

“Final Judgment”
shall have the meaning set forth in Section 9.11(b).

 

“Financial Statements”
shall have the meaning set forth in Section 4.13(b).

 

“First Annual
Period” shall have the meaning set forth in Section 2.8(a)(i).

 

“First Minimum
Milestone Payment” shall have the meaning set forth in Section 2.8(b)(i).

 

“Fundamental
Representations” shall have the meaning set forth in Section 9.5.

 

“GAAP”
means United States generally accepted accounting principles, consistently applied.

 

“Governmental
Authority” means any supranational, national, federal, state or local or foreign judicial, legislative, executive or
regulatory authority.

 

“Governmental
Authorizations” means all licenses, permits, certificates and other authorizations and approvals pertaining to the Products
under the applicable Laws of any Governmental Authority.

 

“Governmental
Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.

 

“Gross Profit”
means the amount equal to [***].

 

“Indemnity Notice”
shall have the meaning set forth in Section 9.3(a).

 

“Indemnified
Party” shall have the meaning set forth in Section 9.3(a).

 

“Indemnifying
Party” shall have the meaning set forth in Section 9.3(a).

 

“Indemnity Threshold”
shall have the meaning set forth in Section 9.6(b).

 

“Independent
Accountant” shall have the meaning set forth in Section 2.6(c).

 

    	 	-5-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Intellectual
Property” means any and all worldwide rights in, arising from or associated with the following, whether protected, created
or arising under the Laws of the United States or any other jurisdiction or under any international convention: (1) all patents
and applications therefor and all reissues, divisions, re-examinations, renewals, extensions, provisionals, substitutions, continuations
and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries including,
without limitation, invention disclosures (“Patent Rights”); (2) all trade secrets and other proprietary information
which derives independent economic value from not being generally known to the public (collectively, “Trade Secrets”);
(3) all copyrights, copyrights registrations and applications therefor (“Copyrights”); (4) all uniform resource
locators, e-mail and other internet addresses and domain names and applications and registrations therefor (“URLs”);
(5) all trade names, corporate names, logos, slogans, trade dress, trademarks, service marks, and trademark and service mark registrations
and applications therefor and all goodwill associated therewith (“Trademarks”) and (6) any similar, corresponding
or equivalent rights to any of the foregoing anywhere in the world.

 

“Inventories”
means all inventory of finished goods Products owned by Seller on the Closing Date.

 

“Inventory Excess
Amount” shall have the meaning set forth in Section 2.7(g)(ii).

 

“Inventory Shortfall
Amount” shall have the meaning set forth in Section 2.7(g)(i).

 

“Knowledge of
Purchaser” means the actual knowledge any of the individuals listed on Schedule 1.1(a)(i) has or would have following
reasonable inquiry into the subject matter in the ordinary course of performing each of their respective duties.

 

“Knowledge of
Seller” means the actual knowledge any of the individuals listed on Schedule 1.1(a)(ii) has or would have following
reasonable inquiry into the subject matter in the ordinary course of performing each of their respective duties.

 

“Laws”
means any federal, state, foreign or local law, common law, statute, ordinance, rule, regulation, code or Governmental Order.

 

“Liabilities”
means any and all Losses, debts, liabilities and obligations, whether accrued or unaccrued, fixed, known or unknown, absolute or
contingent, matured or unmatured or determined or determinable, including all costs and expenses relating thereto.

 

“Licensed Intellectual
Property” shall have the meaning set forth in Section 4.9(b)(i).

 

“Licensed Know-How”
shall have the meaning set forth in Section 6.12.

 

“Liens”
means any lien, security interest, mortgage, pledge, assessment, hypothecation, easement, title retention clause, title defect,
right of first refusal, charge or similar encumbrance.

 

    	 	-6-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Loss”
or “Losses” means any liabilities, losses, damages, fines or penalties that are suffered or sustained, or that
have required an outlay or payment of cash or other non-cash consideration, whether resulting from a judgment, a settlement or
an award, including those arising out of any Proceeding, Law or Contract, including the Taxes, costs and expenses (including reasonable
fees and expenses of counsel, consultants, experts, and other professional fees) associated therewith.

 

“Lowenstein”
shall have the meaning set forth in Section 11.17(a).

 

“Material Adverse
Effect” means any event, fact, condition, occurrence, change or effect that is or would reasonably be expected to be
materially adverse to the Exploitation of the Products or the Purchased Assets, taken as a whole; provided, however,
that none of the following shall be deemed, either alone or in combination, to constitute a Material Adverse Effect, or be taken
into account in determining whether there has or will be a Material Adverse Effect: (a) changes in political or economic conditions
(including changes in interest or exchange rates) in any country in which Purchased Assets are located or in which the Business
operates, or in the securities, syndicated loan, credit or financial markets of any such country; (b) changes in general market
conditions affecting the Exploitation of the Products in general or within the United States; (c) changes in GAAP; (d) changes
or effects that arise out of or are attributable to the acts or omissions of, or circumstances affecting, Purchaser and/or its
Affiliates; (e) changes or effects that generally affect the markets in which the Products are Exploited; (f) changes or effects
that arise out of or are attributable to the commencement, occurrence, continuation or intensification or reduction or cessation
of any war (whether or not declared), sabotage, armed hostilities or acts of terrorism; (g) changes or effects that arise out of
or are attributable to earthquakes, hurricanes or other natural disasters, epidemics or other outbreaks of disease; (h) changes
or effects that relate to any failure by Seller to meet internal projections or forecasts for any period (including with respect
to the Purchased Assets or Products), or that arise out of or are attributable to market conditions with respect to the Products,
including the availability of generic alternatives or alternative therapies and treatments or the availability of Patent Rights;
and (i) any action taken by Seller as required by this Agreement or with Purchaser’s consent, except, in the case of clauses
(a), (b), (c), (e) and (f), for those changes or effects that have a disproportionate impact
on the Exploitation of the Products relative to other comparable pharmaceutical products.

 

“Maximum Milestone
Payment Amount” shall have the meaning set forth in Section 2.8(a)(ii).

 

“Milestone Overpayment”
shall have the meaning set forth in Section 2.8(e)(iii).

 

"Milestone Payments"
means any or all of the Annual Milestone Payments and/or Quarterly Milestone Payments.

 

“Milestone Payments
Escrow Fund” shall have the meaning set forth in Section 2.8(j).

 

“Milestone Payments
Term” shall have the meaning set forth in Section 2.8(a)(ii).

 

    	 	-7-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“NDC Number”
means the unique 10-digit, 3-segment number assigned by the U.S. Food & Drug Administration to each human drug processed for
commercial distribution, which number is published in the NDC Directory pursuant to Section 510 of the FDA Act.

 

“Net Sales”
means the gross amount received by Purchaser or an Affiliate or Subsidiary of Purchaser, as applicable, for sales of the Products
(other than applicable, sales, use or VAT Taxes), less the following deductions taken by the Purchaser or an Affiliate
or Subsidiary of Purchaser, as applicable, with respect to such sales in accordance with GAAP:

 

		(i)	[***];

 

		(ii)	[***];

 

		(iii)	[***]; and

 

		(iv)	[***].

 

Notwithstanding the foregoing,
sales of Products for patient assistance programs, research or development or complimentary samples shall not be deemed “sales”
for purposes of calculating Net Sales.

 

"Non-Compete
Period" has the meaning set forth in Section 7.1.

 

“NonFAMP Eligible
Transactions” means those transactions relating to a Product that are used to calculate the Non-Federal Average Manufacturer
Price as defined by Veteran’s Health Care Act of 1992.

 

“Objection Notice”
shall have the meaning set forth in Section 2.7(c).

 

“Offset”
shall have the meaning set forth in Section 9.11(a).

 

“Offset Amount”
shall have the meaning set forth in Section 9.11(a).

 

“Offset Notification”
shall have the meaning set forth in Section 9.11(b).

 

"Outside Date"
shall have the meaning set forth in Section 10.1(b).

 

“Owned Intellectual
Property” shall have the meaning set forth in Section 4.9(a).

 

“Partial Acceleration
Milestone Payment” shall have the meaning set forth in Section 2.8(h).

 

“Party”
means each of Purchaser and Seller.

 

“Patent Rights”
shall have the meaning set forth in the definition for Intellectual Property.

 

    	 	-8-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Permitted Encumbrances”
means (i) statutory Liens arising by operation of Law with respect to a Liability incurred in the ordinary course of business and
which is not delinquent; (ii) Liens for Taxes not yet subject to penalties for nonpayment or that are being contested in good faith
by appropriate proceedings; (iii) mechanics’, materialmens’, carriers’, workmens’, warehousemens’,
repairmens’, landlords’ or other like Liens and security obligations that are not delinquent; (iv) Liens set forth
on Schedule 1.1(b) hereto, all of which will be released and, as appropriate, removed of record, at or prior to the Closing
Date in accordance with the terms of this Agreement; and (v) Liens arising under this Agreement.

 

“Person”
means an individual, a limited liability company, joint venture, a corporation, a partnership, an association, a trust, a division
or operating group of any of the foregoing or any other entity or organization.

 

“[***] Supply
Agreement” shall have the meaning set forth in Section 3.1(b)(xiii).

 

“Post-Closing
Tax Period” means any Tax period (or portion thereof) beginning after the Closing Date.

 

“Pre-Closing
Tax Period” means any Tax period (or portion thereof) ending on or before the Closing Date.

 

“Proceeding”
means any claim, action, arbitration, mediation, hearing, proceeding, suit, warning letter, or notice of violation.

 

“Product Registrations”
means all Governmental Authorizations (including NDAs, ANDAs and INDs) and comparable regulatory filings granted to Seller or any
Affiliate thereof by, or applications therefor in the name of Seller or any Affiliate thereof that are pending with, any Governmental
Authority (including applications that are in the process of being prepared by Seller or any Affiliate thereof) required to manufacture,
commercialize, develop, package, label, store, use, market, import, export, distribute and/or sell any of the Products.

 

“Products”
means the products listed on Schedule 1.1(c) hereto.

 

“Property Taxes”
shall have the meaning set forth in Section 11.8(b).

 

“Purchased Assets”
shall have the meaning set forth in Section 2.1, it being understood that the Purchased Assets do not include the Excluded
Assets.

 

“Purchased Documents”
means originals, or if originals are unavailable, copies of all books, records, files and papers, whether in hard copy or computer
format, to the extent related to the Products or Product Registrations (including with respect to research and development, medical
safety or regulatory affairs), including (i) all documents, if any, relating to the calculation of baseline AMP (but excluding
any proprietary methodology documents created by Seller or any of its Affiliates with respect to the calculation of baseline AMP),
(ii) an electronic version of each Product’s Medical Information Inquiry Database and the documents set forth in Schedule
1.1(d), (iii) any and all regulatory files (including correspondence with regulatory authorities) owned by or in the possession
or control of Seller or any Affiliate thereof to the extent relating to the Purchased Assets or the operation of the Business (including
safety and adverse event data) and (iv) copies of all books, records, files and papers, whether in hard copy or computer format,
to the extent related to NonFAMP Eligible Transactions from the third fiscal quarter of 2012 through the Closing Date.

 

    	 	-9-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Purchase Price”
shall have the meaning set forth in Section 2.6(a).

 

“Purchaser”
has the meaning set forth in the preamble of this Agreement.

 

“Purchaser Disclosure
Schedules” shall have the meaning set forth in Article V.

 

“Purchaser Indemnified
Parties” shall have the meaning set forth in Section 9.1.

 

“Quarterly
Milestone Payment” shall have the meaning set forth in Section 2.8(c)(i)Section 2.8(a)(ii).

 

“Quarterly Reports”
shall have the meaning set forth in Section 2.8(d).

 

“Representatives”
means, with respect to any Person, the directors, managers, employees, independent contractors, agents or consultants of such Person.

 

“Required Third
Party Consents” means the consents and approvals set forth on Schedule 1.1(e).

 

“Retained Liabilities”
shall have the meaning set forth in Section 2.5.

 

"Sale Profit"
shall have the meaning set forth in Section 2.8(h).

 

“Sale Transaction”
shall have the meaning set forth in Section 2.8(h).

 

“Second Annual
Period” shall have the meaning set forth in Section 2.8(b)(ii).

 

“Second Minimum
Milestone Payment” shall have the meaning set forth in Section 2.8(b)(ii).

 

“Seller”
shall have the meaning set forth in the preamble of this Agreement.

 

“Seller Company
Identifiers” shall have the meaning set forth in Section 6.7(a).

 

“Seller Disclosure
Schedules” shall have the meaning set forth in Article IV.

 

“Seller Indemnified
Parties” shall have the meaning set forth in Section 9.2.

 

“Services Agreement”
means a services agreement, dated as of the Closing Date, in the form set forth as Exhibit A hereto.

 

    	 	-10-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Side Letter”
shall have the meaning set forth in Section 3.1(b)(xiv).

 

“Solvent”,
when used with respect to any Person, means that, as of any date of determination, (a) the amount of the “fair saleable value”
of the assets of such Person on a going concern basis will, as of such date, exceed (i) the value of all “liabilities of
such Person, including contingent and other liabilities” as of such date, as such quoted terms are generally determined in
accordance with applicable United States federal laws governing determinations of the insolvency of debtors and (ii) the amount
that will be required to pay the probable liabilities of such Person on its existing debts (including contingent liabilities) as
such debts become absolute and matured, (b) such Person will not have, as of such date, an unreasonably small amount of capital
for the operation of the businesses in which it is engaged or proposed to be engaged following such date and (c) such Person will
be able to pay its liabilities, including contingent and other liabilities, as they mature. For purposes of this definition, each
of the phrases “not have an unreasonably small amount of capital for the operation of the businesses in which it is engaged
or proposed to be engaged” and “able to pay its liabilities, including contingent and other liabilities, as they mature”
means that such Person will be able to generate enough cash from operations, asset dispositions or refinancing, or a combination
thereof, to meet its obligations as they become due.

 

“Subsidiary”
or “Subsidiaries” means an entity as to which Seller or Purchaser or any other relevant entity, as the case
may be, owns directly or indirectly 50% or more of the voting power or other similar interests. Any Person which comes within this
definition as of the date of this Agreement but thereafter fails to meet such definition shall from and after such time not be
deemed to be a Subsidiary of Seller or Purchaser or any other relevant entity, as the case may be. Similarly, any Person which
does not come within such definition as of the date of this Agreement but which thereafter meets such definition shall, from and
after such time, be deemed to be a Subsidiary of Seller or Purchaser or any other relevant entity, as the case may be.

 

“Tax”
or “Taxes” means all taxes, levies or other assessments, including income, excise, property, sales or use, value
added, profits, license, withholding (with respect to compensation or otherwise), payroll, employment, net worth, capital gains,
transfer, stamp, social security, environmental, occupation and franchise taxes, imposed by any Taxing Authority, and including
any interest, penalties and additions attributable thereto.

 

“Tax Return”
or “Tax Returns” means any return, report, declaration, information return, statement or other document filed
or required to be filed with any Taxing Authority, in connection with the determination, assessment or collection of any Tax or
the administration of any Laws relating to any Tax.

 

“Taxing Authority”
means any Governmental Authority, body or instrumentality exercising any authority to impose, regulate or administer the imposition
of Taxes.

 

“Territory”
means the United States and its territories and possessions, including Puerto Rico and U.S. military bases abroad.

 

    	 	-11-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

“Third Party
Claim” shall have the meaning set forth in Section 9.4(a).

 

“Total Consideration”
means the total amount of Closing Consideration and Contingent Consideration in connection with any Sale Transaction.

 

“Trade Secrets”
shall have the meaning set forth in the definition for Intellectual Property.

 

“Trademarks”
shall have the meaning set forth in the definition for Intellectual Property.

 

“Trademark License-Back
Agreement” means a trademark license agreement, dated as of the Closing Date, in the form set forth as Exhibit B
hereto.

 

“Transfer Taxes”
means any federal, state, county, local, foreign and other sales, use, transfer, value added, conveyance, documentary transfer,
stamp, recording, registration or other similar Tax (including any notarial fee) imposed in connection with, or otherwise relating
to, the transactions contemplated by this Agreement or the recording of any sale, transfer or assignment of property (or any interest
therein) effected pursuant to this Agreement.

 

“Treasury Regulations”
means the regulations promulgated by the Treasury Department under the Code.

 

“Unaudited Financial
Statements” shall have the meaning set forth in Section 4.13(b).

 

“URLs”
shall have the meaning set forth in the definition for Intellectual Property.

 

“Withheld Milestone
Payments” shall have the meaning set forth in Section 9.11(a).

 

Section
1.2           Other Definitional and Interpretive Provisions.
(a) The words “hereof”, “herein”, “hereto” and “hereunder” and words of similar
import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

(b)          The
terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

 

(c)          The
terms “dollars” and “$” shall mean United States of America dollars.

 

(d)          The
term “including” (and with correlative meaning “include”) shall mean “including, without limitation.”

 

    	 	-12-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(e)          Reference
to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are permitted
by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity.

 

(f)          Reference
to any agreement (including this Agreement), document or instrument means such agreement, document or instrument as amended, modified
or supplemented and in effect from time to time in accordance with the terms thereof and, if applicable, the terms hereof.

 

(g)          When
a reference is made in this Agreement to an Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article
of, a Section of, an Exhibit to or a Schedule to, this Agreement unless otherwise indicated.

 

(h)          The
Parties acknowledge that: (i) this Agreement is the result of negotiations between the Parties and shall not be deemed or
construed as having been drafted by any one Party; (ii) each Party and its counsel have reviewed and negotiated the terms
and provisions of this Agreement (including any exhibits and disclosure schedules attached hereto) and have contributed to its
revision; (iii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall
not be employed in the interpretation of this Agreement; and (iv) the terms and provisions of this Agreement shall be construed
fairly as to all Parties and not in favor of or against any Party, regardless of which party was generally responsible for the
preparation of this Agreement.

 

Article
II

 

PURCHASE AND SALE

 

Section
2.1           Purchase and Sale of Assets. Upon the terms
and subject to the conditions set forth herein, at the Closing, Seller shall sell, convey, assign and transfer to Purchaser, and
Purchaser shall purchase, acquire and accept from Seller, free and clear of all Liens, other than Permitted Encumbrances, all of
Seller’s right, title and interest in, to and under those assets described in the following clauses (a) through (i) related
to Seller’s Products (collectively, the “Purchased Assets”):

 

(a)          all
the Contracts relating to the Products set forth on Schedule 2.1(a), including with respect to the Licensed Intellectual
Property (the “Assumed Contracts”);

 

(b)          all
of the Owned Intellectual Property;

 

(c)          all
Product Registrations;

 

(d)          all
customer lists for each Product and research data to the extent related to the Products and in the possession or control of Seller
or any Affiliate thereof;

 

(e)          all
Inventories;

 

    	 	-13-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(f)          all
the Purchased Documents; provided, however, that Seller shall have the right to retain one copy (subject to the confidentiality
provisions set forth in Section 6.11) of all or any portion of the Purchased Documents to comply with applicable Laws and
regulatory guidance;

 

(g)          all
refunds for Taxes relating to the Purchased Assets with respect to a Post-Closing Tax Period;

 

(h)          all
of Seller’s rights under warranties, guaranties, indemnities and similar rights against third parties, including any predecessors
in title, to the extent related to the Assumed Liabilities or the Exploitation of the Purchased Assets and the Products on or after
the Closing Date, including rights to proceeds under insurance policies in respect of damage or loss to the Purchased Assets which
have not been fully remediated as of the Closing (“Covered Proceeds”); and

 

(i)          all
of Seller’s claims, counterclaims, causes of action and all other rights of any kind against any third party in connection
with the Assumed Liabilities or related to the Exploitation of the Purchased Assets on or after the Closing Date.

 

Section
2.2           Consents. Purchaser acknowledges that certain
consents to the transactions contemplated by this Agreement (other than the Required Third Party Consents) may be required from
counterparties to Contracts and that such consents may not be obtained prior to Closing. Seller shall use its commercially reasonable
efforts (which shall not require Seller to pay any money or other consideration to any Person, to initiate any claim or proceeding
against any Person or to otherwise grant any accommodation (financial or otherwise) to any Person) (i) to obtain such approval
or consent and (ii) if such approval or consent cannot be obtained, to secure an arrangement reasonably satisfactory to Purchaser
ensuring that Purchaser will receive the benefits under the Purchased Asset for which such consent is being sought and Purchaser
will bear the burden of the Liabilities related to such Purchased Asset; provided, however, that notwithstanding
anything to the contrary herein or otherwise (A) Seller shall have no obligation to obtain such consent or approval or to provide
such an alternative arrangement other than the undertaking to use commercially reasonable efforts to obtain or provide the same
as set forth in this ‎Section 2.2, and (B) Purchaser shall indemnify Seller in respect of all Liabilities incurred by
Seller in respect of any such alternative arrangement and the underlying Purchased Asset. To the extent that, in connection with
obtaining a third party’s consent under any Assumed Contract, one or more of the parties hereto enter into an agreement with
such third party that provides for an allocation of Liability among the parties hereto with respect to such Assumed Contract that
is inconsistent with the terms of this Agreement, the parties agree that, as among themselves, the provisions of this Agreement
shall control.

 

Section
2.3           Excluded Assets. Nothing herein contained shall
be deemed to sell, transfer, assign or convey the Excluded Assets to Purchaser, and Seller shall retain all right, title and interest
to, in and under the Excluded Assets. “Excluded Assets” means all assets, properties, interests and rights of
Seller other than the Purchased Assets to be sold by Seller, including each of the following assets:

 

    	 	-14-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(a)           all
cash, cash equivalents, bank deposits or similar cash items and accounts receivable of Seller;

 

(b)           all
books and records of Seller other than the Purchased Documents; provided, however, that Purchaser shall have the
right to make copies of any portions of any such retained books and records to the extent related to any of the Purchased Assets;

 

(c)           all
rights of Seller to (i) the Seller Company Identifiers and (ii) any other Intellectual Property, other than Intellectual Property
included in the Purchased Assets;

 

(d)           all
insurance policies or rights to proceeds thereof relating to the Purchased Assets or the Products (except Covered Proceeds);

 

(e)           subject
to Section 2.1(i), all rights, claims or causes of action of Seller against third parties in connection with the Exploitation
of the Purchased Assets and the Products prior to the Closing Date;

 

(f)           all
Tax Returns and financial statements of Seller and all records (including working papers) related thereto;

 

(g)          all
refunds for Taxes relating to the Purchased Assets with respect to a Pre-Closing Tax Period;

 

(h)          all
of Seller’s rights in respect of real property, including leasehold interests;

 

(i)           the
membership interests in and other equity or ownership interests in Seller;

 

(j)           all
rights that accrue to Seller under this Agreement and the Ancillary Agreements; and

 

(k)           all
of Seller’s causes of action, claims, credits, demands or rights of set-off against third parties, to the extent related
to any Excluded Asset.

 

Section
2.4           Assumption of Liabilities.

 

(a)          Upon
the terms and subject to the conditions of this Agreement, Purchaser agrees, effective at the Closing, to assume and to satisfy
and discharge when due the Liabilities of Seller (other than the Retained Liabilities), specifically set forth below (all of such
Liabilities and other than the Retained Liabilities being herein collectively referred to as the “Assumed Liabilities”):

 

(i)          all
Liabilities arising from the Exploitation of any Products after the Closing Date, including Liabilities for returns, rebates and
chargebacks related to any of the Products shipped after the Closing Date;

 

    	 	-15-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         all
Liabilities for Taxes relating to the Purchased Assets or the Products with respect to a Post-Closing Tax Period, including those
allocated in accordance with Section 11.8(b);

 

(iii)        all
Liabilities for materials and services relating to the Purchased Assets contracted for in the ordinary course of business prior
to the Closing pursuant to an Assumed Contract, but scheduled to be delivered or provided thereafter, and all Liabilities to customers
under purchase orders for Products that have not yet been shipped at Closing, in each case to the extent not related to any breach
of Seller occurring prior to the Closing;

 

(iv)        all
Liabilities under Assumed Contracts (including Liabilities to customers under purchase orders made in the ordinary course of the
sale and marketing of the Products consistent with past practice for any Product that has not been shipped prior to the Closing)
relating to the period following the Closing Date, other than any Liabilities to the extent arising out of, or resulting from,
a breach of any such Assumed Contract by Seller prior to the Closing Date;

 

(v)         all
Liabilities arising out of or relating to any product liability, breach of warranty or similar claim for injury to any Person or
property that resulted from the use or misuse of the Products on or after the Closing Date or otherwise relates to the Products
sold (including any Proceeding relating to any such Liabilities) on or after the Closing Date, which, in the case of any split
lots of Product, shall be determined based on the percentage of any such lot sold on or after the Closing Date;

 

(vi)        all
other Liabilities relating to the Purchased Assets or the Products, or Purchaser’s use thereof, solely to the extent that
such are not Retained Liabilities, including to any Governmental Authority, and all fees arising from or related to any Product
Registrations and Intellectual Property included in the Purchased Assets, but only to the extent not related to or arising out
of any act, omission or event occurring prior to the Closing; and

 

(vii)       all
Liabilities for branded prescription drug fees allocable to the period on and after the Closing Date.

 

Section
2.5           Retained Liabilities. Notwithstanding any provision
in this Agreement, Seller shall retain and be responsible only for the following Liabilities (the “Retained Liabilities”):

 

(a)           all
Liabilities of Seller and/or any Affiliate of Seller other than Assumed Liabilities, including all Liabilities related to the Excluded
Assets;

 

(b)           all
Liabilities of Seller and/or any of its Affiliates under the Ancillary Agreements;

 

    	 	-16-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)           all
Liabilities of Seller and/or any of its Affiliates in respect of any Proceeding (whether class, individual or otherwise in nature,
in law or in equity) commenced or asserted prior to the Closing, or based on acts or omissions of Seller and/or any of its Affiliates
or their respective equityholders, officers, directors or managers occurring prior to the Closing, and arising out of or to the
extent relating to or otherwise in any way relating to the Purchased Assets or the Products, including, without limitation, any
Liability to any equityholder of Seller or any Affiliate of Seller and including all Liabilities arising out of or related to the
litigation described on Schedule 4.6 of the Seller Disclosure Schedules;

 

(d)           all
Liabilities of Seller to its suppliers for materials and services relating to the Products that were delivered or provided to Seller
prior to Closing;

 

(e)           all
Liabilities arising out of or relating to any product liability, breach of warranty or similar claim for injury to any Person or
property that resulted from the use or misuse of the Products prior to the Closing Date or otherwise relates to the Products sold
(including any Proceeding relating to any such Liabilities) prior to the Closing Date, which, in the case of any split lots of
Product, shall be determined based on the percentage of any such lot sold prior to the Closing Date;

 

(f)            any
Liability under Seller’s employee benefits or compensation arrangements;

 

(g)           all
Liabilities for branded prescription drug fees allocable to the period prior to the Closing Date;

 

(h)           all
Liabilities for Taxes relating to the Purchased Assets or the Products with respect to a Pre-Closing Tax Period, including those
allocated in accordance with Section 11.8(b); and

 

(i)            all
amounts required to be paid under and in connection with the termination of the [***] Supply Agreement.

 

Section
2.6           Purchase Price.

 

(a)           On
the terms and subject to the conditions set forth herein, in consideration of the sale and transfer of the Purchased Assets, at
the Closing, Purchaser shall (i) assume the Assumed Liabilities and (ii) pay an amount in cash equal to Sixty Million Dollars
($60,000,000) (the “Closing Purchase Price” and together with the aggregate amount of all Milestone Payments
to be made pursuant to, and in accordance with Section 2.8 hereof, the “Purchase Price”) to Seller in
immediately available funds by wire transfer to the account(s) specified in written instructions given by Seller to Purchaser not
less than two (2) Business Days prior to the Closing.

 

    	 	-17-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          To
the extent that Purchaser is required under any provision of Law to deduct and withhold Taxes on any payment hereunder, Purchaser
shall withhold and deduct from the Purchase Price such required amounts and such withheld amounts shall be treated for all purposes
of this Agreement as having been paid to the Persons in respect of which such deductions and withholdings were made; provided,
however, that Purchaser may deduct such amounts only if Purchaser shall (i) give Seller reasonable advance notice of
the intention to make such deduction or withholding; (ii) explain the basis for such deduction or withholding, and (iii) cooperate
with Seller to the extent reasonably requested to obtain any applicable reduction of or relief from such deduction or withholding;
provided, further, that, except as otherwise required by Law or applicable court order, Purchaser shall not withhold
any portion of the Purchase Price if Seller delivers a non-foreign affidavit under Section 1445 of the Code and the Treasury Regulations
promulgated thereunder.

 

(c)          The
allocation of the Purchase Price among the Purchased Assets and Assumed Liabilities shall be prepared by Purchaser within ninety
(90) days following the Closing. Purchaser shall deliver to Seller a copy of such proposed allocation promptly after Purchaser’s
determination of the proposed allocation, and Seller shall have the right to review and raise any objections in writing to the
proposed allocation during the fifteen (15) day period after Seller’s receipt thereof. If Seller does not notify Purchaser
in writing of a disagreement with the proposed allocation during such fifteen (15) day period, the proposed allocation shall become
final. If Seller disagrees with respect to any item in the allocation, the Parties shall negotiate in good faith to resolve the
dispute. If the Parties are unable to agree on the allocation within thirty (30) days after the commencement of such good faith
negotiations (or such longer period as Seller and Purchaser may mutually agree in writing), then the parties shall refer such dispute
to an independent internationally recognized accounting firm (“Independent Accountant”) at that time to review
the allocation, and make a determination as to the resolution of such allocation. The determination of the Independent Accountant
regarding the allocation shall be delivered as soon as practicable following engagement of the Independent Accountant, but in no
event more than sixty (60) days thereafter, and shall be final, conclusive and binding upon Seller and Purchaser, and Purchaser
shall revise the original proposed allocation accordingly. Seller, on the one hand, and Purchaser on the other hand, shall each
pay one-half of the cost of the Independent Accountant. The finalized allocation shall be binding on Seller and Purchaser for all
Tax reporting purposes and Seller and Purchaser agree to refrain from taking any position inconsistent therewith, unless required
by applicable Law or a final determination of a Taxing Authority.

 

Section
2.7           Purchase Price Adjustment.

 

(a)          On
the Closing Date, Seller shall deliver to Purchaser a statement (the “Closing Statement”) containing Seller’s
final calculation of the Closing Date Inventory Value and shall be accompanied with reasonably detailed documentation supporting
Seller’s calculation thereof. The Closing Statement will be in the form as set forth in Schedule 2.7(a).

 

    	 	-18-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          The
Purchaser will have a period of twenty (20) Business Days to review the Closing Statement and all calculations set forth therein.
Seller shall give Purchaser (upon reasonable advance notice and during normal business hours in a manner that does not materially
interfere with Seller’s business) reasonable access to the applicable personnel and books and records of Seller and its Affiliates
as reasonably requested by Purchaser, as well as use commercially reasonable efforts to cause [***] to provide Purchaser reasonable
access to the premises of [***] and the records kept by them of the Inventories, to reasonably enable Purchaser to fully review
the Closing Statement and such access shall be provided in a timely manner to allow Purchaser to complete such review in such twenty
(20) Business Day period.

 

(c)          
The Closing Statement shall be conclusive of the amount of the Closing Date Inventory Value and shall be final and binding upon
the Parties unless on or before the twentieth (20th) Business Day after the date on which the Closing Statement is delivered
to Purchaser, Purchaser delivers to Seller a notice of objection (an “Objection Notice”) to any matter stated
in the Closing Statement. Any Objection Notice shall specify, in reasonable detail to the extent Purchaser has the available information,
those items or amounts as to which Purchaser disputes in good faith and Purchaser shall be deemed to have agreed with all other
items and amounts contained in the Closing Statement and the calculations of the Closing Date Inventory Value set forth therein.

 

(d)          If
Purchaser fails to deliver an Objection Notice within such twenty (20) Business Day period, Purchaser shall be deemed to have waived
its rights to contest the Closing Statement and the calculation of the Closing Date Inventory Value set forth therein shall be
deemed to be final and binding upon the Parties (the “Final Inventory Value”) and such amount shall be used
for the purposes of adjustment of the Maximum Milestone Payment Amount pursuant to Section 2.7(g).

 

(e)          If
Purchaser delivers an Objection Notice to Seller on or before such twenty (20) Business Day period, then the Parties shall meet
within ten (10) Business Days after Purchaser delivers an Objection Notice, by telephone or at a mutually agreeable location to
discuss in good faith and attempt to reconcile their differences with respect to the amount of the Closing Date Inventory Value
that is being challenged by Purchaser (the “Challenged Amount(s)”). In the event the Parties are unable to reach
agreement on the Challenged Amounts, either Party may at any time thereafter submit such remaining disagreements to the Independent
Accountant.

 

(f)          The
Parties shall use commercially reasonable efforts to cause the Independent Accountant, once appointed, to resolve all remaining
disagreements with respect to Challenged Amounts as soon as practicable, but in any event shall direct the Independent Accountant
to render a determination within thirty (30) days after retention of the Independent Accountant. Each Party will be afforded the
opportunity to present to the Independent Accountant any material such Party deems relevant to the determination. The Independent
Accountant shall consider only those items and amounts in Purchaser’s and Seller’s respective calculations of the Challenged
Amounts that are identified as being items and amounts to which Purchaser and Seller have been unable to agree. In resolving any
disputed item, the Independent Accountant may not assign a value to any item greater than the greatest value for such item claimed
by either Party or less than the smallest value for such item claimed by either Party. The Independent Accountant’s determination
of the Challenged Amounts shall be based solely on written materials submitted by the Parties (i.e., not on independent
review) and on the definitions included in this Agreement. The determination of the Independent Accountant shall be conclusive
and binding upon the Parties and shall not be subject to appeal or further review and shall be deemed as the Final Inventory Value
for all purposes hereunder. The costs and expenses of the Independent Accountant in determining any Challenged Amounts shall be
borne equally by Purchaser, on the one hand, and Seller, on the other hand.

 

    	 	-19-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(g)           On
the date of the binding determination of the Final Inventory Value pursuant to the terms of this Section 2.7, either (as
applicable);

 

(i)          the
value of the Maximum Milestone Payment Amount for all purposes hereunder shall be deemed decreased dollar for dollar by the amount
by which the Final Inventory Value is less than [***] (the “Inventory Shortfall Amount”) or

 

(ii)         the
value of the Maximum Milestone Payment Amount for all purposes hereunder shall be increased dollar for dollar by the amount by
which the Final Inventory Value exceeds [***] (the “Inventory Excess Amount”).

 

Section
2.8           Milestone Payments.

 

(a)           Milestone
Payments.

 

(i)          As
additional consideration for the Purchased Assets above and beyond the Closing Purchase Price, Purchaser shall make Annual Milestone
Payments (as defined below) to Seller upon the achievement of certain Gross Profit goals in accordance with the specific terms
of this Section 2.8. Annual Milestone Payments (as defined below) shall be earned and payable in accordance with the terms
of this Section 2.8, when, in respect of each applicable four calendar quarter period during the Milestone Payments Term
beginning on April 1 and ending on the subsequent March 31 of the following calendar year (each an “Annual Period”,
other than in respect of the first period which shall run from the Closing Date through and including March 31, 2017, hereinafter
referred to as the “First Annual Period”), Gross Profit arising out of the sale of the Products in each such
Annual Period, or the First Annual Period, as applicable, exceeds [***] (an “Annual Gross Profit Milestone”).

 

(ii)         During
the period from and after the Closing Date, through the [***] anniversary thereof (the “Milestone Payments Term”),
if an Annual Gross Profit Milestone is met, Seller shall be entitled to receive from Purchaser an aggregate amount equal to [***]
of all of Purchaser’s Gross Profit in excess of [***] arising out of Purchaser’s sale of the Products in such applicable
Annual Period (or with respect to the First Annual Period, from the Closing Date through and including March 31, 2017) (each payment
in respect of an Annual Gross Profit Milestone, an “Annual Milestone Payment”); provided, that
the aggregate sum of all Annual Milestone Payments made to Seller pursuant to this Agreement shall not exceed [***], minus any
Offset Amounts claimed by Purchaser under Section 9.11 and subject to adjustment in accordance with Section 2.7(f)
(the “Maximum Milestone Payment Amount”).

 

    	 	-20-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)           Minimum
Milestone Payments.

 

(i)          In
respect of the First Annual Period, Seller shall be entitled to a minimum Annual Milestone Payment of [***] less
the aggregate amount in respect of any Offset Amount claimed by Purchaser in accordance with Section 9.11 less,
if applicable, the Inventory Shortfall Amount, or plus, if applicable, the Inventory Excess Amount (the “First
Minimum Milestone Payment”); provided, that in the event the Inventory Shortfall Amount exceeds [***],
such excess (the "Inventory Shortfall Excess") shall reduce future Milestone Payments until the Inventory Shortfall
Excess has been reduced to $0; and

 

(ii)         In
respect of the Annual Period from April 1, 2017 and ending on March 31, 2018 (the “Second Annual Period”), Seller
shall be entitled to a minimum Annual Milestone Payment of [***] less the aggregate amount of any Offset Amount claimed
by Purchaser in accordance with Section 9.11 and less the Inventory Shortfall Excess, if any (the “Second
Minimum Milestone Payment”).

 

(c)           Quarterly
Advances Against Annual Milestone Payments.

 

(i)          During
each Annual Period throughout the Milestone Payments Term, Purchaser shall make quarterly payments to Seller, as advances against
the Annual Milestone Payments to be make for such Annual Period (each, a “Quarterly Milestone Payment”), as
follows:

 

(A)         In
respect of the First Annual Period, Purchaser shall pay to Seller an amount equal to 25% of the First Minimum Milestone Payment
on June 30, 2016 and on the last day of each of the next three calendar quarters;

 

(B)         In
respect of the Second Annual Period, Purchaser shall pay to Seller an amount equal to 25% of the Second Minimum Milestone Payment
on June 30, 2017 and on the last day of each of the next three calendar quarters; and

 

(C)         In
respect of each Annual Period after the Second Annual Period, Purchaser will make Quarterly Milestone Payments to Seller on the
last day of each calendar quarter during such Annual Period equal to 25% of 90% of Purchaser’s good faith estimate of the
Annual Milestone Payment expected to be due for such Annual Period (calculated based on Purchaser’s budget for Gross Profit
attributable to Net Sales of the Products for such Annual Period). A copy of the budget, and any revisions thereof, in each case
prepared in good faith by Purchaser, shall be delivered to Seller no later than thirty (30) days after the start of any such Annual
Period, or thirty (30) days after such revisions are made.

 

    	 	-21-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         All
required Quarterly Milestone Payments shall be subject to reduction (without duplication) to the extent of any Inventory Shortfall
Excess and any Withheld Milestone Payments created pursuant to Section 9.11 below.

 

(iii)        All
or a portion of the Quarterly Milestone Payments made pursuant to clause (i)(C) above shall be subject to repayment to Purchaser
in the circumstances set forth in Section 2.8(e) below based on the calculation of Gross Profit for the relevant Annual
Period. The Quarterly Milestone Payments made pursuant to clauses (c)(i)(A) or (B) represent the Minimum Annual Milestone
Payments due for the First Annual Period and Second Annual Period, respectively, and are not subject to repayment under Section
2.8(e) below.

 

(d)           Quarterly
Reports.

 

No later than forty-five
(45) days after the end of each calendar quarter, commencing with the quarter ending June 30, 2016, Purchaser shall provide to
Seller, a statement for such calendar quarter containing (i) a Net Sales and a Gross Profit summary showing all sales of the Products
by customer and units, (ii) a summary of all deductions relevant to the calculation of Gross Profit of the Products for such calendar
quarter, together with copies of all material documentation to support allowable deductions used in computing Gross Profit of the
Products during such calendar quarter, (iii) any applicable Offset notification or notification of Withheld Milestone Payments
in accordance with the terms of Section 9.11, and (iv) a summary of all payments of Contingent Consideration received by
Purchaser or its Affiliates during such calendar quarter in connection with any Sale Transaction (the “Quarterly Reports”).
It is understood that such Quarterly Reports will be provided for information purposes only.

 

(e)           Annual
Milestone Payment Statements and Calculation of Annual Milestone Payments.

 

(i)          No
later than sixty (60) days after the end of each Annual Period, Purchaser shall deliver to Seller, an annual statement (an “Annual
Milestone Payment Statement”), containing (i) a report on Net Sales for the four calendar quarters of the Annual Period
in the same format as the Quarterly Reports and containing the same level of detail, (ii) a reasonably detailed calculation of
Purchaser’s annual Gross Profit related to the Products for such Annual Period, which shall be calculated in accordance with
GAAP, (iii) a list of all Quarterly Milestone Payments previously made as an advance against such Annual Milestone Payment, (iv)
a list of all payments of Contingent Consideration received by Purchaser or its Affiliates during such Annual Period in connection
with any Sale Transaction, and (iv) a certificate signed by the Chief Financial Officer of Purchaser certifying that to the best
of his or her knowledge, information and belief, after reasonable investigation, the information set forth in the Annual Milestone
Payment Statement is true and correct in all material respects. Such Annual Milestone Payment Statement shall set forth the total
aggregate amount of each of (A) the Annual Milestone Payment, and (B) the portion of any Contingent Consideration, that in each
case Seller is entitled to receive from Purchaser for the relevant Annual Period and the remaining amount of the Annual Milestone
Payment to be paid or the amount of any overpayment thereof.

 

    	 	-22-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         Any
Annual Milestone Payment due under this Section 2.8 shall be computed by deducting therefrom all Quarterly Milestone Payments
and Withheld Milestone Payments allocable thereto, and any balance due to Seller shall be paid by Purchaser, not later than five
(5) Business Days following the final determination of the amount of such Annual Milestone Payment in accordance with the terms
of Section 2.8(f); provided, however that the Annual Milestone Payment for the First Annual Period will not
be less than the First Minimum Milestone Payment and the Annual Milestone Payment for the Second Annual Period will not be less
than the Second Minimum Milestone Payment.

 

(iii)        In
the event that during any Annual Period, the aggregate of the four Quarterly Milestone Payments is greater than the final determination
of the amount of the Annual Milestone Payment, Purchaser shall be entitled to offset the amount of (A) the aggregate sum of the
four Quarterly Milestone Payments previously made in respect of such Annual Period less (B) the applicable finally
determined Annual Milestone Payment (the “Milestone Overpayment”), against future Quarterly Milestone Payments
which Purchaser is obligated to make to Seller. In the event that the Purchaser is not able to offset the entire amount of the
Milestone Overpayment against the next two subsequent Quarterly Milestone Payments following the final determination of any Annual
Milestone Payment, then Seller shall pay to Purchaser the difference equal to (A) the Milestone Overpayment less
(B) the amount of the Milestone Overpayment offset by the Purchaser against such subsequent two Quarterly Milestone Payments, not
later than five (5) Business Days following demand therefor by Purchaser.

 

(f)           Procedures
Applicable to Annual Milestone Payments Dispute Resolutions.

 

(i)          Seller
will have a period of twenty (20) Business Days to review the Annual Milestone Payment Statement and all calculations set forth
therein. Purchaser shall give Seller access to the relevant financial personnel and books and records of Purchaser as reasonably
requested by Purchaser to enable it to fully review the Annual Milestone Payment Statement and such access shall be provided in
a timely manner to allow Seller to complete such review in such twenty (20) Business Day period.

 

    	 	-23-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         The
Annual Milestone Payment Statement shall be conclusive of the amount of the applicable Annual Milestone Payment and (if applicable)
the portion of any Contingent Consideration payable to Seller pursuant to the terms of this Agreement, and shall be final and binding
upon the Parties unless before the twentieth (20th) Business Day after the date on which the Annual Milestone Payment
Statement is delivered to Seller, Seller delivers to Purchaser an Objection Notice to any matter stated in the Annual Milestone
Payment Statement. Any Objection Notice shall specify, in reasonable detail, those items or amounts as to which Seller disputes
in good faith, and Seller shall be deemed to have agreed with all other items and amounts contained in the Annual Milestone Payment
Statement and the calculations of the Annual Milestone Payment and (if applicable) the portion of any Contingent Consideration
payable to Seller set forth therein.

 

(iii)        
If Seller fails to deliver an Objection Notice within such twenty (20) Business Day period, Seller shall be deemed to have waived
its rights to contest the Annual Milestone Payment Statement and the calculation of the Annual Milestone Payment and (if applicable)
the portion of any Contingent Consideration payable to Seller set forth therein shall be deemed to be final and binding upon the
Parties.

 

(iv)        If
Seller delivers an Objection Notice to Purchaser on or before such twenty (20) Business Day period, then the Parties shall meet
within ten (10) Business Days after Seller delivers an Objection Notice, by telephone or at a mutually agreeable location to discuss
in good faith and attempt to reconcile their differences with respect to the Annual Milestone Payment Statement or the amount of
the Annual Milestone Payment or portion of any Contingent Consideration that is being challenged by Seller (the “Challenged
Amount(s)”). In the event the Parties are unable to reach agreement on the Challenged Amounts, Seller may at any time
thereafter submit such remaining disagreements to the Independent Accountant.

 

(v)         The
Parties shall use commercially reasonable efforts to cause the Independent Accountant, once appointed, to resolve all remaining
disagreements with respect to Challenged Amounts as soon as practicable, but in any event shall direct the Independent Accountant
to render a determination within thirty (30) days after retention of the Independent Accountant. The Independent Accountant shall
be granted access to the records of Purchaser during reasonable business hours for the purpose of verifying, at Seller’s
expense, Gross Profit for the Annual Period under review. The results of the Independent Accountant’s audit shall be final
and binding on all Parties. If Purchaser or Seller is required to reimburse the other Party for an underpayment or overpayment
(in any amount) such Party shall do so within five (5) Business Days of their receipt of notice of the results of the Independent
Accountant’s audit.

 

    	 	-24-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(g)           Full
Acceleration of Milestone Payments. If any of the following events occurs at any time prior to expiration of the Milestone
Payments Term, Purchaser shall pay to Seller by wire transfer of immediately available funds no later than five (5) Business Days
after the occurrence of such event an amount equal to the Maximum Milestone Payment Amount less the aggregate amount
of all Quarterly Milestone Payments already paid by Purchaser to Seller less Withheld Amounts:

 

(i)          Purchaser
dissolves, or is adjudicated insolvent or bankrupt;

 

(ii)         a
Change of Control occurs; or

 

(iii)        if
Purchaser (x) materially breaches any of the covenants set forth in Section 6.17(a)(i), (y) Purchaser does
not cure such breach during the applicable Cure Period after its receipt of written notice of such breach as provided in such section,
and (z) a court has “finally determined” that Purchaser has breached the covenants set forth in Section
6.17(a)(i). For purposes of this Section 2.8(g)(iii), a “finally determined” breach of the covenant shall
occur on the date of any final decision, order, judgment or decree of a court of competent jurisdiction regarding such breach,
which final decision, order, judgment or decree is not subject to further proceedings or appeals and is finally binding upon the
Parties.

 

(h)           Partial
Acceleration of Milestone Payments. Notwithstanding anything to the contrary herein or otherwise, Purchaser may transfer, assign
or otherwise sell both of the Products together in a single or related transactions to any one Person or related Persons prior
to the expiration of the Milestone Payments Term (a “Sale Transaction”), subject in all respect to the terms
set forth in this Section 2.8(h). Purchaser shall pay to Seller by wire transfer of immediately available funds no later
than five (5) Business Days after the consummation of any such Sale Transaction an amount equal to the lesser of (x) [***] of the
Sale Profit and (y) the remaining Maximum Milestone Payment Amount (the “Partial Acceleration Milestone Payment”).
For all purposes hereof, “Sale Profit” shall be equal to [***]. To the extent any Contingent Consideration shall
be payable to Purchaser as a result of any such Sale Transaction, Purchaser shall further pay to Seller an amount equal to [***]
of such Contingent Consideration received by Purchaser, which shall be due and payable to Seller not later than five (5) Business
Days following the final determination of such amount in accordance with the procedures set forth in Section 2.8(f). Notwithstanding
anything to the contrary herein, if the sum of (A) a Partial Acceleration Milestone Payment plus (B) the Milestone
Payments calculated as payable but not paid because of any offsets against or reductions to such amounts validly taken in accordance
with the terms of this Agreement, calculated as of the date of the consummation of the applicable Sale Transaction, is less than
the Maximum Milestone Payment Amount, such Sale Transaction shall not be permitted hereunder and shall be deemed null and void
for all purposes, unless such third party purchaser of the Products in connection with such Sale Transaction duly executes a written
agreement to assume all of Purchaser’s obligations hereunder in respect to the remaining Milestone Payments, and provided
that Purchaser shall remain liable in full for the performance of all of its obligations hereunder and for any breach by its assignee.

 

    	 	-25-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(i)           No
Security.  The parties hereto understand and agree that (i) the contingent rights to receive the Quarterly Milestone
Payments shall not be represented by any form of certificate or other instrument, are not transferable, except by operation of
Laws and do not constitute an equity or ownership interest in Purchaser, (ii) Seller shall not have any rights as a securityholder
of Purchaser as a result of Seller’s contingent right to receive the Quarterly Milestone Payments, and (iii) no interest
is payable with respect to the Quarterly Milestone Payments.

 

(j)           Milestone
Payments Escrow Account.  

 

(i)          Purchaser’s
obligation to make Quarterly Milestone Payments pursuant to, and in accordance with, this Section 2.8 shall be secured by
Five Million U.S. Dollars ($5,000,000) (the “Milestone Payments Escrow Funds”), which Milestone Payments Escrow
Funds shall be deposited in full by Purchaser at the Closing into a segregated escrow account designated by the Escrow Agent not
less than two (2) Business Days prior to the Closing, all in accordance with the terms of the Escrow Agreement. Subject to Section
2.8(j)(ii), the Milestone Payments Escrow Funds shall remain in the segregated escrow account until the first to occur of (a)
the [***] anniversary of the Closing Date, on which date all of the then remaining
Milestone Payments Escrow Funds shall be released to Purchaser and (b) the date on which the amount of the difference equal to
(x) the Maximum Milestone Payment Amount (as adjusted pursuant to Section 2.7(g)) less (y) the
aggregate sum of all Milestone Payments previously made to Seller pursuant to the terms of this Section 2.8 less
(z) the aggregate Excess Amount held by the Escrow Agent, is equal to, in the aggregate, less than Five Million U.S. Dollars ($5,000,000),
following which the Milestone Payments Escrow Funds shall be released to Purchaser in accordance with the terms of the Escrow Agreement
such that the sum of (A) the amount retained in the Milestone Payments Escrow Funds plus (B) the aggregate sum of
all Milestone Payments made to Seller pursuant to this Section 2.8 is equal to the Maximum Milestone Payment Amount less
any Excess Amount held by the Escrow Agent. 

 

(ii)         
In the event Purchaser consummates a Sale Transaction in accordance with and subject to, the terms of this Agreement, and in connection
with such Sale Transaction the applicable third party purchaser deposits into escrow for
the benefit of Seller and such third party, as of the closing of such Sale Transaction, an amount equal to the remaining Milestone
Payments Escrow Funds on the same terms set forth in this Agreement and the Escrow Agreement, Seller hereby agrees to execute with
Purchaser a joint written instruction directing the Escrow Agent to release any remaining Milestone Payments Escrow Funds to Purchaser.

 

    	 	-26-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Article
III

CLOSING

 

Section
3.1            Closing. (a) The Closing shall take place
remotely via the exchange of documents and signatures by electronic mail and overnight courier service on (i) the second (2nd)
Business Day following the satisfaction (or, to the extent permitted hereby and by applicable Law, waiver) of the conditions set
forth in Article VIII (other than the conditions that by their nature are to be satisfied by actions to be taken on the
Closing Date, but subject to the waiver or satisfaction of such conditions) or (ii) at such other time and place as the Parties
may mutually agree in writing. The date on which the Closing occurs is called the “Closing Date.” The Closing
shall be deemed to occur and be effective as of 12:01 a.m. on the Closing Date.

 

(b)           At
the Closing, Seller shall deliver or cause to be delivered to Purchaser the following instruments and documents, in each case,
in form and substance reasonably acceptable to Purchaser:

 

(i)           a
receipt for payment of the Closing Purchase Price;

 

(ii)          a
certificate of an authorized officer of Seller as to the resolutions adopted by the members, board of managers or similar governing
body of Seller relating to the transactions contemplated hereby;

 

(iii)         executed
copies of the Required Third Party Consents;

 

(iv)         assignments
of Assumed Contracts, duly executed by Seller or its applicable Affiliate;

 

(v)          the
Bill of Sale, duly executed by an authorized officer of Seller;

 

(vi)         the
Escrow Agreement, duly executed by an authorized officer of Seller;

 

(vii)        (A)
general patent assignments and general trademark assignments, in recordable form, with respect to patents and trademarks included
within the Purchased Assets, duly executed by Seller;

 

(B)         general
assignments executed by all of the Seller Affiliates assigning to Purchaser all right, title and interest they may have in and
to any of the Purchased Assets;

 

(viii)      physical
or, to the extent available, electronic copies of the Purchased Documents including copies of all the Purchased Documents comprising
the NDA;

 

    	 	-27-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ix)          executed
copies of the FDA transfer letters referenced in Section 6.10;

 

(x)           a
duly executed non-foreign affidavit under Section 1445 of the Code and the Treasury Regulations promulgated thereunder;

 

(xi)          the
Services Agreement, duly executed by an authorized officer of Seller;

 

(xii)         the
Trademark License-Back Agreement, duly executed by an authorized officer of Seller;

 

(xiii)        a
new supply agreement with [***], substantially in the form attached hereto as Exhibit F (the “[***] Supply Agreement”),
duly executed by an authorized officer of Seller and [***], together with an assignment thereof from Seller to Purchaser consented
to by [***];

 

(xiv)       a
side letter, in form and substance reasonably satisfactory to Purchaser, duly executed by authorized officers of the applicable
Affiliates of Seller, addressing only those matters set forth in Exhibit G (the “Side Letter”);

 

(xv)        evidence
reasonably satisfactory to Purchaser of the termination of (A) that certain Supply Agreement for Inderal® LA dated
as of February 4, 2014 between the Seller and [***] (the “[***] Supply Agreement”), together with evidence that
all payments required in connection with such termination have been paid, and (B) that distribution agreement between the Company
and Rouses Point Pharmaceuticals LLC to the extent related to distribution rights with respect to the Products;

 

(xvi)       either
(A) evidence in form and substance reasonably satisfactory to Purchaser that those Liens on the Purchased Assets (other than Permitted
Encumbrances) set forth on Schedule 1.1(b) have been or will be released at the Closing or (B) written authorization from
the appropriate Lien holders authorizing Purchaser to file terminations or releases of such Liens set forth on Schedule 1.1(b);
and

 

(xvii)      copies
of wholesaler inventory reports and an inventory report from [***], each as of the day prior to the Closing Date.

 

(c)          At
the Closing, Purchaser shall deliver or cause to be delivered to Seller, the following: (x) the Closing Purchase Price, as provided
in Section 2.6(a), and (y) the following instruments and documents, in each case, in form and substance reasonably acceptable
to Seller:

 

(i)          Assignments
of Assumed Contracts duly executed by Purchaser;

 

    	 	-28-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(ii)         executed
assumption agreements and all other instruments appropriate to evidence Purchaser’s assumption of the Assumed Liabilities;

 

(iii)        certificates
of an authorized officer of Purchaser as to the resolutions adopted by the Boards of Directors of Purchaser relating to the transactions
contemplated hereby;

 

(iv)        the
Escrow Agreement, duly executed by an authorized officer of Purchaser;

 

(v)         the
Services Agreement, duly executed by an authorized officer of Purchaser;

 

(vi)        the
Trademark License-Back Agreement, duly executed by an authorized officer of Purchaser; and

 

(vii)       the
Side Letter, duly executed by an authorized officer of Purchaser.

 

(d)          At
the Closing, Purchaser shall deliver or cause to be delivered to the Escrow Agent the Milestone Payments Escrow Fund pursuant to
the Escrow Agreement and in accordance with Section 2.8(a).

 

Article
IV

REPRESENTATIONS AND WARRANTIES OF SELLER

 

Except as set forth in
the correspondingly numbered section of the disclosure schedules attached hereto that relates to such Section of this Agreement
(the “Seller Disclosure Schedules”), Seller hereby makes the representations and warranties contained in this
Article IV to Purchaser.

 

Section
4.1           Organization. Seller is (i) a limited liability
company duly organized, validly existing and in good standing under the Laws of Delaware and (ii) is duly qualified or licensed
to do business and is in good standing in each jurisdiction in which such qualification or licensing is necessary under applicable
Laws or where the Exploitation of Seller’s Products requires such qualification, except where the failure to be so qualified
would not have a Material Adverse Effect. Seller has no Subsidiaries.

 

Section
4.2           Authority; Binding Effect. (a) Seller has
all requisite limited liability company power and authority to execute and deliver this Agreement and to consummate the transactions
contemplated hereby and perform its obligations hereunder. The execution, delivery and performance by Seller of this Agreement
and the consummation of the transactions contemplated hereby have been duly authorized by all necessary limited liability action
on behalf of Seller.

 

    	 	-29-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          This
Agreement has been duly executed and delivered by Seller and, assuming
the valid execution and delivery by Purchaser, constitutes a valid and binding obligation of Seller, and each Ancillary Agreement
will be, prior to the Closing, duly executed and delivered by Seller and will, assuming the valid execution and delivery by Purchaser,
from and after the Closing, constitute a valid and binding obligation of Seller, in each case enforceable against Seller in accordance
with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium
or similar laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement
is sought in a proceeding in equity or law) (the “Bankruptcy and Equity Exception”).

 

Section
4.3           No Conflicts; Consents. The execution, delivery
and performance of this Agreement and the Ancillary Agreements by Seller and the consummation of the transactions contemplated
hereby and thereby do not and will not (i) violate any provision of the organizational documents of Seller; (ii) subject to obtaining
the Required Third Party Consents as well as the other consents referred to in Schedule 4.3 of the Seller Disclosure Schedules,
conflict with, or result in the breach of, constitute a default under, result in the termination, cancellation or acceleration
(whether after the giving of notice or the lapse of time or both) of any right or obligation of Seller under, or to a loss of any
benefit to which Seller is entitled under, any Assumed Contract, or any other Contract to which the assets of Seller or any of
its Affiliates are subject to the extent such relate to the Purchased Assets; and (iii) assuming compliance with the matters set
forth in Section 4.4 and Section 5.5, violate or result in a breach of or constitute a default under any Law or other
restriction of any Governmental Authority to which Seller is subject; except, with respect to clauses (ii) and (iii),
for any violations, breaches, conflicts, defaults, terminations, cancellations or accelerations as would not reasonably be expected
to be material to the Business, Purchased Assets or the Products.

 

Section
4.4           Governmental Authorization. The execution and
delivery of this Agreement and the Ancillary Agreements by Seller or any Affiliate thereof does not require any consent or approval
of any Governmental Authority included within the Required Third Party Consents.

 

Section
4.5           Absence of Material Changes. Except as otherwise
contemplated or permitted by this Agreement, from December 31, 2014 to the date of this Agreement:

 

(a)          there
has not been any Material Adverse Effect; and

 

(b)          other
than with respect to the transactions contemplated by this Agreement and the exploration of strategic alternatives for the Purchased
Assets by Seller, Seller operated the Purchased Assets, in all material respects, in the ordinary course of business.

 

Section
4.6           No Litigation. No proceeding by or before any
Governmental Authority is pending against or, to the Knowledge of Seller, threatened in writing against Seller with respect to
the Purchased Assets that would reasonably be expected to be material to the Business, the Purchased Assets and the Products, taken
as a whole, or that in any manner challenges or seeks to prevent, enjoin, alter or materially delay the transactions contemplated
by this Agreement or the Ancillary Agreements. None of Seller or any of its Purchased Assets are subject to any Governmental Order
or arbitration award that is material to the Purchased Assets, taken as a whole, or that imposes any material limitation on the
ability of Seller to operate its Business as currently conducted.

 

    	 	-30-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
4.7           Compliance with Laws. Except as to matters otherwise
set forth in this Agreement:

 

(a)          Since
February 4, 2014, Seller and its Affiliates have operated the Business in material compliance with all Laws applicable to the Purchased
Assets, including the FDA Act; and

 

(b)          Seller
possesses all Governmental Authorizations necessary for the operation of the Business and the Purchased Assets as currently conducted;
and

 

(c)          since
February 4, 2014, no Governmental Authority has notified Seller or any Affiliate of Seller in writing that Seller or an Affiliate
of Seller (with respect to the Product, the Purchased Assets or the operation of the Business) is in violation of any applicable
Law.

 

Section
4.8           Product Registrations; Regulatory Compliance.

 

(a)          Schedule
4.8(a) of the Seller Disclosure Schedules sets forth, as of the date hereof, a list of all Product Registrations with respect
to any Products in the United States, which constitute all material registrations, applications, approvals, licenses or permits
granted by any Governmental Authority and used by Seller or any Affiliate of Seller in the Exploitation of the Products since February
4, 2014.

 

(b)          All
of the Products sold under the Product Registrations are, and at all times since February 4, 2014, have been manufactured and marketed
in accordance with the specifications and standards contained in such Product Registrations and in accordance with applicable Laws,
except where the failure to comply therewith would not reasonably be expected to be material to the Business, the Purchased Assets
and the Product, taken as a whole.

 

(c)          Seller
is the sole and exclusive owner of the Product Registrations, free and clear of any Liens, other than Permitted Encumbrances.

 

(d)          (i) The
Product Registrations are in full force and effect, (ii) all product fees, establishment fees and other fees invoiced by or
payable to any Governmental Authority with respect to any of the Product Registrations for the annual period commencing October 1,
2015, have been paid (other than any branded prescription drug fees that are Assumed Liabilities) and (iii) there are no Proceedings
pending (or, to the Knowledge of Seller, threatened) which could result in the revocation, cancellation or suspension of any of
the Product Registrations.

 

(e)          No
right of reference has been granted to any Person with respect to any of the Product Registrations.

 

    	 	-31-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(f)          To
the Knowledge of Seller, there are no pending requirements to conduct any Phase IV or other clinical studies with respect
to any Product of Seller in the United States for any approved indication.

 

(g)          Neither
Seller nor any of Seller’s Affiliates or any of their respective contractors has (nor, to the Knowledge of Seller, has any
other Person) at any time since February 4, 2014: (i) received or been subject to a warning letter, untitled letter, Form FDA 483,
or any other similar Governmental Authority notice or action relating to any Product; (ii) been subject to any Governmental Authority
detention, seizure, injunction, consent decree, notice of criminal investigation, indictment, sentencing memorandum, plea agreement,
court order, target or no-target letter, or other investigation relating to any Product; or (iii) initiated or been subject to
any product recall, market withdrawal, stock replacement or post-sale warning relating to any Product.

 

Section
4.9           Intellectual Property.

 

(a)          Schedule
4.9(a)(i) – (iv) of the Seller Disclosure Schedules set forth a true and correct list of all (i) Patent Rights, (ii)
applications and registrations for Trademarks, (iii) URL registrations and (iv) applications and registrations for Copyrights,
in each case to the extent owned by Seller or any Seller Affiliate and used in connection with the Exploitation of Products as
of the date of this Agreement (“Owned Intellectual Property”).

 

(b)          Except
as set forth on Schedule 4.9(b)(i) – (iii) of the Seller Disclosure Schedule:

 

(i)          there
is no action or proceeding pending, nor any notice of any objection or claim (other than objections or claims that have been previously
resolved) asserted in writing or, to the Knowledge of Seller, threatened by any Person, with respect to or challenging, the ownership,
validity or enforceability of any Owned Intellectual Property (or, to the Knowledge of Seller, any Intellectual Property licensed
to Seller or a Seller Affiliate pursuant to an Assumed Contract (“Licensed Intellectual Property”));

 

(ii)         the
Owned Intellectual Property and the rights of Seller or a Seller Affiliate to any Licensed Intellectual Property are free and clear
of any Liens, other than Permitted Encumbrances; and

 

(iii)        
none of the Owned Intellectual Property (nor, to the Knowledge of Seller, the rights of Seller or a Seller Affiliate to any Licensed
Intellectual Property) is the subject of (A) any pending (or, to the Knowledge of Seller, threatened) material adverse claim, judgment,
injunction, order, decree or agreement restricting (1) its use in connection with any Product or (2) assignment thereof to
Purchaser as contemplated hereunder, or (B) any other pending (or, to the Knowledge of Seller, threatened) material litigation
or claim of infringement.

 

    	 	-32-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)          Except
for the rights and assets set forth on Schedule 4.9(c) of the Seller Disclosure Schedules, the (i) Owned Intellectual
Property, (ii) the rights of Seller to Licensed Intellectual Property under the Assumed Contracts, (iii) any Intellectual Property
with respect to the Seller Company Identifiers and (iv) the Licensed Know-How, collectively, include all of the material Intellectual
Property used by Seller or any Affiliate of Seller to Exploit the Products since February 4, 2014.

 

(d)          Except
as set forth on Schedule 4.9(d), the Exploitation of Seller’s Products in the manner in which such Products have been
Exploited since February 4, 2014, does not infringe, misappropriate or otherwise violate any Intellectual Property or proprietary
right of any Person.

 

(e)          Except
as set forth on Schedule 4.9(e) of the Seller Disclosure Schedule, Seller has not granted any license, option or other rights
with respect to any of its Owned Intellectual Property or, with respect to the Products, any rights of Seller to any Licensed Intellectual
Property to any other Person, in each case to the extent such license, option or other rights is material to the Exploitation of
the Products.

 

Section
4.10         Assets.

 

(a)          Except
as otherwise provided in this Agreement, Seller owns or has the legal right to use all of its Purchased Assets. Seller has good
and marketable title to all its Purchased Assets (other than Product Registrations and Intellectual Property, which are the subject
of Section 4.8 and Section 4.9, respectively), free of Liens, except for Permitted Encumbrances.

 

(b)          Except
for the rights and assets set forth on Schedule 4.10 of the Seller Disclosure Schedules, the Purchased Assets, together
with the rights granted to Purchaser under the Ancillary Agreements, constitute all of the assets and rights of Seller, its Affiliates
and/or [***] pertaining to the Products or used or held for use by Seller in the Exploitation of the Products. Except as set forth
on Schedule 4.10 of the Seller Disclosure Schedules, neither [***], nor any Affiliate of Seller has any rights to or interest
in any of the Purchased Assets, except for such rights or interest that will be assigned to Purchaser at the Closing.

 

Section
4.11         Taxes.

 

(a)          Seller
has duly and timely filed, including extensions (or caused to be filed) with the appropriate Taxing Authorities all income and
other material Tax Returns relating to its Purchased Assets required to be filed. No claim has ever been made in writing by a Taxing
Authority in any jurisdiction where Seller does not file Tax Returns that Seller is or may be subject to taxation by that jurisdiction
as a result of its operation, ownership or use of Purchased Assets.

 

(b)          Seller
has paid (or caused to be paid) all income and other material Taxes relating to its Purchased Assets due and payable (whether or
not shown on any Tax Return) on or prior to the Closing Date. Seller has withheld or collected (or caused to be withheld or collected)
all material Taxes relating to its Purchased Assets required to be withheld or collected.

 

    	 	-33-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)           There
are no Liens for Taxes, nor, to the Knowledge of Seller, is any Taxing Authority in the process of imposing any Lien, on the Purchased
Assets, other than for Permitted Encumbrances set forth in clause (ii) of such definition. There are no written claims,
assessments, deficiencies or other adjustments for Taxes against Seller which, if not satisfied or resolved, would result in a
Lien on the Purchased Assets, other than for Permitted Encumbrances set forth in clause (ii) of such definition, that would survive
the Closing Date or in a Liability of Purchaser or its Affiliates as a transferee of or successor to Seller’s Purchased Assets.

 

(d)           Seller
has not waived any statute of limitations, agreed to any extension of time, or entered into any written agreement in respect of
Taxes, the nonpayment or underpayment of which would result in a Lien on its Purchased Assets, other than for Permitted Encumbrances
set forth in clause (ii) of such definition, that would survive the Closing Date, or in a Liability of Purchaser or its Affiliates
as a transferee of or successor to such Purchased Assets.

 

Section
4.12         Contracts.

 

(a)           Schedule 4.12(a)
of the Seller Disclosure Schedules sets forth, as of the date of this Agreement, a true, correct and complete list of all of the
Assumed Contracts (including all amendments or modifications thereto), to which Seller is a party which are used in the Exploitation
of the Products or by which any of its Purchased Assets are bound, including:

 

(i)          any
Contract that, in accordance with its terms, requires aggregate payments of [***] or more within the twelve (12) month period following
the date hereof and that is not cancelable without Liability on sixty (60) or fewer days’ notice to the other party thereto;

 

(ii)         any
Contracts or agreements relating to or evidencing indebtedness in excess of [***] which is secured in whole or part by the Purchased
Assets;

 

(iii)        any
Contracts that contain any non-compete or exclusivity provisions (or obligates Purchaser or any of its Affiliates to enter into
any non-compete or exclusivity arrangements following the Closing) with respect to any line of business or geographic area;

 

(iv)        any
Contract that requires (or would require upon the happening of a contingency) the disposition of any assets or line of business
of Seller prior to Closing, or by Purchaser or any of its Affiliates following the Closing;

 

(v)         any
Contract that grants a contractual counterparty “most favored nation” or similar status;

 

    	 	-34-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(vi)        any
Contract that restricts the conduct of any line of business (including the ability to research, develop, distribute, sell, supply,
market or manufacture any product (including products under development) for any indication in any product market, therapeutic
area or geographic area) by Purchaser or any of its Affiliates following the Closing;

 

(vii)       any
Contract that requires or obligates Purchaser or any of its Affiliates to purchase specified minimum amounts of any product or
material or to perform or conduct research, clinical trials or development for the benefit of any Person other than Purchaser or
any of its Affiliates;

 

(viii)      any
Contract that prohibits or limits in any material respect the right of Seller prior to Closing, or Purchaser or any of its Affiliates
following the Closing, to make, sell or distribute any products or services or use, transfer, license, distribute or enforce any
of its Intellectual Property;

 

(ix)         any
Contract that could reasonably be expected to account for sales of one or more of the Products by Seller or any Seller Affiliate
of [***] or more in the aggregate during the fiscal years ending December 31, 2015 or 2016;

 

(x)          any
Contract that is a settlement agreement, other than (A) releases or separation agreements entered into with former employees
or current or former independent contractors and (B) settlement agreements under which there are no continuing obligations,
Liabilities or rights (excluding releases);

 

(xi)         any
Contract pursuant to which Seller is granted a license, covenant not to sue, option or other right with respect to any Licensed
Intellectual Property that is material to the Exploitation of the Products;

 

(xii)        any
Contract pursuant to which Seller grants a third party a license, covenant not to sue, option or other right with respect to any
Purchased Intellectual, excluding licenses, covenants not to sue, options and other rights granted in the ordinary course of business;
and

 

(xiii)       any
Contract that contains any liability or obligation to indemnify any Person against any Tax Liability or to share any Tax Liability
with any Person (other than commercial Contracts, the primary purpose of which is not related to Taxes, none of which are Assumed
Contracts).

 

(b)          Seller
has made available to Purchaser true, complete and correct copies of all Assumed Contracts including any and all amendments, supplements
or modifications thereto, or detailed descriptions of any oral Assumed Contracts, to which it is a party. Each Assumed Contract
is a legal, valid and binding obligation, and is enforceable against Seller, and, to the Knowledge of Seller, the other party thereto,
and is in full force and effect, subject to the Bankruptcy and Equity Exception. Neither Seller nor, to the Knowledge of Seller,
any other party thereto (i) is in breach or violation of, or default under, or has delivered a notice of termination of, any
such Assumed Contract and no event has occurred that, with the giving of notice or lapse of time or both, would constitute a breach
or default of any such Assumed Contract, (ii) has not communicated any intention or threat to Seller, to reduce the prices
it will pay to Seller pursuant thereto, to terminate or to cancel any such Assumed Contract or has failed to renew or extend the
term of any such Assumed Contract upon the expiration of any such term.

 

    	 	-35-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)          From
and after the Closing, the Purchaser will have no obligation to make any payment to or perform any obligation for the benefit of
any Affiliate of Seller (whether pursuant to an Assumed Contract or otherwise), except to the extent set forth herein or in an
Ancillary Agreement

 

(d)          Schedule
4.12(d) of the Seller Disclosure Schedules sets forth, as of the date of this Agreement, a true, correct and complete list,
with respect to the Products, any Contract between Seller or any Seller Affiliate and each of (A) the ten (10) largest customers
and (B) the two sole suppliers of the Products during either the fiscal year ended December 31, 2014 or the fiscal year ended December
31, 2015.

 

Section
4.13         Financial Statements.

 

(a)          Seller
has provided to Purchaser a correct and complete copy of an audited balance sheet (including any related notes thereto) of Seller
for the year ended December 31, 2014 together with the audited statement of income and cash flows for the year ended December 31,
2014 (the “Audited Financial Statements”). The Audited Financial Statements were prepared in accordance with
GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto), are consistent
with and were prepared from the books and records of Seller, and fairly present in all material respects the financial condition,
results of its operations and income and cash flows of Seller as of the of the respective dates thereof and for the respective
periods, except as otherwise set forth in the notes thereto.

 

(b)          Seller
has provided to Purchaser a correct and complete copy of the unaudited balance sheet of Seller for the three (3) month period ended
September 30, 2015, together with the unaudited consolidated statement of income and cash flows for the three (3) month period
ended on September 30, 2015 (the “Unaudited Financial Statements” and, collectively with the Audited Financial
Statements, the “Financial Statements”). The Unaudited Financial Statements were prepared in accordance with
GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in any notes thereto), are consistent
with and were prepared from the books and records of Seller, and fairly present in all material respects the financial condition,
results of its operations and income and cash flows of Seller as of the respective dates thereof and for the respective periods
indicated, except that the Unaudited Financial Statements do not contain notes and are subject to normal year-end adjustments (none
of which would be materially adverse).

 

    	 	-36-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(c)          Section
4.13(c) of the Seller Disclosure Schedule sets forth, in all material respects, a complete and correct calculation of Net Sales
and Gross Profits of Seller and its Affiliates, based on unaudited financial statements available as of the date hereof, with respect
to the Products (calculated on a consolidated basis and consistent with and prepared from the books and records of Seller) for
the year ended December 31, 2015.

 

(d)          Seller
maintains books and records accurately reflecting its material assets and material liabilities and a system of internal controls
that management reasonably believes is sufficient to ensure that transactions are recorded as necessary to permit preparation of
financial statements of Seller in conformity with GAAP and to maintain asset accountability, and to provide adequate assurance
that material transactions and access to assets are authorized only by management. Such books and records are accurate and complete
in all material respects. Seller does not maintain any off-the-book accounts. Seller has disclosed to Purchaser any known or, to
the knowledge of Seller, alleged fraud, respecting Seller or any Affiliate of Seller since February 4, 2014, that involves management
or other employees who have had a significant role in the internal control over financial reporting.

 

Section
4.14         Suppliers and Customers. No customer or supplier identified
in Section 4.14 of the Seller Disclosure Schedule has, since January 1, 2015, ceased, failed to renew or materially altered
its relationship with Seller or an Affiliate of Seller with respect to the Business in a manner adverse to Seller or such Affiliate
or, to the Knowledge of Seller, has threatened in writing to cease or materially alter such relationship in a manner materially
adverse to Seller or its Affiliate. No such customer has notified Seller or an Affiliate of Seller in writing, that it shall stop,
or materially decrease the rate of, buying Products from Seller or an Affiliate of Seller which would be materially adverse to
Seller or its Affiliate. No such supplier has notified Seller or an Affiliate of Seller in writing that it shall stop, or materially
decrease the rate of, supplying materials, products or services to Seller or an Affiliate of Seller with respect to the Business
which would be materially adverse to Seller.

 

Section
4.15         Brokers. Except as set forth on Schedule 4.15 of
the Seller Disclosure Schedule (whose fees will be paid by Seller), no broker, finder or investment banker is entitled to any brokerage,
finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements
made by or on behalf of Seller.

 

Section
4.16         Inventories. As of the Closing, the Inventories: (i) are
in material compliance with all applicable specifications, (ii) have been manufactured in all material respects in accordance with
current Good Manufacturing Practices, as set forth in the United States Code of Federal Regulations, and (iii) are not misbranded
or adulterated, within the meaning of the Food, Drug and Cosmetics Act.

 

Section
4.17         Ordinary Course. Except as set forth on Schedule 4.17
of the Seller Disclosure Schedule, since January 1, 2015, the Seller and each of its Affiliates has maintained the Purchased Assets
and Exploited the Products in the ordinary course of business consistent in all material respects, with past practice. Except as
set forth on Schedule 4.17 of the Seller Disclosure Schedule, since September 30, 2015, neither Seller nor any Affiliate
of the Seller has offered any discounts or sales promotions intended to increase sales of the Products, except as required under
Contracts existing as of such date.

 

    	 	-37-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
4.18         Base Period AMP. The base period AMP set forth on Schedule
4.18 for each of the Products has been calculated in accordance with all applicable Laws, and to Seller’s knowledge,
there are no facts or circumstances that would require a restatement of the base period AMP for any Product.

 

Section
4.19         No Other Representations or Warranties. EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED IN THIS Article IV (AS MODIFIED BY THE SELLER DISCLOSURE SCHEDULES),
NEITHER SELLER NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED (BY STATUTE OR OTHERWISE), REPRESENTATION OR WARRANTY WITH
RESPECT TO SELLER, THE PURCHASED ASSETS, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE ASSUMED LIABILITIES AND ANY OTHER
RIGHTS OR OBLIGATIONS TO BE TRANSFERRED HEREUNDER OR PURSUANT HERETO, AND SELLER DISCLAIMS ANY OTHER REPRESENTATIONS OR WARRANTIES,
WHETHER MADE BY SELLER OR ANY OF ITS AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR REPRESENTATIVES, AND WITHOUT LIMITING
THE EXPRESS REPRESENTATIONS AND WARRANTIES OF SELLER SET FORTH HEREIN (AS MODIFIED BY THE SELLER DISCLOSURE SCHEDULES), IT IS THE
EXPLICIT INTENT AND UNDERSTANDING OF EACH PARTY HERETO THAT PURCHASER TAKES THE PURCHASED ASSETS “AS IS,” “WHERE
IS” AND “WITH ALL KNOWN AND UNKNOWN FAULTS.” EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY CONTAINED
IN THIS Article IV (AS MODIFIED BY THE SELLER DISCLOSURE SCHEDULES) OR IN THE ANCILLARY AGREEMENTS, SELLER HEREBY DISCLAIMS
ALL LIABILITY AND RESPONSIBILITY FOR ANY REPRESENTATION, WARRANTY, PROJECTION, FORECAST, STATEMENT, OR INFORMATION MADE, COMMUNICATED
OR FURNISHED (ORALLY OR IN WRITING) TO PURCHASER OR ITS AFFILIATES OR REPRESENTATIVES (INCLUDING ANY OPINION, INFORMATION, PROJECTION
OR ADVICE THAT MAY HAVE BEEN OR MAY BE PROVIDED TO PURCHASER BY ANY DIRECTOR, OFFICER, EMPLOYEE, AGENT, CONSULTANT OR REPRESENTATIVE
OF SELLER OR ANY OF ITS AFFILIATES). SELLER MAKES NO REPRESENTATIONS OR WARRANTIES TO PURCHASER REGARDING THE PROBABLE SUCCESS
OR PROFITABILITY OF THE PURCHASED ASSETS OR THE PRODUCTS. 

 

Article
V

 

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Except as set forth in
the section of the disclosure schedules attached hereto that relates to such Section of this Agreement (the “Purchaser
Disclosure Schedules”), Purchaser hereby represents and warrants to Seller as follows:

 

    	 	-38-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
5.1           Organization and Qualification. Purchaser is
a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to conduct its business as it is presently being conducted and to own and lease its properties
and assets.

 

Section
5.2           Corporate Authorization. No vote of holders
of capital stock of Purchaser or any of its Affiliates is necessary to approve this Agreement or the transactions contemplated
by this Agreement.  Purchaser has all requisite corporate power and authority to execute and deliver this Agreement and each
Ancillary Agreement to which it will be a party, and to perform its obligations hereunder and thereunder. The execution, delivery
and performance by Purchaser of this Agreement and each such Ancillary Agreement, and the performance by Purchaser of its obligations
hereunder and thereunder, have been duly authorized by all requisite or other legal entity action on the part of Purchaser.

 

Section
5.3           Binding Effect. This Agreement has been duly
executed and delivered by Purchaser and constitutes a valid and binding obligation of Purchaser, and each Ancillary Agreement will
be, prior to the Closing, duly executed and delivered by Purchaser and will, after the Closing, constitute a valid and binding
obligation of Purchaser, in each case, enforceable against Purchaser in accordance with its terms subject to the Bankruptcy and
Equity Exception.

 

Section
5.4           No Conflict; Consents. The execution, delivery
and performance by Purchaser of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not
(i) violate any provision of the certificate of incorporation, bylaws or other organizational documents of Purchaser; (ii) result
in a breach of, or default under, or right to accelerate with respect to, any term or provision of any Contract to which Purchaser
or any of its Affiliates is a party or is subject; (iii) assuming compliance with the matters set forth in Section 4.4 and
Section 5.5, violate or result in a breach of or constitute a default under any Law or other restriction of any Governmental
Authority to which Purchaser is subject; or (iv) require any consents, waivers, authorizations or approvals of, filings with, any
Persons which have not been obtained by Purchaser (other than as contemplated by Section 5.5).

 

Section
5.5           Governmental Authorization. The execution and
delivery of this Agreement by Purchaser do not and will not require any material consent or approval of any Governmental Authority,
except for the consents or approvals set forth in Schedule 5.5 of the Purchaser Disclosure Schedules.

 

Section
5.6           Financing. Purchaser has, and will have at the
Closing, sufficient immediately available funds necessary to pay the Closing Purchase Price, deposit the Milestone Payments Escrow
Funds with the Escrow Agent, to consummate the transactions contemplated by this Agreement and to perform its obligations in connection
with this Agreement and such transactions and to pay any expenses it incurs in connection therewith. In no event shall the receipt
or availability of any funds or financing by Purchaser or any of its Affiliates in connection with the transactions contemplated
by this Agreement be a condition to any of Purchaser’s obligations hereunder.

 

    	 	-39-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
5.7           Compliance with Laws.

 

(a)          The
businesses of each of Purchaser and its Subsidiaries are being conducted in compliance in all material respects with applicable
Laws. No material audit or, to the Knowledge of Purchaser, investigation, or review by any Governmental Authority with respect
to Purchaser or any of its Subsidiaries is pending or, to the knowledge of Purchaser, threatened, nor has any Governmental Authority
indicated an intention to conduct the same, in each case which would be reasonably expected to adversely affect the Exploitation
of the Products or Purchaser's ability to consummate the Transaction.

 

(b)          Purchaser
and each of its Subsidiaries has obtained and is in compliance with all licenses necessary for it to own, lease or operate its
properties, rights and other assets and to conduct its business and operations as presently conducted in all material respects
and all such licenses are in full force and effect in all material respects. No material default under, or material violation of,
any material License has occurred. To Purchaser’s knowledge there is not currently threatened any revocation, adverse modification
or cancellation of any material license.

 

Section
5.8           Condition of the Purchased Assets. PURCHASER
ACKNOWLEDGES AND AGREES THAT IT (I) HAS MADE ITS OWN INQUIRY AND INVESTIGATION INTO, AND, BASED THEREON, HAS FORMED AN INDEPENDENT
JUDGMENT CONCERNING SELLER, THE PURCHASED ASSETS, THE PRODUCTS, THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE ASSUMED LIABILITIES
AND ANY OTHER ASSETS, RIGHTS OR OBLIGATIONS TO BE TRANSFERRED HEREUNDER OR PURSUANT HERETO, AND (II) HAS BEEN FURNISHED WITH, OR
GIVEN ADEQUATE ACCESS TO, SUCH INFORMATION ABOUT SELLER, THE PURCHASED ASSETS, THE PRODUCTS, THE ASSUMED LIABILITIES AND ANY OTHER
RIGHTS OR OBLIGATIONS TO BE TRANSFERRED HEREUNDER OR PURSUANT HERETO, AS IT HAS REQUESTED. EXCEPT FOR THE SPECIFIC REPRESENTATIONS
AND WARRANTIES EXPRESSLY MADE BY SELLER IN Article IV OF THIS AGREEMENT AND IN THE ANCILLARY AGREEMENTS, (I) PURCHASER ACKNOWLEDGES
AND AGREES THAT (A) SELLER IS NOT MAKING AND HAS NOT MADE ANY REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY,
IN RESPECT OF THE PURCHASED ASSETS, SELLER, SELLER’S AFFILIATES, OR ANY OF SELLER’S OR ITS AFFILIATES’ RESPECTIVE
BUSINESSES, ASSETS, LIABILITIES, OPERATIONS, PROSPECTS OR CONDITION (FINANCIAL OR OTHERWISE), INCLUDING WITH RESPECT TO MERCHANTABILITY
OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY ASSETS, THE NATURE OR EXTENT OF ANY LIABILITIES, THE PROSPECTS OF THE PURCHASED ASSETS
OR THE PRODUCTS, THE EFFECTIVENESS OR THE SUCCESS OF ANY OPERATIONS, OR THE ACCURACY OR COMPLETENESS OF ANY CONFIDENTIAL INFORMATION
MEMORANDA, DOCUMENTS, PROJECTIONS, MATERIAL OR OTHER INFORMATION (FINANCIAL OR OTHERWISE) REGARDING THE PURCHASED ASSETS OR THE
PRODUCTS, SELLER OR SELLER’S AFFILIATES FURNISHED TO PURCHASER OR ITS REPRESENTATIVES OR MADE AVAILABLE TO PURCHASER AND
ITS REPRESENTATIVES IN SELLER’S ELECTRONIC DATA ROOM, MANAGEMENT PRESENTATIONS OR IN ANY OTHER FORM IN EXPECTATION OF, OR
IN CONNECTION WITH, THE TRANSACTIONS CONTEMPLATED HEREBY, AND (B) NO OFFICER, AGENT, REPRESENTATIVE OR EMPLOYEE OF SELLER OR ANY
OF SELLER’S AFFILIATES HAS ANY AUTHORITY, EXPRESS OR IMPLIED, TO MAKE ANY REPRESENTATIONS, WARRANTIES OR AGREEMENTS NOT SPECIFICALLY
SET FORTH IN THIS AGREEMENT AND IN THE ANCILLARY AGREEMENTS AND SUBJECT TO THE LIMITED REMEDIES HEREIN PROVIDED; (II) PURCHASER
SPECIFICALLY DISCLAIMS THAT IT IS RELYING UPON OR HAS RELIED UPON ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES THAT MAY HAVE BEEN
MADE BY ANY PERSON, AND ACKNOWLEDGES AND AGREES THAT SELLER HAS SPECIFICALLY DISCLAIMED AND DOES HEREBY SPECIFICALLY DISCLAIM ANY
SUCH OTHER REPRESENTATION OR WARRANTY MADE BY ANY PERSON; (III) PURCHASER SPECIFICALLY DISCLAIMS ANY OBLIGATION OR DUTY BY SELLER
TO MAKE ANY DISCLOSURES OF FACT NOT REQUIRED TO BE DISCLOSED PURSUANT TO THE SPECIFIC REPRESENTATIONS AND WARRANTIES SET FORTH
IN Article IV OF THIS AGREEMENT OR IN THE ANCILLARY AGREEMENTS; AND (IV) PURCHASER IS ACQUIRING THE PURCHASED ASSETS AND
THE ASSUMED LIABILITIES IN “AS IS” CONDITION AND ON A “WHERE IS” BASIS, SUBJECT ONLY TO THE SPECIFIC REPRESENTATIONS
AND WARRANTIES SET FORTH IN Article IV OF THIS AGREEMENT (AS MODIFIED BY THE SELLER DISCLOSURE SCHEDULE ) OR IN THE ANCILLARY
AGREEMENTS AS FURTHER LIMITED BY THE SPECIFICALLY BARGAINED FOR EXCLUSIVE REMEDIES SET FORTH IN Article IX.

 

    	 	-40-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
5.9           Litigation. There is no material action, order,
writ, injunction, judgment or decree outstanding, or Proceeding, labor dispute (other than routine grievance procedures or routine,
uncontested claims for benefits under any benefit plans for any officers, employees or agents of Purchaser), arbitration, investigation
or reported claim, pending or, to the Knowledge of Purchaser, threatened, before any court, Governmental Authority or arbitrator,
which seeks to delay or prevent the consummation of the transactions contemplated by this Agreement or would, if successful, materially
and adversely affect the Business or the Purchased Assets or ability of Purchaser to consummate the transactions contemplated by
this Agreement.

 

Section
5.10         Brokers. No broker, finder or investment banker is entitled
to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement
based upon arrangements made by or on behalf of Purchaser.

 

Section
5.11         Solvency. Immediately after the Closing, and after giving
effect to the transactions contemplated by this Agreement, Purchaser will be Solvent.

 

    	 	-41-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Article
VI

COVENANTS

 

Section
6.1           Information and Documents. (a) From and
after the date hereof and pending Closing, upon reasonable advance notice, Seller shall (and shall cause each of its Affiliates
to) (i) permit Purchaser and its Representatives to have reasonable access, during regular business hours to all offices and facilities,
and the assets, books, records, agreements, documents, data, files and personnel of, and such other information relating to the
Purchased Assets (including the Books and Records), (ii) furnish, or cause to be furnished, to Purchaser any financial and operating
data and other information that is available with respect to Seller’s Purchased Assets as Purchaser from time to time reasonably
requests and (iii) instruct the personnel, and their counsels and financial advisors to cooperate with Purchaser in its investigation
of the Purchased Assets, including instructing its accountants to give Purchaser access to their work papers; provided,
however, that no such access shall unreasonably interfere in any material respect with Seller’s or any of its Affiliate’s
operation of business; and provided further that Seller may restrict the foregoing access to the extent that (A) in
the opinion of Seller’s counsel (a copy of which is provided to Purchaser), any applicable Law requires Seller or any of
its Affiliates to restrict or prohibit access to any information, (B) in the reasonable judgment of Seller, the disclosure
of information would result in Seller or any of its Affiliates being in violation of confidentiality obligations to a third party,
or (C) disclosure of any such information or document could result in the loss or waiver of the attorney-client privilege.
If Seller seeks to withhold information from Purchaser for any reason permitted by this Section 6.1, Seller and Purchaser
shall cooperate in good faith to implement appropriate and mutually agreeable measures to permit the disclosure of such information
in a manner to remove the basis for the objection, including by arrangement of appropriate clean room procedures, redaction or
entry into a customary joint defense agreement with respect to any information to be so provided. It is further agreed that, prior
to Closing, except for announcements or filings required by applicable securities laws, Purchaser and its Representatives shall
not make any announcements or statements targeted at, or otherwise communicate directly with, any of the customers, manufacturers
or suppliers of Seller or its Affiliates, in connection with the transactions contemplated by this Agreement, whether in person
or by telephone, mail or other means of communication, without the specific prior authorization by Seller, which authorization
shall not be unreasonably withheld, conditioned or delayed.

 

(b)          All
information received by Purchaser and given by or on behalf of Seller in connection with this Agreement and the transactions contemplated
hereby shall be held by Purchaser and its Affiliates, agents and Representatives as “Confidential Information”,
as defined in, and pursuant to the terms of, the Confidentiality Agreement.

 

Section
6.2           Conduct.

 

(a)          From
and after the date hereof until the earlier of the date on which this Agreement is terminated pursuant to ARTICLE X and
the Closing, except (1) as set forth on Schedule 6.2 of the Seller Disclosure Schedules or as otherwise required by this
Agreement or (2) as Purchaser shall otherwise consent in writing, which consent shall not be unreasonably withheld, Seller agrees
that it shall (and shall cause its Affiliates to) Exploit the Products and maintain the Purchased Assets in the ordinary course
of business, and use commercially reasonable efforts to preserve intact the Purchased Assets and related relationships with customers,
suppliers and other third parties. From and after the date hereof until the Closing, except (x) as set forth on Schedule 6.2
of the Seller Disclosure Schedules or as otherwise required by this Agreement, or (y) as Purchaser shall otherwise consent in writing,
which consent shall not be unreasonably withheld, Seller covenants and agrees that, with respect to its Purchased Assets, it shall
(and shall cause its Affiliates to):

 

    	 	-42-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(i)          not
incur, create or assume any Lien, other than Permitted Encumbrances;

 

(ii)         not
incur or suffer to exist any indebtedness except (A) for working capital borrowings incurred in the ordinary course of business,
(B) incurrence of trade payables in the ordinary course of business or (C) indebtedness incurred in the ordinary course
of business or (D) indebtedness incurred solely in connection with Retained Liabilities or Excluded Assets;

 

(iii)        not
amend, modify or terminate any material term of, or waive any material right under, any Assumed Contract or amend or modify any
agreement that would increase the liability of Purchaser under the Services Agreement;

 

(iv)        not
enter into any Contract, agreement or commitment that would constitute an Assumed Contract if it were in effect on the date of
this Agreement or would increase the liability of Purchaser under the Services Agreement;

 

(v)         not
divest, sell, assign, license, transfer, abandon, cancel, convey, lease or otherwise dispose of any assets that would constitute
Purchased Assets;

 

(vi)        not
adopt a plan or agreement of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization
or other material reorganization of Seller;

 

(vii)       not
change the accounting policies or procedures except to the extent required to conform with GAAP;

 

(viii)      not
settle any Proceeding (i) that would (A) materially affect the Exploitation of any Product after the Closing or adversely
affect, in a material manner, the expected Net Sales or Gross Profit of the Business in respect of the period after the Closing
(B) result in its operations with respect to any Product being subject to any Governmental Order or other equitable relief
or admission of wrongdoing or (ii) for an amount, individually or in the aggregate, exceeding [***]; provided, that
clause (ii) shall not apply to any Proceeding that is solely related to a Retained Liability;

 

(ix)         not
withdraw, amend, modify or terminate any Product Registrations;

 

(x)          submit
all adverse event reports required to be submitted to any Governmental Authority under any Law;

 

    	 	-43-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(xi)         not
dispose of or permit to expire, terminate or otherwise lapse any rights in, to or for the use of any Purchased Intellectual Property
that is material to the Exploitation of the Products;

 

(xii)        not
grant any license, covenant not to sue or other right under any Purchased Intellectual Property;

 

(xiii)       not
offer any discounts or sales promotions other than as required under Contracts existing as of January 1, 2016; and

 

(xiv)      not
authorize, agree or resolve or consent to any of the foregoing.

 

(b)          Nothing
contained in this Agreement is intended to give Purchaser, directly or indirectly, the right to control or direct any Seller’s
or its Affiliate’s businesses or operations prior to the consummation of the transactions contemplated by this Agreement.
Prior to the consummation of the transactions contemplated by this Agreement, Seller and Purchaser shall exercise, consistent with
and subject to the terms and conditions of this Agreement, complete control and supervision over their respective operations.

 

Section
6.3           Member Approvals; Efforts to Consummate Generally.

 

(a)          On
or prior to the date hereof, Seller shall obtain all approvals of its and its Affiliates' members, board of managers or analogous
governing body required to be obtained under Seller’s and its Affiliates organizational documents and applicable Law in order
to consummate the transactions contemplated by this Agreement.

 

(b)          Subject
to the terms and conditions of this Agreement (and without limiting the requirements of Section 6.3, each Party shall use
its reasonable best efforts to cause the Closing to occur as soon as possible after the date hereof, including (i) satisfying
the conditions precedent set forth in Article VIII within the control of such Party and (ii) drafting, negotiating,
executing and delivering to each other in good faith such other agreements, documents, instruments and/or certificates, and doing
such other acts and things, as may be reasonably necessary or desirable for the implementation of this Agreement and the Ancillary
Agreements and the consummation of the transactions contemplated hereby and thereby.

 

(c)          Seller
shall use commercially reasonable best efforts to give all notices to, make all filings with and obtain all third party consents,
including the Required Third Party Consents, necessary to be obtained from any Persons (including Governmental Authorities) to
consummate the transactions contemplated hereby and by the Ancillary Agreements without resulting in any breach or violation of,
a default under, or an acceleration of any obligations or the creation of a Lien on the Products or the Purchased Assets (without
the expenditure of any funds therefor other than filing, recordation or similar fees and related legal fees and expenses, which
shall be borne by Seller).

 

    	 	-44-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.4           Bulk Transfer Laws. Notwithstanding anything
else to the contrary in this Agreement, Purchaser hereby waives compliance by Seller with the requirements and provisions of any
“bulk-transfer” Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of
the Purchased Assets to Purchaser.

 

Section
6.5           Insurance. As of the Closing Date, the coverage
under all insurance policies related to the Purchased Assets shall continue in force only for the benefit of Seller and not for
the benefit of Purchaser or any of its Affiliates, except to the extent set forth herein. Purchaser agrees to arrange for its own
insurance policies with respect to the Purchased Assets covering all periods and, except in connection with enforcing its rights
to indemnification pursuant to Article IX, agrees not to seek, through any means, to benefit from any of Seller’s
insurance policies that may provide coverage for claims relating in any way to the Purchased Assets prior to the Closing.

 

Section
6.6           Trade Notification. Subject to the provisions
set forth below, Seller and Purchaser shall agree on the method and content of the notifications to customers of the sale of the
Purchased Assets to Purchaser. Seller and Purchaser agree that said notifications are to provide sufficient advance notice of the
sale and the plans associated therewith.

 

Section
6.7           Seller-Labeled Products.

 

(a)          From
and after Closing, Purchaser and its Affiliates may use, reproduce and display, and Seller hereby grants (effective upon Closing)
to Purchaser and its Affiliates, a non-exclusive, paid-up and royalty-free right and license to use, reproduce and display, the
NDC Numbers, company names, company marks and company trade dress of Seller and its Affiliates and distributors related to the
Products (collectively, the “Seller Company Identifiers”), solely to the extent the foregoing are affixed to:
(i) the Inventory of finished, packaged Products that are included in the Purchased Assets, (ii) any finished, packaged Products
that, as of the date hereof, are scheduled to be delivered by [***] in April 2016 or (iii) in respect of rebate coupons or other
promotional materials related to Products bearing Seller’s NDC Numbers consistent with past practice; provided, that
the license set forth in this Section 6.7(a) shall continue until Purchaser and its Affiliates have disposed of all such
Inventory.

 

(b)          Except
as set forth in Section 6.7(a) and except for the rights to Trademarks that are included in the Purchased Assets, Purchaser
and its Affiliates shall have no right under this Agreement to use any of the trademarks, service marks, brand names, certification
marks, trade dress, logos or domain names containing the name of any Seller or any of their respective Affiliates or distributors,
or any word or expression confusingly similar thereto or constituting an abbreviation or extension thereof or any logos containing
or comprising the foregoing or any NDC Numbers of Seller or any of their respective Affiliates or distributors.

 

    	 	-45-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.8           NDC Numbers.

 

(a)          As
soon as reasonably possible, but in any event no later than nine (9) months after the Closing Date, Purchaser shall obtain a new
NDC Number and labeler code for such Product. Purchaser, at its own expense, shall prepare and file with the FDA any and all reports,
documents and materials, and take such other actions, as are necessary to undertake the foregoing.

 

(b)          Purchaser
shall fully reimburse Seller and its Affiliates and distributors for any increased cost or Liability (including any returns, rebates
or chargeback claims) associated with any changes in pricing, including any changes in wholesale acquisition cost, made by Purchaser
or any of its Affiliates to any Product that bears an NDC Number of Seller or any of its Affiliates. Purchaser shall pay any such
reimbursement within thirty (30) days of receiving a written request for such reimbursement from Seller, which shall be accompanied
by supporting documentation that reasonably evidences the increased cost or Liability to be reimbursed. Purchaser shall notify
Seller promptly of any such changes in pricing to a Product that bears an NDC Number of Seller or any of its Affiliates or distributors.

 

(c)          Purchaser
shall fully cooperate with Seller and its Affiliates and distributors by providing whatever assistance, product sales and other
information and access as may be required by Seller or any of its Affiliates or distributors to comply with any reporting obligations
that arise as a result of the sale by Purchaser of Product bearing an NDC Number of Seller or any of its Affiliates, and to enable
Seller and its Affiliates, one time within the period of 12 months from and after the date of last commercial sale to an end customer
of Product bearing an NDC Number of Seller or any Affiliate thereof, to audit the books and records of Purchaser and its Affiliates
with respect to any such sales (provided, that such audit takes place upon reasonable advance written notice to Purchaser,
during normal business hours of Purchaser and does not materially interfere with Purchaser’s business). Purchaser represents
and warrants that all Product sales and other information provided to Seller or any of its Affiliates or distributors in connection
with the foregoing shall be accurate and complete in all material respects, and shall be calculated in accordance with applicable
Laws and regulatory guidance.

 

(d)          Subject
to appropriate confidentiality protection, after the Closing Date and for a period of [***] years thereafter (except with respect
to government claims not subject to a statute of limitations, such as Medicaid rebate claims, which shall continue as long as there
is potential for a claim), Purchaser and its Affiliates shall reasonably cooperate (at Seller’s expense) with Seller and
its Affiliates, distributors and Representatives, subject to confidentiality protections reasonably satisfactory to Purchaser,
during normal business hours and upon reasonable advance notice, to provide reasonable access to records maintained by Purchaser
and its Affiliates relating to Purchaser and its Affiliates’ distribution of Seller’s Seller-Labeled Products or related
regulatory filing and reporting requirements and activities with respect to Seller’s Seller-Labeled Products, including,
without limitation, government price reporting (“Distribution Activities”), to provide reports reasonably requested
by Seller or its Affiliates or distributors regarding such records and information, and to permit copying at the expense of Seller
or, for the purposes of (i) any financial reporting or Tax matters relating to Distribution Activities, (ii) any claims
or litigation involving Distribution Activities or (iii) any investigation being conducted by any federal, state or local
Governmental Authority relating to Distribution Activities.

 

    	 	-46-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.9           No-Shop.

 

(a)          From
the date hereof until the Closing or earlier termination of this Agreement in accordance with the terms hereof, Seller and its
Affiliates shall not, and shall not authorize or permit any of their Representatives to, directly or indirectly, (i) knowingly
encourage, solicit, initiate, facilitate or continue inquiries regarding an Acquisition Proposal; (ii) enter into discussions or
negotiations with, or provide any information to, any Person concerning a possible Acquisition Proposal other than to state that
Seller, its Affiliates and each of their Representatives are restricted from entering into, continuing or participating in such
discussions or negotiations pursuant to the terms of this Section 6.9; or (iii) enter into any agreements or other instruments
(whether or not binding) regarding an Acquisition Proposal. Seller and its Affiliates shall immediately cease and cause to be terminated,
and shall cause their Representatives to immediately cease and cause to be terminated, all existing discussions or negotiations
with any Persons conducted heretofore with respect to, or that could reasonably be expected to lead to, an Acquisition Proposal
and shall revoke all access in favor of any Person (other than Purchaser and its Representatives) to any virtual data room established
for the purposes of evaluating a potential acquisition of all or a part of the Purchased Assets or the Business. For purposes of
this Section 6.9, “Acquisition Proposal” shall mean any inquiry, proposal or offer from any Person (other
than Purchaser or any of its Affiliates) concerning (i) the direct or indirect purchase, whether by sale, merger or otherwise,
or license of all or any portion of the Purchased Assets (including by way of the purchase of the equity interests of Seller or
any Affiliate thereof); or (ii) the disclosure, directly or indirectly, to any Person of any confidential information or data concerning
the Purchased Assets or the Business except as necessary to conduct business in the ordinary course consistent with past practice.

 

(b)          Seller
agrees that the rights and remedies for noncompliance with this Section 6.9 shall include having such provision specifically
enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall
cause irreparable injury to Purchaser and that money damages would not provide an adequate remedy to Purchaser.

 

Section
6.10         Transfer of Product Registrations, Related Applications and
Dossiers.

 

(a)          On
the Closing Date, Seller shall deliver a letter to the FDA transferring the rights to the Product Registrations to Purchaser (or
its designee) in the form attached hereto as Exhibit C. On the Closing Date, Purchaser shall deliver a letter to the FDA
assuming responsibility for the Product Registrations from Seller. As soon as practical after the Closing Date and in no event
more than sixty (60) calendar days following the Closing Date, Seller shall deliver to Purchaser, or its Affiliate as directed
by Purchaser, in physical and electronic form, the regulatory documentation in the possession or control of Seller or any Affiliate
of Seller related to such Product Registrations.

 

    	 	-47-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          Promptly
after the Closing and in any event within thirty (30) calendar days after the Closing, Seller and Purchaser shall make all appropriate
filings and submissions with Governmental Authorities, including the Centers for Medicare & Medicaid Services, the Veteran's
Administration and the FDA to transfer all regulatory responsibilities (excluding all Retained Liabilities and except as contemplated
by Section 6.8 (NDC Numbers) and the Services Agreement) attaching thereto of each Product, from Seller to Purchaser.

 

(c)          Without
limiting the Parties’ respective obligations under Section 6.10(a) with respect to any Product that is marketed in
the United States on the basis of an existing Product Registration, (i) Seller shall use all commercially reasonable efforts to
complete the transfer of the corresponding Product Registrations as promptly as practicable after the Closing Date to the benefit
of Purchaser or its Affiliates as directed by Purchaser in accordance with this Section 6.10(c) and (ii) Purchaser or its
Affiliates shall use all commercially reasonable efforts to assist Seller in the transfer of such Product Registrations, accept
the transfer of the corresponding Product Registrations and formalize with Seller and any applicable Governmental Authority, as
promptly as practicable after the Closing Date, all necessary documents. Following the transfer of the Product Registration, neither
Seller nor any Affiliate of Seller shall retain any rights in the Product Registration, including any rights to use or reference.

 

Section
6.11         Confidentiality. From and after the Closing:

 

(a)          The
Confidentiality Agreement will terminate without further action by the parties thereto.

 

(b)          Seller
shall treat (and shall cause each of its Affiliates to treat) as confidential and shall safeguard any and all information, knowledge
and data included in the Purchased Assets by using the same degree of care, but no less than a reasonable standard of care, to
prevent the unauthorized use, dissemination or disclosure of such information, knowledge and data as Seller or its Affiliates used
with respect thereto prior to the execution of this Agreement.

 

(c)          Purchaser
shall treat as confidential and shall safeguard any and all information, knowledge or data included in any information relating
to the business of Seller, other than the Business, Products, the Purchased Assets or the Assumed Liabilities, and except as otherwise
agreed to by Seller in writing; provided, however, that nothing in this Section 6.11(c) shall prevent the
disclosure of any such information, knowledge or data to any agents, advisors, directors, officers or employees of Purchaser to
whom such disclosure is necessary or desirable in the conduct of Purchaser’s business if such Persons are informed by Purchaser
of the confidential nature of such information and are directed by Purchaser to comply with the provisions of this Section 6.11(c).

 

(d)          Purchaser
and Seller acknowledge that the confidentiality obligations set forth herein shall not extend to information, knowledge and data
that is publicly available or becomes publicly available through no act or omission of the Party owing a duty of confidentiality,
or becomes available on a non-confidential basis from a source other than a party owing a duty of confidentiality so long as such
source is not known by such Party to be bound by a confidentiality agreement with or other obligations of secrecy to the other
Party.

 

    	 	-48-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(e)          In
the event of a breach of the obligations hereunder by Purchaser or Seller, the non-breaching party, in addition to all other available
remedies, will be entitled to injunctive relief to enforce the provisions of this Section 6.11 in any court of competent
jurisdiction.

 

Section
6.12         Know-How License. Effective as of the Closing, Seller hereby
grants to Purchaser (on behalf of itself and its Affiliates) a perpetual, irrevocable, transferable (as set forth in this Section
6.12), sublicensable (as set forth in this Section 6.12), non-exclusive, paid-up, royalty-free, worldwide right and
license to use and otherwise exploit the trade secrets, technical information, data and know-how owned by Seller or any Affiliate
of Seller related to the Products (the “Licensed Know-How”) in developing, commercializing, manufacturing, using,
packaging, marketing, promoting, importing, exporting, researching, transporting, selling and distributing the Products. Purchaser
may (but it is not obligated to) transfer the foregoing license, and/or grant sublicenses thereunder, to (a) any of its Affiliates,
and (b) any acquirer of any of the assets or business of Purchaser and its Affiliates relating to any of the Products.

 

Section
6.13         Correspondence. Seller authorizes Purchaser on and after
the Closing Date to receive and open all mail and other communications received by Purchaser relating to the Purchased Assets and
to deal with the contents of such communications in good faith and in a proper manner. Seller shall use commercially reasonable
efforts to promptly deliver, or cause to be delivered, to Purchaser any mail or other communications received by Seller or any
Affiliate of Seller from any Person (including the FDA) related to the Purchased Assets (including any mail or other communications
in respect of the Products, the subject matter of this Agreement and the Ancillary Agreements).

 

Section
6.14         Escrow Account. On or prior to the Closing Date, Purchaser,
Seller and the Escrow Agent shall enter into the Escrow Agreement. Any distributions to Purchaser Indemnified Parties of the Milestone
Payments Escrow Funds or any Excess Amount shall be made either as permitted pursuant to such Escrow Agreement or pursuant to joint
written instructions of Purchaser and Seller to the Escrow Agent instructing the Escrow Agent to make such distributions in accordance
with the terms of the Escrow Agreement. Each Party agrees to execute any joint instructions required to enable the Party to receive
a distribution of the Milestone Payments Escrow Funds or any Excess Amount to which it is entitled hereunder.

 

Section
6.15         Pharmacovigilance. Prior to the Closing, Seller shall cooperate
with Purchaser and shall facilitate and assist in negotiating arrangements between the third party that currently provides pharmacovigilance
services to Seller and the third party that currently provides pharmacovigilance services to Purchaser for the reporting of adverse
events and provision of other required regulating information with respect to the Products, all in form and substance reasonably
satisfactory to Purchaser. Until such arrangements are in place, Seller shall promptly report adverse events to Purchaser to permit
Purchaser to comply with applicable Law.

 

    	 	-49-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.16         Warehousing Services. Prior to the Closing, Seller shall
cooperate with Purchaser and shall use commercially reasonable efforts to facilitate and assist in negotiating arrangements between
[***] and Purchaser, in connection with the provision of certain warehousing and other services by [***] for Purchaser with respect
to the Products.

 

Section
6.17         Milestone Payments Covenants.

 

(a)          From
and after the Closing Date and continuing until the earlier of (x) the expiration the Milestone Payments Term (except, solely
in the case of clause (i) below, until the [***] anniversary of the Closing Date and subject to the provision of notice
and the Cure Period set forth in Section 6.17(b)) or (y) the date on which the Maximum Milestone Payment Amount has
been paid pursuant to Section 2.8, Purchaser shall:

 

(i)          operate
in good faith and use commercially reasonable efforts to market and sell the Products in the ordinary course of business; and

 

(ii)         keep
complete and accurate books and records of all sales of the Products, and provide to Seller reasonable access to such books and
records and the offices and facilities in which such books and records are housed, and to its Chief Financial Officer as and to
the extent required pursuant to Section 2.8 in connection with Seller’s review of the Annual Milestone Payment Statement.

 

(b)          Seller
shall promptly notify Purchaser in writing of any alleged breach of Section 6.17(a)(i). Following the receipt of such notice
of breach, Purchaser shall have thirty (30) days to cure such breach, which time period may be extended for up to an additional
sixty (60) days (the “Cure Period”) if Purchaser is using commercially reasonable efforts to timely cure such
breach.

 

Section
6.18         Certain Financial Information. Within two (2) Business
Days after Seller obtains audited Financial Statements for the year ended December 31, 2015, but not later than June 1, 2016, Seller
shall deliver to Purchaser the audited Financial Statements of Seller for the year ended December 31, 2015, including a balance
sheet, statement of operations and statement of income and cash flows certified by the Chief Financial Officer of Seller as (i)
prepared in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the
notes thereto), (ii) consistent with and were prepared from the books and records of Seller, and (iii) fairly presenting in all
material respects the financial condition, results of its operations and income and cash flows of Seller as of the date thereof
and for the period thereof, except as otherwise set forth in the notes thereto. In addition, no later than March 31, 2016, Seller
shall deliver to Purchaser the unaudited Financial Statements of Seller for the year ended December 31, 2015, including a balance
sheet, statement of operations and statement of income and cash flows certified by the Chief Financial Officer of Seller as (A)
prepared in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the
notes thereto), (B) consistent with and were prepared from the books and records of Seller, and (C) fairly presenting in all material
respects the financial condition, results of its operations and income and cash flows of Seller as of the date thereof and for
the period thereof, except as otherwise set forth in the notes thereto.

 

    	 	-50-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
6.19         Wrong-Pocket Assets. If at any time or from time to time
after the Closing Date, a Seller any of its Affiliates, on the one hand, or Purchaser or any of its Affiliates, on the other, shall
receive or otherwise possess any asset (including cash) that should belong to Purchaser, on the one hand, or Seller, on the other,
pursuant to this Agreement, such Person shall promptly transfer, or cause to be transferred, such asset to the Person so entitled
thereto. Prior to any such transfer in accordance with this ‎Section 6.19, the Person receiving or possessing such asset shall
hold such asset in trust for such other Person.

 

Section
6.20         Consultation and Cooperation. In connection with any claims
with respect to, or enforcement of: (i) any of Seller’s rights under warranties, guaranties, indemnitees and similar rights
against third parties, including any predecessors in title, to the extent related to the Exploitation of the Purchased Assets and
the Products prior to the Closing Date, or (ii) any other rights, claims or causes of action of Seller against third parties in
connection with the Exploitation of the Purchased Assets and the Products prior to the Closing Date, Seller hereby agrees to consult
and reasonably cooperate in good faith with Purchaser prior to the commencement of any such claim or enforcement and Seller shall
refrain from commencing any Proceeding or asserting any such right to the extent Purchaser in good faith concludes that any such
claim or enforcement may reasonably be expected to have an adverse effect on the ability of Purchaser to Exploit the Purchased
Assets and the Products in a manner consistent with Purchaser’s ordinary course of business with respect to the Purchased
Assets and the Products.

 

Article
VII

NON-COMPETE

 

Section
7.1           Non-Compete. For a period of seven (7) years
from and after the Closing Date (the "Non-Compete Period"), neither Seller nor any Affiliate thereof (which, for
the purposes of this Section 7.1, shall not include JCP IICI AIV, LP or any of its respective Affiliates) shall market
or sell, or license to any other party the right to market or sell, the Products, or any “AB-rated” generic thereof,
in the Territory (a “Competing Business”); provided, that, notwithstanding the foregoing, Seller
and its Affiliates shall not be restricted from:

 

(a)          collectively
owning less than five percent (5%) of any class of securities of any publicly traded company conducting a Competing Business if
such securities are held as a passive investment; or

 

(b)          acquiring
one or more Persons or businesses that include within its business a Competing Business, so long as (i) the Competing Business
comprises no more than twenty-five percent (25%) of the acquired business (and is not reasonably expected to comprise more than
25% of the acquired business prior to the end of the Non-Compete Period), based on net sales attributable to such Competing Business
as compared to the aggregate net sales of the acquired business as a whole, and (ii) Seller or its Affiliate, as applicable, completes
the sale of the Competing Business within six (6) months of the acquisition; provided, however, that if such sale
is subject to regulatory approval, then such six- (6) month period shall be extended until five (5) Business Days after all regulatory
approvals have been received, but only to the extent that the parties to such sale are using commercially reasonable efforts to
obtain any such approvals.

 

    	 	-51-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Article
VIII

CONDITIONS TO CLOSING

 

Section
8.1           Conditions to the Obligations of Purchaser and Seller.
The respective obligations of each of the Parties to consummate the transactions contemplated by this Agreement shall be subject
to the satisfaction or, to the extent permitted by applicable Law, waiver of the following conditions precedent:

 

(a)          There
shall be no Governmental Order in existence that prohibits or materially restrains the transactions contemplated by this Agreement
or the Ancillary Agreements, and there shall be no Proceeding pending by any Governmental Authority seeking such a Governmental
Order.

 

Section
8.2           Conditions to the Obligations of Purchaser.
The obligation of Purchaser to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction
or, to the extent permitted by applicable Law, waiver of the following conditions precedent:

 

(a)          The
representations and warranties of Seller contained herein shall be true and correct in all material respects as of the Closing,
as if made as of the Closing (except for those representations and warranties that address matters as of a particular date, which
need be true and correct only as of such date), (disregarding for purposes of this clause (a) any Material Adverse Effect,
materiality or similar qualifier contained in such other representations and warranties, other than the representations and warranties
made in Section 4.5(a)). Purchaser shall have received a certificate of Seller, dated as of the Closing Date and signed
by an officer of Seller in such capacity, certifying as to the fulfillment of the foregoing.

 

(b)          Seller
shall have performed in all material respects its agreements and obligations contained in this Agreement required to be performed
by it at or before the Closing. Purchaser shall have received a certificate of Seller, dated as of the Closing Date and signed
by an officer of Seller in such capacity, certifying as to the fulfillment of the foregoing.

 

(c)          Seller
shall have made or caused to be made delivery to Purchaser of the items required by Section 3.1(b).

 

(d)          There
shall have been no material reduction in or termination of and/or Seller or its Affiliates shall not have received written notice
of any material reduction in or termination of any Contracts relating to the sale of the Propranolol ER Product that would reasonably
be expected to result in a decrease in the annual sales of such Product by [***] or more, measured by volume.

 

    	 	-52-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(e)          No
event shall have occurred since the date hereof which has had a Material Adverse Effect.

 

(f)          Purchaser
shall have executed agreements in form reasonably satisfactory to it, with one or more third party distributor with respect to
the distribution of the Inventories; provided, however, that the foregoing condition shall terminate in the event Purchaser has
not executed any such agreement(s) within forty five (45) days after the date hereof.

 

(g)          Purchaser
shall have executed an agreement in form reasonably satisfactory to it, with [***] relating to the provision of warehousing and
other services by [***] to the Purchaser relating to the Products; provided, however, that the foregoing condition shall terminate
in the event Purchaser has not executed any such agreement within forty five (45) days after the date hereof.

 

Section
8.3           Conditions to the Obligations of Seller. The
obligation of Seller to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction or, to
the extent permitted by applicable Law, waiver of the following conditions precedent:

 

(a)          The
representations and warranties of Purchaser contained herein shall be true and correct in all material respects as of the Closing,
as if made as of the Closing (except for those representations and warranties that address matters as of a particular date, which
need be true in all material respects only as of such date). Seller shall have received a certificate of Purchaser, dated as of
the Closing Date and signed by an officer of Purchaser in such capacity, certifying as to the fulfillment of the foregoing.

 

(b)          Purchaser
shall have performed in all material respects its agreements and obligations contained in this Agreement required to be performed
by it at or before the Closing. Seller shall have received a certificate of Purchaser, dated as of the Closing Date and signed
by an officer of Purchaser in such capacity, certifying as to the fulfillment of the foregoing.

 

(c)          Purchaser
and its Affiliates shall have made or caused to be made delivery to Seller of the items required by Section 3.1(c).

 

Section
8.4           Frustration of Closing Conditions. Neither of
Seller or Purchaser may rely on the failure of any condition set forth in this Article VIII to be satisfied if such failure
was caused by such Party’s failure to act in good faith or to use its reasonable best efforts to cause the Closing to occur,
as required by Section 6.4.

 

    	 	-53-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Article
IX

INDEMNIFICATION

 

Section
9.1           Indemnification by Seller. Subject to the provisions
of this Article IX, from and after the Closing, Seller agrees to and shall defend, indemnify and hold harmless Purchaser
and its Affiliates, and, if applicable, their respective directors, officers, agents, employees, successors and assigns (collectively,
the “Purchaser Indemnified Parties”) from and against any Losses to the extent arising out of or related to:

 

(a)          any
breach of any representation or warranty of Seller or any Affiliate of Seller contained in this Agreement or any Ancillary Agreement,
or any failure to perform or breach by Seller or an Affiliate of Seller of any of its covenants or agreements contained in this
Agreement or any Ancillary Agreement that by their express terms contemplate performance prior to or on the Closing Date;

 

(b)          any
failure of Seller or any Affiliate of Seller to perform or any breach by Seller or any Affiliate of Seller of any of its covenants
or agreements contained in this Agreement or any Ancillary Agreement that by their terms expressly contemplate performance after
the Closing Date; or

 

(c)          any
Retained Liability.

 

Section
9.2           Indemnification by Purchaser. Subject to the
provisions of this Article IX, from and after the Closing, Purchaser agrees to and shall defend, indemnify and hold harmless
Seller and its Affiliates, and, if applicable, their respective directors, officers, agents, employees, successors and assigns
(collectively, the “Seller Indemnified Parties”) from and against any and all Losses to the extent arising out
of or related to:

 

(a)          
any breach of any representation or warranty of Purchaser contained in this Agreement or any Ancillary Agreement, or any failure
to perform or breach by Purchaser of any of its covenants or agreements in this Agreement or any Ancillary Agreement
that by their express terms contemplate performance prior to or on the Closing Date;

 

(b)          any
failure to perform or breach by Purchaser of any of its covenants or agreements in this Agreement or any Ancillary Agreement that
by their terms expressly contemplate performance after the Closing Date;

 

(c)          any
Assumed Liability, or

 

(d)          the
Exploitation of the Products by the Purchaser following the Closing (except for Liabilities expressly agreed to be borne by Seller
pursuant to this Agreement or any Ancillary Agreement).

 

    	 	-54-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.3           Notice of Direct Claims. (a) If any of
the Persons to be indemnified under this Article IX (the “Indemnified Party”) has suffered or incurred
any Loss subject to indemnification under this Article IX that does not involve a Third Party Claim, the Indemnified Party
shall so notify the Party responsible for providing indemnification therefor under this Agreement (the “Indemnifying Party”)
promptly in a writing describing such Loss, the basis for indemnification hereunder, the amount or estimated amount of such Loss,
if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and
containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred (an “Indemnity
Notice”). A failure by the Indemnified Party to give notice in a timely manner pursuant to this Section 9.3 shall
not limit the obligation of the Indemnifying Party under this Article IX, except (i) to the extent such Indemnifying Party
is materially prejudiced thereby or (ii) as provided by Section 9.5. In the event that the Indemnifying Party agrees to
or is determined to have an obligation to reimburse the Indemnified Party for Losses as provided in this Article IX, the
Indemnifying Party shall, subject to the provisions of Section 9.6, promptly (but, in any event, within 30 calendar days)
pay such amount to the Indemnified Party by wire transfer of immediately available funds to the account specified in writing by
the Indemnified Party; provided, that the Indemnifying Party may defer making such payment if it objects in a written
statement to the claim made in an Indemnity Notice and delivers such statement to the Indemnifying Party prior to the expiration
of such 30- calendar day period; provided, further that an Indemnifying Party’s failure to object within such
30- calendar day period to any claim set forth in an Indemnity Notice shall be deemed to be the Indemnifying Party’s acceptance
of, and waiver of any objections to, such claim. If an Indemnifying Party shall so object in writing to any claim or claims made
in any Indemnity Notice, the Indemnifying Party and the Indemnified Party shall attempt in good faith for a period of 20 calendar
days following the Indemnified Party’s receipt of such objection notice to agree upon the respective rights of the parties
with respect to each of such claims. If no such agreement can be reached after such 20- calendar day period of good faith negotiation,
either the Indemnifying Party or the Indemnified Party may initiate a Proceeding for purposes of having the matter settled in accordance
with the terms of this Agreement.

 

(b)          Except
when a notice, report or other filing must be filed immediately pursuant to applicable Law, Purchaser shall provide notice and
an opportunity to comment to Seller before Purchaser files any report, notification or filing with any Governmental Authority or
third party in connection with an event that would be reasonably likely to result in a Loss subject to the indemnification provisions
of Section 9.1. In the event Purchaser is required to file a report, notification or filing immediately, Purchaser shall,
to the extent permitted by Law provide simultaneous notice to Seller when it submits such report, notification or filing to the
applicable Governmental Authority.

 

Section
9.4           Third Party Claims.

 

(a)          If
any Proceeding is instituted by or against a third party with respect to which the Indemnified Party intends to seek indemnity
under this Article IX (a “Third Party Claim”), the Indemnified Party shall promptly notify the Indemnifying
Party of such Third Party Claim and tender to the Indemnifying Party the conduct or defense of such Third Party Claim. A failure
by the Indemnified Party to give notice and to tender the conduct or defense of the Third Party Claim in a timely manner pursuant
to this Section 9.4 shall not limit the obligation of the Indemnifying Party under this Article IX, except (i) to
the extent such Indemnifying Party is materially prejudiced thereby, (ii) with respect to out-of-pocket expenses incurred during
the period in which notice was not provided, and (iii) if such notice is not given within the applicable time period provided under
Section 9.5

 

    	 	-55-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          The
Indemnifying Party shall have the right to defend the Indemnified Party against such Third Party Claim as provided herein. If the
Indemnifying Party notifies the Indemnified Party that the Indemnifying Party elects to assume the defense of the Third Party Claim
(such election to be without prejudice to the right of the Indemnifying Party to dispute whether such claim is an indemnifiable
Loss under this Article IX), then the Indemnifying Party shall have the right to defend such Third Party Claim with counsel
selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party, in all appropriate proceedings, to a final
conclusion or settlement in accordance with this Section 9.4(b). The Indemnifying Party shall use reasonably diligent and
good faith efforts to defend or prosecute such Third Party Claim and shall keep the Indemnified Party reasonably advised of the
status of such claim and defense thereof and shall consider in good faith recommendations made by the Indemnified Party with respect
thereto. The Indemnifying Party shall have full control of such defense and proceedings, including any compromise or settlement
thereof; however, neither Party shall enter into any settlement agreement without the written consent of the Indemnified Party
(which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, such consent shall not
be required if (i) the settlement agreement contains a complete and unconditional general release by the third party asserting
the Third Party Claim to all Indemnified Parties affected by the claim, (ii) the settlement agreement does not contain any admission
of liability by or other obligation on the part of the Indemnified Party or sanction or restriction upon the conduct or operation
of any business by the Indemnified Party or its Affiliates and (iii) the settlement does not require any payment to be made by
the Indemnified Party to any Person. The Indemnified Party may participate in, but not control, any defense or settlement of any
Third Party Claim controlled by the Indemnifying Party pursuant to this Section 9.4(b), and the Indemnified Party shall
bear its own costs and expenses with respect to such participation; provided, however, that if the Indemnifying
Party assumes control of the defense of such claim and the Indemnifying Party and the Indemnified Party have, in the opinion of
legal counsel, materially conflicting interests or different defenses available with respect to such claim that cause the Indemnified
Party to hire its own separate counsel with respect to such proceeding, the reasonable fees and expenses of a single counsel to
the Indemnified Party shall be considered “Losses” for purposes of this Agreement.

 

(c)          If
the Indemnifying Party does not notify the Indemnified Party that the Indemnifying Party elects to defend the Indemnified Party
pursuant to Section 9.4(b) within thirty (30) calendar days after receipt of any Claim Notice, then the Indemnified Party
shall defend, and be reimbursed by the Indemnifying Party for its reasonable cost and expense in regard to the Third Party Claim
with counsel selected by the Indemnified Party, in all appropriate proceedings, which proceedings shall be prosecuted diligently
by the Indemnified Party; provided, that if it is ultimately determined that the Indemnified Party would not be entitled
to indemnification hereunder, even if the facts alleged in the Third Party Claim were true as alleged, the Indemnified Party shall
promptly repay in full such reimbursed amounts to the Indemnifying Party. In the circumstances described in this Section 9.4(c),
the Indemnified Party shall defend any such Third Party Claim in good faith and have full control of such defense and proceedings;
provided, however, that the Indemnified Party may not enter into any compromise or settlement of such Third Party
Claim if indemnification is to be sought hereunder, without the Indemnifying Party’s consent (which consent shall not be
unreasonably withheld, conditioned or delayed). The Indemnifying Party may participate in, but not control, any defense or settlement
controlled by the Indemnified Party pursuant to this Section 9.4(c), and the Indemnifying Party shall bear its own costs
and expenses with respect to such participation.

 

    	 	-56-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(d)          If
requested by the Party controlling the defense of a Third Party Claim, the other Party agrees, at the sole cost and expense of
such controlling Party (but only if the controlling Party is actually entitled to indemnification hereunder), to cooperate with
the controlling Party and its counsel in contesting any Third Party Claim being contested, including providing access to documents,
records and information. In addition, the Party that is not controlling the defense will make its personnel available at no cost
to the Indemnifying Party for conferences, discovery, proceedings, hearings, trials or appeals as may be reasonably required by
the Indemnifying Party. The Party not controlling the defense also agrees to cooperate with the controlling Party and its counsel
in the making of any related counterclaim against the Person asserting the Third Party Claim or any cross complaint against any
Person and executing powers of attorney to the extent necessary.

 

Section
9.5           Expiration. Each Party’s obligation to
indemnify any Indemnified Party under this Article IX shall expire and terminate as follows, unless a claim therefor is
asserted in writing in accordance with the terms of this Agreement prior to the applicable survival date, failing which such claim
shall be waived and extinguished: the date that is (i) thirty (30) days after the statute of limitations expires with respect to
any claim for indemnification under based on a breach of Section 4.1, Section 4.2, Section 4.10(a), Section
5.1, or Section 5.2 (“Fundamental Representations”), (ii) twelve (12) months from the Closing Date,
in the case of any claim for indemnification based on the representations or warranties of the other Party contained in this Agreement
other than the Fundamental Representations and Section 4.16, or (iii) the [***] anniversary of the Closing Date in the case
of indemnification for a breach of Section 4.16 or in respect of any other matter not addressed in the foregoing sub-clauses
(i) or (ii) or (iii), excluding claims related to Section 9.1(b), Section 9.1(c), Section
9.2(b), Section 9.2(c) or Section 9.2(d). Each Party’s obligation to indemnify any Indemnified Party in
connection with Section 9.1(b), Section 9.1(c), Section 9.2(b), Section 9.2(c) or Section 9.2(d),
as applicable, shall, in each case, survive indefinitely. For the avoidance of doubt, none of the covenants or agreements contained
in this Agreement shall survive the Closing other than those that by their terms expressly contemplate performance after the Closing
Date, which such covenants and agreements shall survive the Closing until fully performed.

 

Section
9.6           Limitations on Indemnification and other Matters.

 

(a)          De
Minimis. Notwithstanding any other provision of this Agreement to the contrary, no Indemnifying Party shall be required to
indemnify, defend or hold harmless any Indemnified Party pursuant to Section 9.1(a) or Section 9.2(a) against, or
reimburse any Indemnified Party for, any Losses with respect to any individual claims (or series of related claims) unless such
claim (or series of claims) involves Losses in excess of [***] (nor shall such item be applied to or considered for purposes of
calculating the Indemnity Threshold).

 

    	 	-57-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          Threshold.
Except for Losses arising out of a breach of a Fundamental Representation, no Indemnifying Party shall be liable to provide indemnification
pursuant to Section 9.1(a) or Section 9.2(a) for any Losses suffered by any Indemnified Party unless the aggregate
of all Losses suffered by the Indemnified Parties exceeds, on a cumulative basis, an amount equal to [***] (the “Indemnity
Threshold”), and then an Indemnifying Party shall only be liable to provide indemnification to the extent of any such
excess Losses.

 

(c)          Cap.
In no event shall any Indemnified Party be liable to provide indemnification pursuant to Article IX for Losses in the aggregate
in excess of an amount equal to [***] (the “Cap”), other than with respect to claims for indemnification for
Losses arising out of the breach of a Fundamental Representation, fraud or intentional misconduct of an Indemnifying Party in respect
of a provision of this Agreement. In no event shall an Indemnifying Party be liable for Losses in excess of an aggregate amount
equal to the Purchase Price.

 

(d)          Waiver.
The waiver of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with
any such covenant or agreements, will not affect the right to indemnification or any other remedy based on such representations,
warranties, covenants and agreements.

 

(e)          Read
Out of Materiality Qualifiers. Solely for purposes of calculating Losses hereunder, any materiality or Material Adverse Effect
qualifications in the representations (other than Section 4.5(a) above), warranties, covenants and agreements herein shall
be disregarded.

 

(f)          Exclusion
of Certain Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, EXCEPT TO THE EXTENT ARISING OUT OF OR ASSERTED
IN A THIRD PARTY CLAIM OR ARISING OUT OF A RETAINED LIABILITY OR AN ASSUMED LIABILITY OR FRAUD OR INTENTIONAL MISCONDUCT, NO INDEMNIFIED
PARTY SHALL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, TREBLE, REMOTE, SPECIAL, EXEMPLARY, OPPORTUNITY COST, CONSEQUENTIAL OR PUNITIVE
DAMAGES OR DAMAGES FOR, MEASURED BY OR BASED ON LOST PROFITS, LOSS OF REVENUE OR INCOME, DIMUNITION IN VALUE, MULTIPLE OR EARNINGS,
PROFITS OR CASH FLOWS, OR OTHER SIMILAR MEASURES OR FOR ANY LOSS OF BUSINESS REPUTATION OR OPPORTUNITY THAT ARISES OUT OF OR RELATES
TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF.

 

(g)          Adjustment
to Purchase Price. Seller and Purchaser agree to treat all payments made either to or for the benefit of the other Party under
this Agreement as adjustments to the Purchase Price for Tax purposes to the extent permitted under applicable Tax Law.

 

    	 	-58-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.7           Losses Net of Insurance, Etc. Any indemnifiable
Losses with respect to any matter shall be net of (i) any amounts recovered by the Indemnified Party pursuant to any indemnification
by or indemnification agreement with any third party and (ii) any insurance proceeds or other cash receipts or sources of reimbursement
received as an offset against such Loss (each Person named in clauses (i) and (ii), a “Collateral Source”),
in each case net of any costs of recovery or collection from any such Collateral Source. No Indemnifying Party shall have an indemnification
payment obligation in respect of any contingent liability unless and until such liability becomes due and payable.

 

Section
9.8           Reimbursement. If an Indemnified Party recovers
an amount from a Collateral Source in respect of a Loss that is the subject of indemnification hereunder after all or a portion
of such Loss has been paid by an Indemnifying Party pursuant to this Article IX, the Indemnified Party shall promptly remit
to the Indemnifying Party the amount received from the third party in respect thereof, net of all costs associated with the recovery
thereof, up to the amount of the Loss paid by the Indemnifying Party.

 

Section
9.9           Subrogation. If the Indemnifying Party makes
any payment on any Loss pursuant to Section 9.1 or Section 9.2, the Indemnifying Party shall be subrogated, to the
extent of such payment, to all rights and remedies of the Indemnified Party to any insurance benefits or other claims of the Indemnified
Party with respect to such claim. Without limiting the generality or effect of any other provision hereof, each Indemnified Party
shall duly execute upon request all instruments reasonably necessary to evidence and perfect the subrogation rights detailed herein
and otherwise reasonably cooperate in the prosecution of such claims (at the expense of the Indemnifying Party).

 

Section
9.10         Sole Remedy/Waiver. Should the Closing occur, the remedies
provided for in this Article IX shall be the sole and exclusive remedies of any Indemnified Party in respect of this Agreement,
the Ancillary Agreements, the Purchased Assets, the Products, the Excluded Assets, the Assumed Liabilities, the Retained Liabilities
or the transactions contemplated hereby or by the Ancillary Agreements, other than (i) for actions for specific performance or
other equitable remedies or (ii) for claims against a Party directly arising out of the fraud or intentional misconduct of such
Party. In furtherance of the foregoing, each Party hereby waives (on behalf of itself and the relevant Indemnified Parties) any
provision of applicable Law to the extent that it would limit or restrict the agreement contained in this Section 9.10,
and each Party hereby waives (on behalf of itself and the relevant Indemnified Parties) for periods following the Closing any and
all rights, claims or causes of action it or its Affiliates or relevant Indemnified Parties may have (other than pursuant to this
ARTICLE IX or as described in clauses (i) or (ii) of this Section 9.10) against the other Party or its Affiliates
or Representatives.

 

    	 	-59-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
9.11         Milestone Payment Offset.

 

(a)          Subject
to and in accordance with the provisions of this Section 9.11, Purchaser shall have the right to withhold from any Milestone
Payment otherwise due under Section 2.8 up to the amount, in the aggregate, equal to the amount of Losses estimated in good
faith by Purchaser in respect of any pending claims for indemnification asserted by a Purchaser Indemnified Party against Seller
pursuant to, and in accordance with, the terms of this Article IX, as set forth in a written notice delivered by Purchaser
to Seller, calculated after giving effect to all applicable caps, thresholds, limitations and exclusions set forth in Section
9.5 and Section 9.6 (“Withheld Milestone Payments”); provided, however, that if the
aggregate amount of all Withheld Milestone Payments exceeds [***] (such excess, the “Excess Amount”), then Purchaser
shall promptly deposit with the Escrow Agent an amount equal to the Excess Amount, to be held by the Escrow Agent in the indemnity
subaccount provided for in the Escrow Agreement, and deliver to the Escrow Agent the notice(s) of claim appropriately identifying
the indemnity claim(s) to which the Excess Amount relates. The Withheld Milestone Payment shall become due and payable when the
indemnity claim(s) to which such Withheld Milestone Payment relates are “finally determined” and the portion thereof
in excess of the Excess Amount that is not released from escrow shall, consistent with such final determination, either be paid
over by Purchaser to Seller within five (5) Business Days of such final determination, or be deemed an “Offset Amount”
with respect to the Milestone Payment(s) from which such amounts were withheld by Purchaser, as applicable. In the case of the
Excess Amount, at the time the related claims are “finally determined,” the applicable party shall deliver to the Escrow
Agent within two (2) Business Days of such finally determined judgment a written certificate as contemplated by the Escrow Agreement,
requesting that the Excess Amount (or applicable portion thereof) be disbursed by the Escrow Agent in accordance with such determination
no later than five (5) Business Days after the Escrow Agent receives such certificate, all in accordance with the terms of the
Escrow Agreement. In addition, the Escrow Agent shall distribute any Excess Amount held in accordance with the terms of any joint
notification received by it in accordance with the terms of the Escrow Agreement.

 

(b)          Upon
any Losses relating to a claim for indemnification by a Purchaser Indemnified Party against Seller being “finally determined”,
Purchaser shall have the right, but not the obligation, to cause such “finally determined” Losses to be paid to it
by an offset (an “Offset”, and the amount of any such Losses so “Offset” is referred to as an “Offset
Amount”). The calculation of any Offset Amount shall be subject to all limitations, procedures and other provisions detailed
in this Article IX, including all caps, thresholds, limits and exclusions set forth in Section 9.5 and Section
9.6.

 

(c)          Losses
shall be deemed to be “finally determined” to require indemnification by Seller for purposes of this Article IX
if (i) Purchaser and Seller have agreed that such Losses are indemnifiable by Seller in accordance with the terms of Section
9.3 or (ii) such Losses are determined to be indemnifiable by Seller pursuant to a final decision, order, judgment or decree
of a court of competent jurisdiction which is not subject to further proceedings or appeals and is binding upon the Parties (a
“Final Judgment”). Solely to the extent that Losses under this Article IX are finally determined to be
indemnifiable by Seller in accordance with the immediately preceding sentence, Purchaser may exercise an Offset in respect of such
Losses by notifying Seller thereof in writing in the applicable Annual Milestone Payment Statement that Purchaser is electing to
Offset (the “Offset Notification”). Such Offset Notification shall (i) describe in particular the claim for
indemnification with respect to which such set off rights have been exercised and (ii) attach a copy of the Indemnity Notice, and
all other applicable documentation evidencing the final determination of the claimed Offset Amount (including, if applicable, a
Final Judgment providing for the final determination of Seller’s obligation to indemnify the Purchaser Indemnified Party
for such Losses).

 

    	 	-60-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Article
X

TERMINATION

 

Section
10.1         Termination. This Agreement may be terminated at any time
prior to the Closing:

 

(a)          by
written agreement of Purchaser and Seller;

 

(b)          by
either Purchaser or Seller, by giving written notice of such termination to the other Party, if the Closing shall not have occurred
on or prior to May 16, 2016 (the “Outside Date”); provided, however, that the right to terminate
this Agreement pursuant to this Section 10.1(b) shall not be available to any Party hereto whose action or failure to fulfill
any obligation under this Agreement has been a principal cause of, or resulted in, the failure of the Parties to consummate the
Closing by such date;

 

(c)          by
Seller, if any of the representations or warranties of Purchaser set forth in this Agreement shall not be true and correct, or
if Purchaser has failed to perform any covenant or agreement on the part of such Purchaser set forth in this Agreement (including
an obligation to consummate the Closing), in each case, such that the conditions to the Closing set forth in Section 8.3(a)
or Section 8.3(b) would not be satisfied as of the Closing Date and the breach or breaches causing such representations
or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, are not cured within
twenty (20) Business Days after written notice thereof is delivered to Purchaser;

 

(d)          by
Purchaser, if any of the representations or warranties of Seller  set forth in this Agreement shall not be true and correct,
or if Seller has failed to perform any covenant or agreement on the part of Seller set forth in this Agreement (including
an obligation to consummate the Closing), in each case, such that the conditions to the Closing set forth in Section 8.2(a)
or Section 8.2(b) would not be satisfied as of the Closing Date and the breach or breaches causing such representations
or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, are not cured within
twenty (20) Business Days after written notice thereof is delivered to Seller; or

 

Section
10.2          Effect of Termination. (a) In the event of the termination
of this Agreement in accordance with Section 10.1 hereof, this Agreement shall thereafter become void and have no effect,
and no Party hereto shall have any liability to the other Party hereto or their respective Affiliates, directors, officers or employees;
provided, that (i) no such termination shall relieve the obligations of the Parties hereto contained in this Section
10.2 and in Section 6.1(b) (“Information and Documents”), Section 11.1 (“Notices”),
Section 11.6 (“Public Disclosure”), Section 11.7 (“Return of Information”),
Section 11.8 (“Expenses, Transfer Taxes and Property Taxes”), Section 11.10 (“Governing
Law; Jurisdiction”), Section 11.11 (“Waiver of Jury Trial”), and Section 11.16 (“Non-Recourse”)
hereof and (ii) nothing herein shall relieve any Party from Liability for any breach of any representation, warranty or covenant
set forth in this Agreement prior to such termination.

 

    	 	-61-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          In
the event this Agreement shall be terminated and at such time any Party is in material breach of or default under any term or provision
hereof, such termination shall be without prejudice to, and shall not affect, any and all rights to damages that the other Party
may have hereunder or otherwise under applicable Law. The damages recoverable by the non-defaulting Party shall include all attorneys’
fees reasonably incurred by such Party in connection with the transactions contemplated hereby.

 

Article
XI

MISCELLANEOUS

 

Section
11.1         Notices.

 

(a)          All
notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall
be in writing and shall be deemed to have been given (a) when personally delivered, (b) when transmitted (except if not
a Business Day then the next Business Day) via facsimile to the number set out below (with transmission confirmed) or to the address
set out below, (c) the day following the day (except if not a Business Day then the next Business Day) on which
the same has been delivered prepaid to a reputable national overnight air courier service or (d) the third Business Day following
the day on which the same is sent by certified or registered mail, postage prepaid. Notices, demands and communications, in
each case to the respective Parties, shall be sent to the applicable address or facsimile number set forth below, unless another
address or facsimile number has been previously specified in writing by such Party:

 

To Seller:

 

Cranford Pharmaceuticals, LLC

11 Commerce Drive, 1st Floor

Cranford, New Jersey 07016

Facsimile: [Fax number]

Attn: Greg
Ford, President

 

    	 	-62-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

with a copy to:

 

Lowenstein Sandler LLP

65 Livingston Avenue

Roseland, New Jersey 07068

Facsimile: [Fax number]

Attn: Michael J. Lerner

 

to Purchaser:

 

ANI Pharmaceuticals, Inc.

210 Main Street West

Baudette, MN 56623

Telephone: [Tel. number]

Facsimile: [Fax number]

Attn: Arthur Przybyl

 

with a copy to:

 

Dentons US LLP

1221 Avenue of the Americas

New York, NY 10020

Telephone: [Tel. number]

Facsimile: [Fax number]

Attn: Paul A. Gajer

 

(b)          This
Agreement and any signed agreement entered into in connection herewith or contemplated hereby, and any amendments hereto or thereto,
to the extent signed and delivered by means of a facsimile machine or scanned pages via electronic mail, shall be treated
in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were
the original signed version thereof delivered in person. No Party hereto or to any such contract shall raise the use of a facsimile
machine or email to deliver a signature or the fact that any signature or contract was transmitted or communicated through the
use of facsimile machine or email as a defense to the formation of a contract and each such Party forever waives any such defense.
This Agreement is not binding unless and until signature pages are executed and delivered by each of Purchaser and Seller.

 

Section
11.2         Amendment; Waiver. Any provision of this Agreement may
be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by Purchaser
and Seller, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any Party
in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

 

    	 	-63-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
11.3         Assignment. No Party to this Agreement may assign any of
its rights or obligations under this Agreement; provided, that (i) either Party may assign all or part of its rights
under this Agreement without consent to any of its Affiliates, in each case, so long as such assigning Party shall remain liable
in full for the performance of its obligations hereunder and for any breach thereof by its assignee, and (ii) Purchaser may assign
all or part of its rights under this Agreement to any third party to whom it sells both of the Products in a single transaction,
subject to and in accordance with the terms of Section 2.8(h).

 

Section
11.4         Entire Agreement. This Agreement (including all Schedules
and Exhibits hereto) contains the entire agreement between the Parties hereto with respect to the subject matter hereof and supersedes
all prior agreements and understandings, oral or written, with respect to such matters, except for (i) the Confidentiality Agreement
which will remain in full force and effect for the term provided for therein and (ii) any written agreement of the Parties that
expressly provides that it is not superseded by this Agreement.

 

Section
11.5         Parties in Interest. This Agreement shall inure to the
benefit of and be binding upon the Parties hereto and their respective successors and permitted assigns. Nothing in this Agreement,
express or implied, is intended to confer upon any Person other than Purchaser, Seller, or their successors or permitted assigns,
any rights or remedies under or by reason of this Agreement, provided, that (i) the provisions of Article IX
shall inure to the benefit of the Indemnified Parties and (ii) the provisions of Section 11.16 shall inure to the benefit
of the Persons referenced therein.

 

Section
11.6         Public Disclosure. Notwithstanding anything herein to the
contrary, each of the Parties to this Agreement hereby agrees with the other Parties hereto that, except as may be required to
comply with the requirements of any applicable Laws, and the rules and regulations of each stock exchange upon which the securities
of one of the Parties is listed, if any, no press release or similar public announcement or communication shall, if prior to the
Closing, be made or caused to be made concerning the execution or performance of this Agreement unless the Parties shall have consulted
in advance with respect thereto.

 

Section
11.7         Return of Information. If the transactions contemplated
by this Agreement are terminated as provided herein:

 

(a)          notwithstanding
anything in the Confidentiality Agreement to the contrary, Purchaser shall return to Seller or destroy all documents and other
material received by Purchaser, its Affiliates and their respective Representatives from Seller, or any of its respective Affiliates,
relating to the transactions contemplated hereby and by the Ancillary Agreements, whether so obtained before or after the execution
hereof; and

 

(b)          all
confidential information received by Purchaser, its Affiliates and their respective Representatives with respect to a Seller, or
any of its respective Affiliates, the Purchased Assets and the Assumed Liabilities shall be treated in accordance with the Confidentiality
Agreement, which shall remain in full force and effect in accordance with its terms notwithstanding the termination of this Agreement.

 

    	 	-64-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
11.8         Expenses, Transfer Taxes and Property Taxes. (a) Except
as otherwise expressly provided in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be borne by the Party incurring such expenses. Notwithstanding the foregoing, all Transfer Taxes shall
be paid 50% by Purchaser and 50% by Seller.

 

(b)          In
the case of any taxable period that includes (but does not end on) the Closing Date, real, personal and intangible property Taxes
and similar Taxes imposed with respect to the Purchased Assets (“Property Taxes”) shall be allocated between
the Pre-Closing Tax Period and the Post-Closing Tax Period on a per diem basis. Seller shall be responsible for any Property Taxes
for the Pre-Closing Period and Purchaser shall be responsible for any Property Taxes for the Post-Closing Period. Seller and Purchaser
shall promptly reimburse each other in accordance with such allocation for any such Property Taxes which any Party is required
to pay under applicable Law. Liability for any fees payable to any Governmental Authority with respect to the Purchased Assets
shall be allocated in the same manner.

 

Section
11.9         Schedules. The disclosure of any matter in the Disclosure
Schedule shall be deemed to be a disclosure with respect to any other section or subsection of ARTICLE IV of this Agreement
with respect to which its relevance is reasonably apparent on its face, but shall expressly not be deemed to constitute an admission
by Seller or Purchaser, or to otherwise imply, that any such matter is material for the purposes of this Agreement.

 

Section
11.10         Governing Law; Jurisdiction. (a) This Agreement and
its negotiation, execution, performance or non-performance, interpretation, termination, construction and all claims or causes
of action (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of, or relate to this Agreement,
or the transactions contemplated hereby (including any claim or cause of action based upon, arising out of or related to any representation
or warranty made in connection with this Agreement or as an inducement to enter this Agreement), shall be exclusively governed
by, and construed in accordance with, the laws of the State of New York regardless of Laws that might otherwise govern under any
applicable conflict of laws principles.

 

(b)          Any
Proceeding based upon, arising out of, or related to this Agreement and its negotiation, execution, performance, non-performance,
interpretation, termination, construction or the transactions contemplated hereby shall be heard and determined in the courts of
the State of New York sitting in the Borough of Manhattan and the United States District Court for the Southern District of New
York. The Parties hereto hereby irrevocably submit to the exclusive jurisdiction and venue of such courts in any such Proceeding
and irrevocably and unconditionally waive the defense of an inconvenient forum, or lack of jurisdiction to the maintenance of any
such Proceeding. The consents to jurisdiction and venue set forth herein shall not constitute general consents to service of process
in the State of New York and shall have no effect for any purpose except as provided in this Section 11.10 and shall not
be deemed to confer rights on any Person other than the Parties hereto. Each Party hereto agrees that the service of process upon
such Party in any Proceeding arising out of or relating to this Agreement shall be effective if notice is given by overnight courier
at the address set forth in Section 11.1. Each of the Parties also agrees that any final, non-appealable judgment against
a Party in connection with any Proceeding arising out of or relating to this Agreement may be enforced in any court of competent
jurisdiction, either within or outside of the United States. A certified or exemplified copy of such judgment shall be conclusive
evidence of the fact and amount of such judgment.

 

    	 	-65-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
11.11         WAIVER OF JURY TRIAL. TO THE FULLEST EXTENT PERMITTED
BY LAW, THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY
PROCEEDING (whether in contract, in tort, at law or otherwise) BASED UPON, ARISING OUT OF, OR RELATED TO THIS AGREEMENT
OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND
ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE PARTIES HERETO ACKNOWLEDGE
THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN
ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE PARTIES HERETO
FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE
MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS
TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTIONS CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION,
THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

 

Section
11.12         Counterparts. This Agreement may be executed in one or
more counterparts (including by facsimile or electronic .pdf submission), each of which shall be deemed an original, and all of
which shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by
each of the Parties and delivered (by telecopy or otherwise) to the other Party, it being understood that both Parties need not
sign the same counterpart.

 

Section
11.13         Headings. The heading references herein and the table
of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof.

 

    	 	-66-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

Section
11.14         Severability. The provisions of this Agreement shall be
deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the
other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any circumstance,
is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out,
so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder
of this Agreement and the application of such provision to other Persons, entities or circumstances shall not be affected by such
invalidity, illegality or unenforceability, nor shall such invalidity, illegality or unenforceability affect the validity or enforceability
of such provision, or the application thereof, in any other jurisdiction.

 

Section
11.15         Specific Performance. Each of the Parties acknowledges
that the rights of each Party to consummate the transactions contemplated hereby are unique and recognizes and affirms that in
the event of a breach of this Agreement by any Party, money damages may be inadequate and the non-breaching Party may
have no adequate remedy at Law. Accordingly, the Parties agree that prior to a valid termination of this Agreement in accordance
with this Agreement, such non-breaching Party shall have the right, in addition to any other rights and remedies existing
in its favor at Law or in equity, to enforce its rights and the other Party’s obligations hereunder not only by an Proceeding
or Proceedings for damages but also by an Proceeding or Proceedings for specific performance, injunctive and/or other equitable
relief (without posting of bond or other security). Each of the Parties agrees that it shall not oppose the granting of an injunction,
specific performance and other equitable relief when expressly available pursuant to the terms of this Agreement, and hereby waives
(x) any defenses in any Proceeding for an injunction, specific performance or other equitable relief, including the defense
that the other Parties have an adequate remedy at Law or an award of specific performance is not an appropriate remedy for any
reason at Law or equity and (y) any requirement under Law to post a bond, undertaking or other security as a prerequisite
to obtaining equitable relief.

 

Section
11.16         Non-Recourse.

 

(a)          This
Agreement may only be enforced against, and any claim or cause of action based upon, arising out of or related to this Agreement
may only be brought against the entities that are expressly named as Parties hereto and then only with respect to the specific
obligations set forth herein with respect to such Party (or, in the case of Article VI and Article VII, the relevant
Affiliates of Seller). Except to the extent a named Party to this Agreement (and then only to the extent of the specific obligations
undertaken by such named Party in this Agreement) (or, in the case of Article VI and Article VII,, the relevant Affiliates
of Seller), no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent,
attorney or other Representative of any Party hereto shall have any liability (whether in contract or in tort, in law or in equity,
or based upon any theory that seeks to impose liability of an entity party against its owners or Affiliates) for any obligations
or liabilities of any Party hereto under this Agreement or for any claim based on, in respect of, or by reason of, the transactions
contemplated hereby or in respect of any oral representations made or alleged to have been made in connection herewith (except
with respect to claims of fraud or intentional misconduct).

 

    	 	-67-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

(b)          The
provisions of this Section 11.16 are intended to be for the benefit of, and enforceable by, the directors, officers, employees,
incorporators, members, partners, stockholders, Affiliates, agents, attorneys and other Representatives of the Parties hereto,
and each such Person shall be a third party beneficiary of this Section 11.16.

 

Section
11.17         Conflict of Interest.

 

(a)          Lowenstein
Sandler LLP (“Lowenstein”) shall be permitted to represent Seller after the Closing in connection with any matter
relating to the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, after the Closing,
Lowenstein shall be permitted to represent Seller, any of its agents and Affiliates, or any one or more of them, in connection
with any negotiation or transaction with Purchaser or any of its agents or Affiliates under or relating to this Agreement, the
transactions contemplated hereby, and any related matter.

 

(b)          Dentons
US LLP (“Dentons”) shall be permitted to represent Purchaser after the Closing in connection with any matter
relating to the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, after the Closing,
Dentons shall be permitted to represent Purchaser, any of its agents and Affiliates, or any one or more of them, in connection
with any negotiation or transaction with Seller or any of its agents or Affiliates under or relating to this Agreement, the transactions
contemplated hereby, and any related matter.

 

[Remainder of Page
Intentionally Left Blank]

 

    	 	-68-	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

IN WITNESS WHEREOF,
the Parties have executed or caused this Agreement to be executed as of the date first written above.

 

	 	CRANFORD PHARMACEUTICALS, LLC
	 	 	 
	 	By:	                          
	 	 	Name:
	 	 	Title:

 

[SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]

 

    	 	 	 

     

    

 

Confidential Materials Omitted and Filed
Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the
Securities Act of 1933, as amended. Confidential Portions are marked: [***]

 

	 	ANI PHARMACEUTICALS, INC.
	 	 	                                    
	 	By:	 
	 	 	Name:
	 	 	Title:

 

[SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]